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Abstract 
Hepatocellular carcinoma (HCC) is one of the most lethal cancers in the world and 
accounts for the vast majority of all liver cancers. HCC develops in response to various 
factors including viral infections, aflatoxin, alcohol and metabolic diseases. Recent studies 
have highlighted substantial differences in the acquired genomic alterations depending on 
the causative agent. Despite such a mutagen-dependent genetic heterogeneity, HCC is 
almost invariably associated with an underlying inflammatory state, whose direct 
contribution to the acquisition of critical genomic changes is not yet clear.  
The aim of my PhD project has been to understand how chronic inflammation and 
fibrosis affect the cancer genome. We mapped the acquired genomic alterations in human 
and mouse HCCs induced by defects in hepatocyte biliary transporters. These HCCs arise 
as a result of chronic exposure to non-neutralized bile acids that cause the onset of chronic 
inflammation and develop into cancer in the absence of exogenous direct (viruses) or 
indirect (alcohol) mutagens. We first studied the mutational landscapes of human and 
mouse cancer genomes and found a surprisingly low number of somatic point mutations 
with no impairment of cancer genes. We next studied the acquisition of somatic copy 
number variations (CNVs) and used well-established approaches for detecting CNVs from 
SNP arrays and whole genome sequencing data. We also developed a novel method, 
GeneCNV, for the identification of CNVs from targeted re-sequencing screenings. Overall, 
we observed the acquisition of massive gene copy number gains and rearrangements in 
both human and mouse HCCs. Amplifications preferentially occurred at late stages of 
cancer development and frequently targeted the mitogen-activated protein kinase (MAPK) 
signalling pathway, in particular, direct regulators of c-Jun NH2-terminal kinases (JNKs). 
We showed that that pharmacological inhibition of JNK impairs the adenoma-to-
carcinoma progression in mouse. This suggests that JNK inhibition may be a useful 
therapeutic approach to block HCC onset in bile salt export pump (BSEP) deficiency 
patients waiting for liver transplantation.  
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Altogether, this study showed that human BSEP-HCCs and mouse Mdr2-KO HCCs 
acquire a similar genomic signature, thus highlighting the remarkable analogy between 
human and mouse tumours with similar etiopathogenesis. This genomic signature differs 
from that of other HCCs profiled so far, which were for the most part virus induced. This 
demonstrates that HCC in the absence of external agents develops through genomic 
alterations that can be clearly distinguished from those determined by other etiological 
factors.  
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Introduction 
1.1 Overview of human liver cancer 
Liver cancer is the second leading cause of cancer-related deaths and the sixth most 
common cancer type in the world (Ferlay J 2012) (Figure 1). Primary liver cancers include 
hepatocellular carcinoma (HCC), intrahepatic bile duct carcinoma (cholangiocarcinoma), 
hepatoblastoma, bile duct cystadenocarcinoma, hemangiosarcoma and epithelioid 
hemangioendothelioma (Farazi and DePinho 2006). Among primary liver cancers, HCC is 
the most common tumour and accounts for 70-85% of all liver cancers (Perz, et al. 2006). 
HCC is usually associated with high mortality due to unresponsiveness to treatment, and 
tumour relapse after partial hepatectomy (Block, et al. 2003; Llovet 2005). 
 
 
Figure 1: Percentage of deaths and incidence by cancers worldwide 
For each cancer type, the percentage of deaths over the total deaths by cancer and the percentage of 
incidence over the total incidence of cancers worldwide are reported. Original data is taken from 
GLOBOCAN 2012 (Ferlay J 2012), which excludes non-melanoma skin cancer from its study 
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because of the difficulties in collecting (and counting) such tumours 
(http://globocan.iarc.fr/Pages/cancer.aspx). 
 
HCC may arise in response to exposure to external factors such as virus infection, 
aflatoxin and alcohol, or by metabolic diseases including obesity and diabetes (Block, et al. 
2003; El-Serag and Rudolph 2007). The most common cause of HCC in adults is chronic 
viral infections due to hepatitis B (HBV) and hepatitis C (HCV) that account for 78% of 
HCCs (Block, et al. 2003) (Figure 2).  
 
 
Figure 2: Distribution of aetiologies in HCCs 
Shown are the percentages of HCCs associated with the virus infections as compared to other 
causes. Taken from (Block, et al. 2003). 
 
1.2 Genomic landscape of hepatocellular carcinoma 
Genomic re-sequencing of human HCCs has highlighted recurrent mutations in key 
cancer genes such as TP53, CTNNB1, and chromatin regulators (Li, Zhao, et al. 2011; 
Totoki, et al. 2011; Fujimoto, et al. 2012; Guichard, et al. 2012; Huang, et al. 2012; Jiang, 
et al. 2012; Sung, et al. 2012) (Table 1, Figure 3). These studies have also reported 
genomic regions that undergo frequent copy number variations (CNVs) such as 
amplifications of 11q1, 8q and deletions of 4q, 8p and 17p (Totoki, et al. 2011; Guichard, 
et al. 2012; Jiang, et al. 2012) (Figure 3).  
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Table 1: Genomic re-sequencing studies of HCCs 
Screening 
Screening 
Type 
Patients 
Mutated 
genes 
Non 
Synonymous 
mutations 
Mutation 
frequency 
(mutation
/Mbp) 
Guichard, Nature Genetics 2012 WES 24 872 1,056 1.02 
Huang, Nature Genetics 2012 WES 10 347 356 0.99 
Li, Nature Genetics 2011 WES 10 411 429 0.98 
Fujimoto, Nature Genetics 2012 WGS 25 206 1,996 4.2 
Jiang, Genome Research 2012 WGS 4 221 228 3.8 
Totoki, Nature Genetics 2011 WGS 1 71 72 4.11 
Sung, Nature Genetics 2012 WGS 88 NA NA NA 
For each screening reported are the type of screening performed (WES=whole exome sequencing, 
WGS=whole genome sequencing), number of patients analysed, number of mutated genes, number 
of nonsynonymous mutations and average mutation frequency in each screening. Mutation 
frequency in whole exome sequencing is calculated as the number of nonsynonymous mutation 
over the total bases targeted for sequencing. In case of whole genome sequencing the mutation 
frequency is computed as the number of mutations over the total size of the genome. 
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Figure 3: Frequently mutated genes and CNV regions in HCCs  
Shown are the frequently mutated genes (Zhang 2012) and CNV regions reported in the HCC 
studies (Table 1). Frequent HBV integration target genes are shown in blue. 
 
 
These studies highlighted substantial differences in the acquired genomic 
alterations across HCC samples, thus suggesting genetic heterogeneity of HCC depending 
on the initiating agents. For example, genes encoding components of the chromatin-
remodelling complexes are frequently mutated in hepatitis HCV- but not in HBV-
associated HCC (Li, Zhao, et al. 2011). They also revealed a strong dependence of the 
acquired mutation signature on the underlying mutagenic mechanism (Zhang 2012). For 
example, the exposure to different genotoxic chemicals produces distinct mutation 
patterns, namely C:G to A:T transversions in the case of aflatoxin (Fujimoto, et al. 2012; 
Guichard, et al. 2012; Huang, et al. 2012), and T:A to A:T transversions in the case of 
aristolochic acid and vinyl chloride  (Huang, et al. 2012). Moreover, the integration of the 
viral DNA in the host genome has been observed in HBV- but not in HCV-associated 
HCCs (Brechot, et al. 1980; Fujimoto, et al. 2012; Jiang, et al. 2012; Sung, et al. 2012). 
These data clearly show that HCC has a complex pathogenesis, which translates into the 
heterogeneous genomic landscape of these tumours as a consequence to mutagens, 
inflammation and sustained regeneration that all cooperate to promote cancer. 
 
1.3 External factors as oncogenic events of hepatocellular carcinoma 
HCC is a multistep process that involves the progressive accumulation of different 
genetic alterations as a response to mutagens including hepatitis B and C viral infections, 
aflatoxin, alcohol or metabolic diseases. The viral-associated mechanisms driving liver 
cancer are complex. Hepatitis B and C viruses (HBV and HCV, respectively) may help in 
development of cancer either through direct involvement in the transformation or in 
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indirect ways by triggering immune response of the host. HBV infection has been reported 
to promote carcinogenesis through three mechanisms: (i) genomic instability or alteration 
in the function of genes by integration of HBV DNA into the host genome; (ii) modulation 
of cell proliferation and viability due to expression of viral proteins; and (iii) increase in 
genetic damage due to hepatic inflammation caused by virus specific T cells (Sung, et al. 
2012). The direct involvement of HBV in HCC development has been supported by its 
DNA integration in the host genome. DNA integration of HBV in host genome has been 
associated with microdeletions affecting cancer-related genes like telomerase reverse 
transcriptase (TERT), platelet-derived-growth-factor receptor (PDGFRβ), platelet-derived-
growth-factor (PDGFβ), mitogen activated protein kinase 1 (MAPK1), and the activation 
of proto-oncogenes of the myc family, predominantly the N-myc2 oncogene (Farazi and 
DePinho 2006; Kremsdorf, et al. 2006). Additionally, transcriptional activity of hepatitis 
protein x (HBx) has been reported to bind and inactivate p53, resulting in increased 
cellular proliferation and survival (Ueda, et al. 1995). HBx also transactivates many 
growth control genes such as SRC tyrosine kinases, Ras, Raf, MAPK, ERK, JNK and 
others (Farazi and DePinho 2006).  
Unlike HBV, HCV does not integrate in the host DNA. HCV alters host genes 
expression and cellular phenotypes by expression of viral proteins (Levrero 2006) or due to 
inflammatory responses to the oxidative stress as a result of persistent infection (McGivern 
and Lemon 2011). The core proteins and non-structural (NS) proteins, NS3 and NS5A 
have been reported to directly contribute to the oncogenic transformation (Arzumanyan, et 
al. 2013). HCV core proteins have been shown to interact with components of the MAPK 
signalling pathway (such as ERK, MEK and Raf) and NS5A has been shown to inactivate 
p53 by sequestration to the perinuclear membrane (Farazi and DePinho 2006).  
Aflatoxin B1 is a mycotoxin produced by fungi: Aspergillus flavus and Aspergillus 
parasiticus. It usually causes base mutations that may lead to DNA break and oxidative 
damage (Hussain, et al. 2007; Hamid, et al. 2013). For example, it has been shown to have 
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positive association with G:C to T:A transversion in the codon 249 of TP53 (249
ser
, 
arginine to serine) (Hussain, et al. 2007). Other external factors such as alcohol and 
metabolic diseases are often associated with oxidative stress and cirrhosis (Seitz and 
Stickel 2007; Marra, et al. 2008).  
Regardless of the initiating agent, HCC is believed to occur due to increased liver 
cell turnover, induced by chronic liver injury and regeneration, in a context of 
inflammation and oxidative DNA damage (Levrero 2006) (Figure 4).  
 
 
Figure 4: Pathogenesis of HCC 
Shown are the etiological agents and known pathways regulating cell proliferation or apoptosis that 
are affected in HCCs. Dysplastic nodules and macroregenerative nodules are considered as pre-
neoplastic lesions. All HCCs, irrespective of the etiological agent are secondary to inflammation 
(highlighted in red). Taken from (Levrero 2006). 
 
1.4 Inflammation and cancers 
Chronic inflammation has been causally associated with cancer by Rudolf Virchow 
as early as in the 19th century, and is nowadays acknowledged as one of the major risk 
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factors for malignancies (Balkwill and Mantovani 2001). The inflammatory state of 
tumour cells is one of the enabling characteristics that confer the acquisition of alterations 
in the eight hallmarks of cancer (Hanahan and Weinberg 2000, 2011) (Figure 5). Chronic 
inflammation is linked to a variety of cancers including liver, colon, gastric, bladder, 
cervical, oesophageal, ovarian, prostate and thyroid cancers (Mantovani, et al. 2008). 
Inflammatory components (cells, cytokines and chemokines) infiltrate the 
microenvironment of most tumour lesions and have tumour-promoting effects (Mantovani, 
et al. 2008). As a consequence, several anti-inflammatory drugs have been reported to 
prevent tumour onset or to delay tumour progression and are currently used to treat cancer 
(Ulrich, et al. 2006). Furthermore, many interesting insights have been uncovered on the 
molecular events linking chronic inflammation to tumour formation and development. The 
emerging picture suggests a feedback loop between tumours and inflammatory responses. 
Activated innate immune cells stimulate tumour growth and progression via secretion of 
cytokines and pro-inflammatory mediators. Cancer cells in return produce soluble 
mediators that again recruit and activate inflammatory cells, further promoting tumour and 
thus creating a feedback loop (Grivennikov, et al. 2010).  
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Figure 5: Hallmarks of cancer 
Tumour cells are characterized by the acquisition of eight functional capabilities: self-sufficiency 
in growth signals, insensitivity to antigrowth signals, evasion from apoptosis, limitless replicative 
potential, sustained angiogenesis, tissue invasion and metastasis, reprogramming the energy 
metabolism and evading immune suppression. Genome instability and chronic inflammation are 
enabling characteristics that promote the tumour progression. Taken from  (Hanahan and Weinberg 
2000, 2011). 
 
 
Despite its primary role, a clear evidence of a direct mutagenic potential of 
inflammation in cancer is still missing. An inflammatory microenvironment has been 
proposed to increase DNA damage leading to genomic instability through reactive oxygen 
species (ROS) and reactive nitrogen intermediates (RNI) (Elinav, et al. 2013). ROS and 
RNI are activated by macrophages and neutrophils or are induced intracellularly in pre-
malignant cells by inflammatory cytokines  (Mantovani, et al. 2008). They then react with 
DNA packed into chromatin after having diffused through the extracellular matrix, 
penetrated a cell, crossed its cytoplasm, and entered the nucleus. The stability and 
longevity of ROS and RNI released by inflammatory cells and their ability to react with 
chromatin is still a matter of controversy (Grivennikov, et al. 2010).   
 
1.4.1 Role of inflammation in hepatocellular carcinoma 
The majority of HCCs arise in the background of chronic liver injury including 
chronic hepatitis and cirrhosis (Laurent-Puig and Zucman-Rossi 2006). Recent studies 
have indicated that the inflammatory reaction is characteristic of chronic liver injury and 
actively participates in the development of hepatic fibrosis, as well as in the activation of 
the potent regenerative response of liver parenchyma. Inflammation-related signalling 
pathways have been implicated in liver tumour initiation and progression. These include 
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transcription factors of the NF-κB family, signal transducer and activator of transcription 3 
(STAT3), cytokines such as TNF-α, IL-6 and IL-1a and ligands of the epidermal growth 
factor receptor (EGFR) (Berasain, et al. 2009; Alison, et al. 2011) (Figure 6).  
 
Figure 6: Molecular pathways linking inflammation and liver cancer 
Shown are the molecules and signalling pathways that have been associated with liver cirrhosis and 
HCC. The critical components linking inflammation and liver cancer are the transcription factors of 
the NF-κB family, signal transducer and activator of transcription 3 (STAT3), cytokines such as 
TNF-α, IL-6 and IL-1a and ligands of the epidermal growth factor receptor (EGFR). Taken from 
(Berasain, et al. 2009). 
 
 
TNF-α plays an important role in the promotion of HCC in mice induced by 
choline-deficient and ethionine-supplemented diet and also in Mdr2-KO mice, a genetic 
mouse model for inflammation related HCC (Berasain, et al. 2009). NF-κB is known to 
play dual role in the development of liver cancer. Its activation has been associated in the 
liver during neoplastic transformation whereas its hepatocyte-specific inactivation has been 
shown to lead to higher incidence of liver tumours upon treatment with the carcinogen 
DEN (Maeda, et al. 2005). In addition, loss of hepatocyte NF-κB activity enhances 
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chemical carcinogenesis through sustained c-Jun-N-terminal kinase 1 (JNK1) activation 
(Berasain, et al. 2009). High circulating IL-6 levels have been observed in inflammatory 
conditions of the liver, including chronic alcohol consumption, viral infections, or hepatic 
iron accumulation in HCC patients (Naugler and Karin 2008). Furthermore, IL-6 binding 
triggers JAK-STAT3 signalling pathway, which is enhanced in hepatic inflammation and 
HCC (Berasain, et al. 2009).  Similar to cytokines, activation of growth factors expression 
and signalling such as insulin-like growth factor (IGF), hepatocyte growth factor (HGF), 
Wingless (Wnt), transforming growth factor beta (TGFβ), and the EGFR signalling system 
is frequently observed in chronic inflammatory liver diseases and HCC (Breuhahn, et al. 
2006). Though signalling pathways related to inflammation have been liked to tumour 
initiation and progression in liver cancer, the direct potential of inflammation in inducing 
genomic alterations is still unknown. 
 
1.5 Hepatocellular carcinoma induced by defects in biliary transporter genes 
Bile is a vital secretion of liver and is essential for intestinal digestion, absorption 
of lipids and elimination of environmental toxins, carcinogens, drugs, and their 
metabolites. Formation and flux of bile in the liver are maintained by distinct transport 
systems: basolateral (sinusoidal) transport and apical (canalicular) transport (Pauli-Magnus 
and Meier 2005) (Figure 7).  
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Figure 7: Hepatocyte bile transporters 
Shown are the hepatobiliary transporter systems. Basolateral transport system includes MRP1, 
MRP3, MRP4, MRP5, MRP6, NTCP, OATP1A2, OATP1B3, OATP1B1, OATP2B1, OCT1 and 
OAT2. Apical transport system includes MRP2, ABCG5, ABCG8, BSEP, MDR1, MDR3, BCRP 
and FIC1. Efflux transporters are represented in blue and uptake transporters are represented in red. 
Bile salts (BS
-
) are taken via basolateral transporters (NTCP) and organic anions by OATPs ( 
OATP1A2, OATP1B3, OATP1B1 and OATP2B1). MDR3 translocates phosphatidylcholine from 
the inner to the outer leaflet. BSEP excrete the monovalent bile salts while MRP2 excretes organic 
anion conjugates and divalent bile salts. Other MRPs: MRP1, MRP2, MRP4, MRP5 and MRP6 are 
involved in the efflux of organic anions. BS=bile salts; OC= organic conjugates; BA=bile acids; 
OA= organic anion. Taken from (Pauli-Magnus and Meier 2006). 
 
 
Basolateral transporters are involved in hepatic uptake of endogenous and 
exogenous substances from sinusoidal blood plasma. So far, two key players have been 
identified: the sodium dependent pathway represented by the sodium-taurocholate 
cotransporting polypeptide NTCP (SLC10A1) and the sodium independent pathways 
represented by different members of the superfamily of organic anion transporting 
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polypeptides (OATP/SLCO) (Pauli-Magnus and Meier 2005) (Figure 7).  NTCP uptake is 
mostly limited to conjugated bile salts and certain sulphated steroids. NTCP accounts for 
more than 80% of conjugated bile salts uptake in the liver (Pauli-Magnus and Meier 2006). 
The OATP superfamily comprises of 9 human members, many of which are present at 
different expression levels in liver (Hagenbuch and Meier 2004). These transporters are 
involved in the trafficking of several metabolites, conjugated and unconjugated bile salts, 
bromosulfophthalein, neutral steroids, steroid sulfates and glucuronides, and selected 
organic cations (Pauli-Magnus and Meier 2006). They are also involved in uptake of many 
drugs including antihistamine fexofenadine, opioid peptides, digoxin, the HMG CoA-
reductase inhibitor pravastatin, the angiotensin-converting enzyme inhibitor enalapril, and 
the antimetabolite methotrexate. Finally, they aid in the uptake of hepatotoxins phalloidin, 
microcystin and amanitin. Basolateral system also localizes adenosine triphosphate (ATP)-
dependent efflux pumps belonging to the multidrug resistance-associated proteins (MRPs) 
(ABCC): MRP1 (ABCC1), MRP3 (ABCC3), MRP4 (ABCC4), MRP5 (ABCC5), and MRP6 
(ABCC6) (Pauli-Magnus and Meier 2005) (Figure 7). These proteins are multispecific 
transporters for different organic anions. All basolateral transporter genes are extensively 
regulated by transcriptional and posttranscriptional processes that allow adaptation to 
changes in response to the intracellular accumulation of bile salts (Pauli-Magnus and 
Meier 2006). 
Apical (canalicular) transporters mediate the secretion of bile salts and other bile 
constituents across the canalicular membrane of hepatocytes. These are ATP-binding 
cassette transporters that use ATP to pump solutes into bile against steep concentration 
gradients. The members of ABC transporters that are expressed in liver include MRP2 
(ABCC2), ABCG2 (ABCG2), ABCG5 (ABCG5) ABCG8 (ABCG8) MDR1 (ABCB1), 
MDR3 (ABCB4) and BSEP (ABCB11), (Table 2, Figure 7). Multi-drug resistance protein 2 
(MRP2) is a member of multidrug resistance-associated proteins family that recognizes a 
wide spectrum of organic anions, including bilirubin-diglucuronide, glutathione 
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conjugates, leukotriene C4, and divalent bile salt conjugates. ABCC2 encodes MRP2 and 
impairment of this gene due to inactivating mutations causes Dublin-Johnson syndrome 
(Kartenbeck, et al. 1996; Keitel, et al. 2000). ATP-binding cassette sub-family G member 
5 (ABCG5) and ATP-binding cassette sub-family G member 8 (ABCG8) genes are 
involved in excretion of sterols and cholesterol (Figure 7). Mutations in these genes result 
in decreased biliary excretion causing sitosterolemia leading to hypercholesterolemia and 
premature atherosclerosis (Lu, et al. 2001) (Table 2). ABCB1 encodes MDR1 and is 
involved in transporting amphipathic basic or cationic compounds (Figure 7). Though no 
known disease has been associated with defects in this gene in humans, Abcb1 knockout 
mice are reported to be hypersensitive to many drugs and toxins (Schinkel, et al. 1995). P-
glycoprotein 3 (MDR3) and the bile salt export pump (BSEP) are highly conserved 
members of multidrug resistance protein family (Pauli-Magnus and Meier 2005). They 
have been identified as the key players in the secretion of bile salts and other bile 
constituents across the canalicular membrane of hepatocytes (Pauli-Magnus, et al. 2004). 
ABCB11 encodes BSEP, and mediates the cellular excretion of numerous conjugated bile 
salts such as taurine- or glycine-conjugated cholate, chenodeoxycholate, and deoxycholate 
and is the predominant bile salt efflux system of hepatocytes (Figure 7). MDR3 is encoded 
by ABCB4, which translocates phosphatidylcholine from the inner to the outer leaflet of 
the canalicular membrane (Figure 7). Another transporter, FIC (ATP8B1) has been 
reported to regulate the enterohepatic bile salt pool and eliminate the hydrophobic 
substances from the enterohepatic circulation (Pauli-Magnus and Meier 2005). Defects in 
the three genes (ABCB4, ATP8B1 and ABCB11), involved in the regulation and formation 
of bile salts cause progressive familial intrahepatic cholestasis (PFIC) (Davit-Spraul, et al. 
2009; Jacquemin 2012). 
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Table 2: Human canalicular transporter proteins and associated diseases 
Name Gene Chromosome Transport Function Disease 
MRP2 ABCC2 10q24 OA Dublin-Johnson syndrome 
ABCG2 ABCG2 4q22 Multispecific - 
ABCG5 ABCG5 2p21 Sterols Sitosterolemia 
ABCG8 ABCG8 2p21 Sterols Sitosterolemia 
MDR1 ABCB1 7q21 Multispecific - 
MDR3 ABCB4 7q21 PC PFIC3 
BSEP ABCB11 2q24 BS PFIC2 
Reported are the names of the canalicular transporter proteins, gene name, location in the human 
genome, substrate for transporting function and the associated disease. Overexpression of MDR1 
and ABCG2 confers resistance to drugs and inherited defects in the other transporter genes lead to 
diseased state. PC= phosphatidylcholine, BS= bile salts, OA=organic anions, PFIC=progressive 
familial intrahepatic cholestasis.  
 
1.5.1 Bile salt export pump deficiency and paediatric hepatocellular carcinoma 
PFIC designates a heterogeneous group of rare autosomal recessive disorders that 
usually appear in infancy or early childhood and manifest with hepatocellular damage and 
cholestasis due to defects in bile formation (Jacquemin 2012). Three types of PFIC 
(PFIC1, PFIC3 and PFIC2) have been identified and have been associated with inherited 
inactivating mutations in the hepatocyte membrane transporter genes ATP8B1, ABCB4, 
and ABCB11 respectively (Davit-Spraul, et al. 2009; Jacquemin 2012) (Figure 8).  
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Figure 8: Progressive familial intrahepatic cholestasis 
Shown are the types of PFIC and the corresponding mutated genes involved in its development 
along with the function of the gene in the liver. Impairment of ABCB11 (highlighted in red) in 
humans and ABCB4 ortholog in mouse leads to tumour development in the respective species. 
Taken from (Davit-Spraul, et al. 2009) 
 
 
PFIC1 or “Byler disease” is caused by mutations in the ATP8B1 gene (Figure 8). 
This gene encodes a P-type ATPase (FIC1) and is located on the canalicular membrane of 
hepatocytes (Figure 7).  It is mainly expressed in cholangiocytes within the liver. The exact 
mechanism of how mutations in this gene cause cholestasis is unclear. It is assumed that 
the abnormal protein function of FIC1 could indirectly disrupt the biliary secretion of bile 
acids.  This is in agreement with the low biliary bile acid concentrations and the chronic 
diarrhoea present in PFIC1 patients (Jacquemin 2012). Studies have also reported 
substantial down-regulation of the farnesoid X receptor (FXR) in PFIC1 patients with 
mutations in ATP8B1. FXR is a nuclear receptor, which is involved in the regulation of 
bile acid metabolism. Low expression level of FXR subsequently down-regulates BSEP in 
the liver and up-regulates bile acid synthesis and apical sodium bile salt transporter 
(ASBT) in the intestine (Alvarez, et al. 2004; Chen, et al. 2004) leading to hepatocyte bile 
acid overload (Jacquemin 2012).  
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PFIC2 is caused by inherited mutations in the ABCB11 gene (Table 2, Figure 8). 
ABCB11 gene encodes ATP-dependent canalicular BSEP, which is the major exporter of 
primary bile acids (Figure 7 and Figure 8). It is expressed at the hepatocyte canalicular 
membrane in human liver (Davit-Spraul, et al. 2009; Jacquemin 2012). Impairment of 
BSEP causes decrease in biliary bile salts secretion leading to decreased bile flow and 
accumulation of bile salts within the hepatocyte resulting in severe hepatocellular damage 
(Davit-Spraul, et al. 2010). BSEP deficiency represents a phenotypic continuum between 
PFIC2 and a milder form of the disease, known as benign recurrent intrahepatic cholestasis 
(BRIC2) (van Mil, et al. 2004). 
PFIC3 represents an important example of canalicular transport defect leading to 
the development of cholangiopathy. It is caused by defects in ABCB4 gene (Table 2, 
Figure 8). ABCB4 encodes class III multidrug resistance (MDR3) of P-glycoprotein (P-gp) 
protein. MDR3 is a phospholipid translocator, which is involved in the excretion of biliary 
phospholipid and is predominantly expressed in the canalicular membrane of hepatocytes 
(Davit-Spraul, et al. 2010) (Figure 7 and Figure 8). PFIC3 is caused by injuries to bile 
canaliculi and biliary epithelium as a result of the toxicity of bile in which detergent bile 
salts are not inactivated by phospholipids. This suggests that the mechanism of liver 
damage in PFIC3 is most likely related to the absence of biliary phospholipids (Jacquemin 
2012).  
Patients with PFIC2 and PFIC3 may develop liver tumour and monitoring of liver 
cancer in these patients is usually advised (Jacquemin 2012). In particular, PFIC2 patients 
are at high risk of hepatobiliary malignancy (hepatocellular carcinoma or 
cholangiocarcinoma) (Jacquemin 2012). Fatal peripheral cholangiocarcinoma due to 
inherited mutations in ABCB11 in the absence of BSEP expression was observed in some 
PFIC2 patients (Scheimann, et al. 2007). Another study on PFIC2 with severe BSEP 
deficiency reported presence of hepatocellular carcinoma or cholangiocarcinoma in 15% of 
the patients (Strautnieks, et al. 2008). In particular, two protein-truncating mutations in 
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BSEP conferred particular high risk (38%) to develop malignancy compared to less severe 
genotypes (Strautnieks, et al. 2008). These findings further support that BSEP deficiency is 
associated with increased susceptibility to hepatobiliary malignancy. BSEP deficiency is 
hypothesized to cause cholangiocarcinoma through bile-composition shifts or bile-acid 
damage within cells capable of hepatocytic/cholangiocytic differentiation (Scheimann, et 
al. 2007). Bile acids induce mutation via production of ROS and RNS (Bernstein, et al. 
2005). Damage induced by intrahepatocytic accumulation of bile acids is hypothesized to 
lead to hepatocellular carcinoma (Knisely, et al. 2006). This suggests, that the loss of 
functional BSEP results in intrahepatocytic accumulation of bile acids causing liver injury 
resulting in chronic inflammation and to the early onset of hepatocellular carcinoma 
(Knisely, et al. 2006). Since HCCs caused by inactivating mutations in ABCB11 occur in 
the background of chronic inflammation and fibrosis in absence of external mutagens, this 
liver cancer type provides the opportunity to understand the contribution of chronic 
inflammation and fibrosis to the acquired genomic modifications that trigger liver cancer 
in the absence of other mutagenic factors.   
 
1.5.2 Mdr2-KO mouse model of hepatocellular carcinoma 
Mdr2 is a bile transporter gene in mouse, which is an ortholog of human ABCB4 
gene. Homozygous disruption of Mdr2 in mouse has been shown to result in nonsupportive 
inflammatory cholangitis and HCCs (Mauad, et al. 1994). Mdr2-KO mice lack the Mdr2 
encoded P-glycoprotein located on the canalicular membrane of hepatocytes and are 
therefore unable to secrete phosphatidylcholine into bile ducts. The resulting precipitation 
of bile salts induces hepatocellular damage, inflammation and eventually HCC with high 
penetrance (Smit, et al. 1993; Mauad, et al. 1994). In Mdr2-KO mice, HCC progresses 
through well-defined temporal stages starting with inflammation, which then develops into 
dysplasia (from 4 months of age), adenoma-like dysplastic nodules  (7 months) and 
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eventually HCC starting from 10 months that is detectable in virtually 100% of mice by 16 
months of age (Pikarsky, et al. 2004; Katzenellenbogen, et al. 2007) (Figure 9). Moreover, 
since HCCs arise within adenomas (Jang, et al. 1992), each neoplastic nodule offers a 
screenshot of the adenoma-to-carcinoma transition and displays a variable HCC fraction, 
which tends to increase with time. 
 
 
 
Figure 9: Mdr2-KO mice develop HCC on the background of chronic hepatitis 
Shown are the livers of WT and KO mice sacrificed at the indicated time points. Arrowheads 
indicate tumours. Scale in cm (a). Hematoxylin and eosin (H&E) stained sections from livers from 
WT and KO mice of the indicated time points are shown. At 4 months, inflammation and ductular 
proliferation are prominent. At 7 months, there is severe architectural and cytologic dysplasia and 
HCC develops between 9-12 months (highlighted in red), which later disseminates metastases (b). 
The presence of T-cells in the mixed inflammatory infiltrate is highlighted by CD3 immunostaining 
(c). Scale Bars=50 mm. Taken from (Pikarsky, et al. 2004) 
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1.6 Genomic copy number alterations 
1.6.1 Definition and mechanisms of formation 
Copy number variations (CNVs) were first defined as DNA segments of one 
kilobases (kb) or more that are present at variable copy numbers when compared to the 
reference genome (Feuk, et al. 2006). In recent times the description of CNVs has widened 
to include genomic changes as short as 50 bases (Alkan, et al. 2011). CNVs can be broadly 
classified into three classes: amplifications, deletions and insertions (Figure 10). 
Amplifications are described as gains in copy number of a genomic region or chromosome 
(Figure 10). They can be tandem when present in adjacent regions or interspersed when 
separated or distributed along the same chromosome (intrachromosomal) or distinct 
chromosomes (interchromosomal). Deletions are defined as loss of gene copies (Figure 
10). Deletions can be heterozygous (loss of one allele) or homozygous (loss of both 
alleles). Insertions are integration of new genomic DNA (Figure 10). 
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Figure 10: Classes of copy number variations 
Shown are the three classes of CNVs. A gene or region of the genome (DNA segment) can undergo 
amplifications (copy number gains) or deletions (copy number losses) or may have insertion 
events. Amplifications can be interspersed or tandem duplications. 
 
 
So far, four mechanisms have been reported (non-allelic homologous 
recombination (NAHR), non-homologous end joining (NHEJ), fork stalling and template 
switching (FoSTeS), and L1-mediated retrotransposition) for the formation of the majority 
of CNVs (Zhang, et al. 2009) (Figure 11, 12, 13, 14). NAHR is homologous recombination 
event induced by DNA double strand breaks (DSBs) and uses incorrect template for DNA 
repair (Figure 11). Studies have shown that NAHR preferentially occurs at hotspots inside 
low-copy repeats (LCRs) (Lupski 2004) and the segmental duplications caused by NAHR 
are between two LCRs (Stankiewicz and Lupski 2002). High sequence identity of non-
allelic regions and subsequent crossover in the same chromosome may lead to tandem 
duplications and/or deletions when present in direct orientation (Figure 11) (Stankiewicz 
and Lupski 2002; Gu, et al. 2008; Hastings, Lupski, et al. 2009). A crossover between 
direct and inverted repeats in the same chromosome leads to deletions and inversions. 
Instead, crossovers between different chromosomes can result in chromosomal 
translocations (Stankiewicz and Lupski 2002; Gu, et al. 2008; Hastings, Lupski, et al. 
2009). Although restricted to late S or G2 (Lieber 2008), NAHR can occur in both meiotic 
as well as mitotic cells (Gu, et al. 2008). Homologous recombination events involving 
crossing over between homologous chromosomes can lead to loss of heterozygosity (LOH) 
if the same alleles segregate together at mitosis (Hastings, Lupski, et al. 2009). 
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Figure 11: Mechanism of non-allelic homologous recombination (NAHR) 
Shown is the mechanism of NAHR that occurs by unequal crossing over between flanking 
segmental duplications (represented by two red and two green bars on respective homologous 
chromosomes) resulting in reciprocal deletion and duplication of intervening sequence. LCR= low-
copy repeat. Taken from (Malhotra and Sebat 2012). 
 
 
NHEJ is one of the main mechanisms to repair DSBs in eukaryotic cells. It 
proceeds in four steps: i) detection of DSB; ii) bridging of the broken DNA ends; iii) 
modification of DNA ends to make them compatible for ligation; and iv) ligation of the 
DNA ends (Gu, et al. 2008) (Figure 12). NHEJ goes through many rounds of enzymatic 
activity.  DNA ends are first recognized by the Ku protein and followed by recruitment of 
DNA-dependent protein kinase (DNA-PKcs). DNA-PKcs then mediate the activation of 
the Artemis nuclease, which trims back overhangs in preparation for ligation. Finally, 
ligation of the DNA ends is done by DNA ligase IV. Unlike NAHR, NHEJ does not 
require homology and rejoins DNA ends accurately or with small deletions. Alternatively 
it can also cause insertion of free DNA (Hastings, Lupski, et al. 2009). NHEJ can occur 
 32 
throughout the cell cycle (Lieber 2008). Microhomology mediated end-joining (MMEJ) 
also known as alternative non-homologous end-joining, repairs DNA breaks via the use of 
microhomology and always results in deletions (McVey and Lee 2008; Hastings, Ira, et al. 
2009) (Figure 12). MMEJ uses 5–25 base pair (bp) microhomologous sequences during the 
alignment of broken ends before joining, thereby resulting in deletions flanking the 
original break (McVey and Lee 2008). Unlike NHEJ, MMEJ uses Ku80 as the DNA 
binding protein (Hastings, Lupski, et al. 2009). 
 
Figure 12: Mechanism of non-homologous end joining (NHEJ) 
Shown is the mechanism of DNA repair by NHEJ. The different types of DNA double-strand 
breaks fixed by NHEJ combined with other alternate repair mechanisms, including microhomology 
mediated end-joining (MMEJ), leads to diverse repaired products. Taken from (Malhotra and Sebat 
2012) and (Downs, et al. 2007). 
 
 
FoSTeS has been reported to explain nonrecurrent and complex genomic 
rearrangements (Lee, et al. 2007).  According to this DNA replication model (Figure 13), 
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when a replication fork encounters a nick in a template strand, one arm of the fork breaks 
off, thus producing a collapsed fork. At the single double-strand end, the 5′ end of the 
lagging strand is resected, giving a 3′ overhang. The 3′ single-strand end of lagging-strand 
template invades the second fork guided by regions of microhomology, forming a new 
low-processivity replication fork (Gu, et al. 2008). The extended end may dissociate and 
invade new forks repeatedly to form complex rearrangements (Lee, et al. 2007). Template 
switch occurring in front of or behind the position of the original collapse leads to deletion 
or duplication respectively (Malhotra and Sebat 2012). Microhomology-mediated break-
induced replication (MMBIR) is a further generalized model of FoSTeS. MMBIR is used 
to repair DNA breaks when stretches of single-stranded DNA are available and share 
microhomology with the 3′ single-strand end from the collapsed fork (Hastings, Ira, et al. 
2009).  
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Figure 13: Mechanism of fork stalling and template switching (FoSTeS) 
Shown is the mechanism of FoSTeS. FoSTeS occurs as a consequence of single strand breaks and 
invasion to other template strands for DNA synthesis resulting in complex genomic 
rearrangements. Taken from (Malhotra and Sebat 2012). 
 
 
L1 are the only autonomous transposable elements in the human genome. L1-
mediated retrotransposition causes rearrangements in the genome via RNA-mediated 
mechanisms. Though the mechanism is not clearly understood, it has been proposed to 
occur in five steps (Cordaux and Batzer 2009).  In the first step, genomic L1 is transcribed 
by RNA polymerase II from an internal promoter that directs transcription initiation at the 
5′ boundary of the L1 element. The L1 RNA is next exported to the cytoplasm where 
ORF1 (encoding an RNA-binding protein) and ORF2 (encoding a protein with 
endonuclease and reverse-transcriptase activities) are translated. Both proteins exhibit 
strong cis-preference and preferentially associate with the L1 RNA transcript that encoded 
them, to produce a ribonucleoprotein (RNP) particle. The RNP is then transported back 
into the nucleus by a mechanism that is poorly understood. L1 element is then integrated 
into the genome mostly likely by target-primed reverse transcription (Figure 14). 
Hallmarks of the integration process include frequent 5′ truncations, presence of an oligo 
dA-rich tail at the 3′end, and 2-20 bp-long duplications of the target site (Cordaux and 
Batzer 2009). 
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Figure 14: Mechanism of L1-reterotransposition mediated DNA repair 
Shown is the mechanism of L1-reterotransposition mediated DNA repair. L1 elements are 
transcribed and inserted into the DNA target site. Taken from (Malhotra and Sebat 2012). 
ORF=open reading frame 
 
1.6.2 Copy number variations in evolution and diseases 
CNVs have been suggested to play a major driving role in evolution (Redon, et al. 
2006; Zhang, et al. 2009). Gene duplication was proposed as the easiest way to produce 
new genes as early as 1970 by Susumu Ohno (Ohno 1970; Wolfe 2001). CNVs account for 
~12% of variability in human genome (Redon, et al. 2006). CNVs that reach a population 
frequency of greater than 1% are referred to as copy number polymorphisms (Redon, et al. 
2006). CNVs contain hundreds of genes and other functional elements. Significant 
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relationship between the genomic regions affected by CNVs and gene content has been 
reported (Cooper, et al. 2007). For instance regions with high gene density are enriched for 
CNVs (Cooper, et al. 2007). Additionally, CNVs in humans have been reported as 
enriched for olfactory and immunity genes as well as in genes encoding secreted proteins 
(Nguyen, et al. 2006). Furthermore, comparable studies of CNVs between humans and 
chimpanzees have identified functional categories of genes that are likely fixed by positive 
selection and involved in the adaptive phenotypic differentiation between the two species. 
These genes are particularly involved in inflammatory response and cell proliferation 
(Perry, et al. 2008). Moreover, selective advantages of CNVs in genes such as the salivary 
amylase gene, AMY1, the chemokine CCL3L1 and the α-globin have been reported in 
humans (Higgs, et al. 1989; Gonzalez, et al. 2005; Perry, et al. 2007). The average copy 
number of AMY1 in populations with high intake of starch is higher in comparison to 
populations with low intake (Perry, et al. 2007). High copy number of CCL3L1 has been 
proposed to reduce the risk of HIV infection (Gonzalez, et al. 2005) while heterozygous 
deletion of α-globin confers resistance to malaria (Higgs, et al. 1989).  
CNVs can alter transcription of genes by altering dosage, disrupting proximal or 
distant regulatory regions or through perturbation of transcript structure (Henrichsen, 
Chaignat, et al. 2009)  (Figure 15). For example, genes undergoing amplifications or 
deletions may be over-expressed or under-expressed, respectively (Figure 15).  A weak, 
yet positive correlation between CNVs and gene expression has been reported in mouse 
and rats (Guryev, et al. 2008; Henrichsen, Vinckenbosch, et al. 2009). CNVs have also 
been reported to influence the expression of genes located in their vicinity (Guryev, et al. 
2008; Henrichsen, Vinckenbosch, et al. 2009). For example, deletions affecting silencers 
or insulator elements may result in increased gene expression of the transcript 
(Weischenfeldt, et al. 2013). Furthermore, CNVs have been identified as a key contributor 
to natural phenotypic variations (Cahan, et al. 2009).  
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Figure 15: Effect of CNVs on expression 
Shown are the possible ways in which expression of genes may be influenced due to CNVs. A) 
Amplification or deletion of gene may result in over-expression or under-expression. Gene 
expression can also be affected by a deletion of the allele that masks a recessive mutation. B) 
CNVs may disrupt genes either by deletion or amplification, resulting in reduced expression of 
genes. C) Expression of genes can also be altered by the deletion of important regulatory elements 
or of the allele masking a functional polymorphism within an effector. Taken from (Feuk, et al. 
2006). 
 
 
CNVs have been associated with many genetic disorders and complex diseases, 
including glomerulonephritis, autism, and schizophrenia (Table 3). For example, deletion 
of Fc fragment of IgG, low affinity IIIb, receptor (CD16b) (FCGR3B) has been associated 
with glomerulonephritis (Aitman, et al. 2006). Amplification of protease, serine, 1 (trypsin 
1) (PRSS1) has been associated with the onset of hereditary pancreatitis (Le Marechal, et 
al. 2006).   
 
Table 3: CNVs associated with genetic and complex diseases 
Disease Gene / Locus CNV Reference 
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Disease Gene / Locus CNV Reference 
Alzheimer APP Amplification (Rovelet-Lecrux, et al. 2006) 
Autism 16p11.2 
Amplification 
/ deletion (Weiss, et al. 2008) 
Autoimmunity FCGR3B Deletion (Fanciulli, et al. 2007)  
Body mass index NEGR1 Deletion (Willer, et al. 2009)  
Charcot–Marie–Tooth 
neuropathy type 1 17p11.2 
 
Amplification (Raeymaekers, et al. 1991) 
Crohn's disease of the 
colon DEFB4 Deletion (Fellermann, et al. 2006)  
Crohn's disease IRGM Deletion (McCarroll, et al. 2008) 
Epilepsy 15q13.3 Deletion (Helbig, et al. 2009)  
Glomerulonephritis FCGR3B Deletion (Aitman, et al. 2006)  
Hereditary pancreatitis PRSS1 Amplification (Le Marechal, et al. 2006) 
IMR 15q13.3 Deletion 
(Mefford, et al. 2008; Sharp, et 
al. 2008)  
IMR 1q21.1 Deletion (Mefford, et al. 2008)  
Parkinson's SNCA Amplification (Singleton, et al. 2003)  
Psoriasis LCE3C Deletion (de Cid, et al. 2009)  
Schizophrenia 15q13.3 Deletion 
(International Schizophrenia 
2008; Stefansson, et al. 2008)  
Schizophrenia 1q21.1 Deletion 
 (International Schizophrenia 
2008; Stefansson, et al. 2008) 
Schizophrenia 22q11.2 Deletion (Bassett, et al. 2008) 
Susceptibility to HIV-1 CCL3L1 Deletion (Gonzalez, et al. 2005)  
Systemic lupus 
erythematosus C4 Deletion (Yang, et al. 2007) 
Reported are the diseases, genes/locus, type of CNVs and the reference.  
 
1.6.3 Copy number variations and cancer 
Genomic instability has been identified as the most prominent feature of cancer 
cells that may orchestrate the acquisition of cancer hallmark capabilities (Hanahan and 
Weinberg 2011). Somatically acquired amplifications, deletions, and copy neutral loss of 
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heterozygosity (CN-LOH) events frequently occur in cancer (Ciriello, et al. 2013; Zack, et 
al. 2013).  These genomic copy number alterations may occur in a small genomic region of 
the chromosome (focal alterations), or may affect whole chromosome (aneuploidy) or in 
extreme situations may lead to chromosomal instability (CIN) involving abnormal copy 
number states of many chromosomes in the genome (Figure 16) (Tang and Amon 2013). 
 
Figure 16: Genomic copy number alterations in cancer 
Shown are the microscopic (aneuploidy, CIN) and submicroscopic (focal) genomic alterations that 
are observed cancers. Taken from (Tang and Amon 2013). 
 
 
 Somatic CNVs may play passenger or driver roles in tumorigenesis. For instance, 
CIN and aneuploidy observed in retinoblastoma are a consequence of the inactivation of 
retinoblastoma-associated protein and they play a passenger role in cancer development 
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(Zheng and Lee 2002; Gordon, et al. 2012). However, many recurrent CNVs have been 
identified as pathogenic events in solid tumours. For instance, focal amplification of the 
oncogene human epidermal growth factor receptor 2 (HER2) is observed in 30% of breast 
cancers (Slamon, et al. 1987; Cameron, et al. 2008). Similarly, focal amplification of the 
proto-oncogene N-myc, occurs in ~30% of advanced neuroblastomas and is associated with 
rapid tumour progression (Seeger, et al. 1985). Deletion of the tumour suppressor gene 
phosphatase and tensin homolog (PTEN) is observed in 68% of primary prostrate cancer 
(Trotman, et al. 2003; Yoshimoto, et al. 2006). Driver CNVs, tend to reside in the same 
genomic regions across different cancers, especially focal modifications (Beroukhim, et al. 
2010; Kim, et al. 2013; Zack, et al. 2013). High-resolution studies of somatic CNVs across 
multiple cancer types have identified prevalence of arm-level alterations (Beroukhim, et al. 
2010; Kim, et al. 2013; Zack, et al. 2013). Whole-chromosome alterations are recurrently 
observed in several cancer types. For example, gain of chromosome 8 is seen in 10–20% of 
acute myeloid leukaemia, as well as in some solid tumours, including Ewing's Sarcoma 
and desmoid tumours (Qi, et al. 1996; Maurici, et al. 1998; Paulsson and Johansson 2007). 
Trisomy of chromosome 7 harbouring non-random duplication of mutant MET allele has 
been implicated in hereditary papillary renal carcinoma (Zhuang, et al. 1998).  
In addition to somatically acquired CNVs, inherited germline CNVs have also been 
associated with cancer and risk for cancer (Table 4). For example, an inherited CNV of 
NBPF23 is associated with the onset of neuroblastoma (Diskin, et al. 2009).  Similarly, 
deletion at chromosome 2p24.3 was observed to confer stronger risk of aggressive prostate 
cancer (Liu, et al. 2009). Other examples include rare 4q13 duplication in melanoma-
predisposed family, germline microdeletion of 9p21.3 containing KIA1797 and MIR491 
genes in colorectal (Venkatachalam, et al. 2011) and breast cancers (Krepischi, Achatz, et 
al. 2012), respectively. 
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Table 4: Literature review of whole-genome studies associating germline CNVs with 
cancer susceptibility. 
Type of cancer Patients CNVs Germline CNV details Reference 
Familial pancreatic 
cancer
†
 
57 56 
Rare CNVs (not present in the 
DGV and 607 study controls) 
(Lucito, et al. 
2007) 
Familial and early-
onset colorectal 
cancer
†
 
41 7 
Rare CNVs (not present in the 
DGV and 1600 controls from in-
house database) 
(Venkatachalam, 
et al. 2011) 
Familial and early-
onset breast cancer
*
 
68 26 
Rare CNVs (not present in the 
DGV, 100 study controls and 158 
from in-house database) 
(Krepischi, 
Achatz, et al. 
2012) 
Familial melanoma
†
 30 1 
Rare 4q13 duplication (three 
affected individuals from the same 
family; CXC genes) 
(Yang, et al. 
2012) 
Aggressive prostate 
cancer 
498 1 
Recurrent 2p24.3 deletion (12.63% 
in patients in comparison to 8.28% 
in 494 study controls) 
(Liu, et al. 2009) 
Neuroendocrine 
tumours of the ileum 
226 4 
Recurrent 18q22.1 deletion (no 
known genes; (6.19% in patients in 
comparison to 2.06% in 97 study 
controls) 
(Walsh, et al. 
2011) 
Neuroblastoma 846 1 
Recurrent CNV at 1q21.1 (gene 
NBPF23; odds ratio 2.49 [803 
study controls]) 
(Diskin, et al. 
2009) 
Hepatocellular 
carcinoma 
386 6 
Recurrent CNV at 1p36.33 (odds 
ratio 17.0 [687 study controls]) 
(Clifford, et al. 
2010) 
Nasopharyngeal 
carcinoma 
278 8 
Recurrent 6p21.33 deletion (MICA 
and HCP5 genes) Gender-specific 
association (male) 
(Tse, et al. 2011) 
Reported are the type of cancer cohort, number of unrelated patients, relevant CNVs, details on the 
germline CNVs identified and references of the respective studies. Source (Krepischi, Pearson, et 
al. 2012). 
†
Studies of familial cancer or high-risk cancer patients, DGV=Database of Genomic 
Variants.  
 
 
CNVs may contribute to cancer development by altering the expression of tumour 
suppressors, oncogenes or non-coding RNAs such as miRNAs. For instance, amplification 
of oncogene MAPKAPK2 shows increased mRNA and protein expression and is associated 
with an increased risk and poor prognosis for lung cancer in Chinese populations (Liu, et 
al. 2012). RUNX3, a tumour suppressor in gastric cancer is not expressed in 45%-60% of 
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human gastric cancer cells of which around one-third are due to hemizygous deletions (Li, 
et al. 2002). In addition, fusion gene TMPRSS2-ERG formed due to interstitial deletion in 
chromosome 21 is frequently observed in prostrate cancer (Tomlins, et al. 2005). CNVs 
reported in database of genomic variants disrupt nearly 40% of cancer-related genes 
(Shlien and Malkin 2010). Though a linear correlation between CNVs, mRNA and protein 
expressions have not been observed in cancers (Geiger, et al. 2010; Zhang, et al. 2014), 
proteins encoded by amplified oncogenes are often overexpressed (Zhang, et al. 2014).  
 
1.6.4 Methods for detecting copy number variations 
Since CNVs may play an important role in the development of many diseases 
including cancer, their identification is essential for diagnosis and treatment. There are 
three approaches for detecting CNVs: (i) hybridization-based microarrays; (ii) single-
molecule analysis; and (iii) next generation sequencing (NGS) (Alkan, et al. 2011). 
Hybridization-based microarrays are represented by array comparative genomic 
hybridization (aCGH) and single nucleotide polymorphism (SNP) arrays. Microarrays are 
composed of in situ hybridization of fluorescently labelled genomic DNA regions 
corresponding to short or long oligonucleotides (probes). CNVs from microarrays are then 
detected based on the intensity of the fluorescence. In case of aCGH, fluorescently labelled 
genomic DNA from test and reference samples are hybridized to target probes. CNVs are 
then detected based on the signal ratio. In SNP arrays, the genomic DNA of test sample is 
hybridized to short probes with single nucleotide difference. These arrays are used for both 
genotyping and copy number analysis. Though microarrays are cost effective, they are 
limited to identifying CNVs in reference genome that are used for designing the probes 
(Alkan, et al. 2011).  Furthermore, microarrays are less sensitive in detecting single copy 
gains compared to copy loss, thus suggesting bias in detecting CNVs (Greshock, et al. 
2007).   
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Single-molecule analysis includes techniques such as FISH, spectral karyotyping 
and optical mapping that identifies the structure and location of CNVs. These methods are 
particularly useful in identifying balanced structural genomic rearrangements that cannot 
be identified using microarrays. Although these methods are capable to detect novel 
insertions, they have limited throughput and low resolution (Alkan, et al. 2011).  
The advent of NGS has heavily influenced structural variation studies. NGS 
techniques are used for whole genome sequencing (WGS), whole exome sequencing 
(WES) or targeted re-sequencing screenings. NGS allows CNV detection at breakpoint 
resolution and the estimation of absolute copy numbers. Most of the current algorithms use 
read-pair or read depth approach for detecting CNVs (Figure 17). Read-pair methods 
assess the distance between paired-end reads and their orientation in comparison to the 
reference genome to identify CNVs at breakpoint (Tuzun, et al. 2005) (Figure 17). 
Deletions are defined by read-pairs that map far from each other, whereas insertions are 
described by read-pairs mapping very close to one another. Tandem duplications are 
identified by read-pairs that are inconsistent in their orientation (Figure 17). Read-pair 
methods are not suitable for identifying CNVs from WES data because CNVs that have 
breakpoints in untargeted regions cannot be detected. Read depth is another approach for 
detecting CNVs from NGS. This approach assumes that a duplicated region will have 
higher number of reads compared to a diploid genome, whereas a deleted region will have 
lower number of reads (Campbell, et al. 2008) (Figure 17). Read depth approaches can be 
applied for detecting CNVs from both WGS and WES screenings. 
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Figure 17: Approaches for CNV detection from next generation sequencing data 
Shown are the two approaches for detecting CNVs from NGS. Read-pair approach is more suitable 
for WGS data, whereas read depth approach can be applied to both WGS and WES screenings. 
Taken from (Alkan, et al. 2011) 
 
Although WGS provides the most comprehensive CNV profile, WES remains the 
most widely used NGS approach because it is still time and cost effective. In addition, 
WES gives insights into the genomic alterations of protein coding genes, which are often 
the most interesting to follow up. Detection of CNVs from WES data is however 
challenging due to the different size and sequence composition of exons, which result in 
non-uniform sequence coverage (Hodges, et al. 2007; Magi, et al. 2012; Sims, et al. 2014) 
(Figure 18). In addition, since exons are located at variable distances from each other, the 
detection of CNVs at breakpoint resolution is challenging (Liu, et al. 2013; Zhao, et al. 
2013) (Figure 18). Several methods have been developed in recent years to detect CNVs 
from WES data including ExomeCNV (Sathirapongsasuti, et al. 2011), VarScan2 
(Koboldt, et al. 2012), ControlFreeC (Boeva, et al. 2012), ADTEx (Amarasinghe, et al. 
2013), and EXCAVATOR (Magi, et al. 2013).  
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Figure 18: Pictorial representation of challenges in detecting CNVs from WES data 
Shown is the read depth and genome coverage in WES data and WGS screenings. CNV detection 
from WES data is affected due to bias in exon coverage that lead to non-uniform coverage resulting 
in false discovery of CNVs. 
 
ExomeCNV is the first method that was used for detecting CNVs from WES data. 
It compares the read depth of exons between tumour and normal samples and employs 
circular binary segmentation (CBS) to identify breakpoints of copy number change in the 
tumour. ExomeCNV is prone to ambiguous calls because it does not normalizes for the 
difference in the coverage between the samples. VarScan 2 is another widely used method 
that normalizes the coverage between tumour and normal samples and performs 
segmentation using CBS to identify genomic segments of copy number change. It is unable 
to identify CN-LOH events. EXCAVATOR is a recently published method that performs 
three steps of normalization to remove sources of variations due to GC content and 
presence of repetitive sequences. It uses a new segmentation algorithm that exploits the 
distance between the adjacent exons, thus accounting for the sparseness of the exons in 
WES. Similar to VarScan 2, EXCAVATOR does not detect CN-LOH events.  
Although using different technical solutions, the majority of these methods identify 
CNVs between two or more samples (e.g. tumour and matched normal) after dividing the 
genome sequence into segments. Segmentation works by merging adjacent genomic 
regions into longer segments in the attempt to minimize coverage variability within the 
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segments while maximizing it between them. Segmentation has been widely applied to 
aCGH (Tonon, et al. 2005; Kabbarah, et al. 2010) and WGS (Campbell, et al. 2008; Zhang, 
et al. 2013) data, where information is available for long and continuous regions. Although 
it has been adapted by exome-based methods to detect CNVs, the scattered nature of the 
data and the high variability in exon coverage may reduce its efficacy in this context. 
Additionally, these methods use normalizations that rely on the assumption that CNVs do 
not affect many genes. However, this is not applicable to cancers that may undergo large-
scale rearrangements. These exome-based methods do not correct for this assumption 
while calling CNVs, which may reflect in identification of ambiguous CNVs. 
 
1.7 Aim of the thesis 
The aim of my PhD project is to identify the genomic alterations that occur during 
liver cancer progression in the absence of external mutagens  
HCC arises in response to mutagens such as virus infection, aflatoxin and alcohol, 
or as a consequence of metabolic diseases including obesity and diabetes (Block, et al. 
2003; El-Serag and Rudolph 2007). As a result, HCC is heterogeneous in terms of genetic 
make up (Unsal, et al. 1994; Dragani 2010). Recent studies showed a strong dependence of 
the acquired mutation signature on the underlying mutagenesis mechanism, thus 
suggesting that the genetic heterogeneity in HCCs may depend on the causative agents 
(Zhang 2012). HCC is almost invariably associated with an underlying inflammatory state 
regardless of the initiating agent. However, the contribution of chronic inflammation to the 
acquisition of cancer driver genomic changes is still unclear.  
To understand the molecular basis for tumorigenesis and progression in liver cancer 
induced due to chronic inflammation, we studied the genomic landscape of human BSEP-
deficient HCCs (BSEP-HCCs). These tumours develop in response to chronic liver injury 
due to inflammation resulting from accumulation of bile salts (Knisely, et al. 2006) in the 
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absence of external mutagens. To further investigate the role of alterations that occur in 
BSEP-HCCs, we sequenced tumours from Mdr2-KO mice. Mdr2-KO is a genetic mouse 
model that has similar etiopathogenesis as that of BSEP-HCCs. Thus, Mdr2-KO mouse 
model offers an ideal system for studying the cancer progression in these types of tumours.  
We mapped the genomic alterations in both human and mouse HCCs. We used 
known methods to detect mutations and indels from exome sequencing data and CNVs 
from SNP arrays and whole genome sequencing data. In addition, we developed a novel 
method, GeneCNV, to identify CNVs from whole exome and targeted re-sequencing 
screenings. We next characterized the CNV spectrum in both human and mouse HCCs and 
observed a consistent genomic signature within and between species that was unique to 
these types of tumours.  
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Methods  
2.1 Sample description 
2.1.1 Samples from human liver cancer  
Seven children were diagnosed with BSEP-HCC (Table 5). The background liver 
in all patients exhibited parenchymal rather than portal-tract cholestasis, with bile salt 
export pump expression detectable in none of them. Some patients had frank cirrhosis and 
others had only fibrosis, which varied in degree from patient to patient (Table 5). Samples 
7860 175, 1790, 2896, and UKT came from single unencapsulated masses, while sample 
23836 was derived from one of the several HCCs within a single liver. Sample HB4R was 
a relapse that developed within allograft liver 6 years after transplantation. This patient 
underwent chemotherapy before relapse and chirurgical resection. All patients had 
mutations in ABCB11. (Table 5) 
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Table 5: Description human BSEP-HCC samples 
ID Storage 
Tumour 
content 
Background 
liver* 
Sex Age 
ABCB11 
non-silent 
SNVs and 
indels 
Zygosity 
Modification(s) 
on protein 
HGMD 
MutPred 
deleterious 
effect 
BSEP 
expression 
in the 
tumour 
BSEP 
expression 
in 
background 
liver 
Histopathology 
findings 
175 Frozen 90% 
Extensive 
fibrosis 
M 
1Y 
6M 
937C>A Heterozygous Arg313Ser DM Medium 
NO NO 
Two tumours; 
both trabecular 
1331T>C Heterozygous Val444Ala DFP Very low 
1445A>G Heterozygous Asp482Gly DM Very high 
2316T>A Heterozygous Tyr772X DM - 
7860 FFPE 90% Mild fibrosis F 
2Y 
6M 
1331T>C Heterozygous Val444Ala DFP Very low 
NO NO 
Multiple tumours 
(>10); trabecular, 
pseudoglandular 
and clear-cell 
2429delT Heterozygous Leu810PhefsX11 - - 
23836 FFPE 90% Cirrhosis M 
1Y 
3M 
1331T>C Heterozygous Val444Ala DFP Very low 
NO NO 
Single tumour; 
trabecular 
1445A>G Heterozygous Asp482Gly DM Very high 
1462T>C Heterozygous Ser488Pro - - 
1628A>C Heterozygous Asp543Ala - - 
HB4R Frozen 70% 
Scarring; no 
cholestasis 
F 
8Y 
6M 
1331T>C Homozygous Val444Ala DFP Very low NO 
YES 
(allograft) 
Single tumour; 
clear-cell 
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ID Storage 
Tumour 
content 
Background 
liver* 
Sex Age 
ABCB11 
non-silent 
SNVs and 
indels 
Zygosity 
Modification(s) 
on protein 
HGMD 
MutPred 
deleterious 
effect 
BSEP 
expression 
in the 
tumour 
BSEP 
expression 
in 
background 
liver 
Histopathology 
findings 
1790 Frozen 60% 
Moderate 
fibrosis with 
bridging 
M 
11Y 
7M 
378del Homozygous Thr127HisfsX7 - - NO NO 
Single tumour; 
trabecular 
2896 Frozen 50% Cirrhosis F 
1Y 
3M 
1331T>C Homozygous Val444Ala DFP Very low 
NO NO 
Three tumours; 
trabecular and 
clear-cell 
1416T>A Homozygous Tyr472X DM - 
2029A>G Homozygous Met677Val - - 
3556G>A Homozygous Glu1186Lys FP Low 
UKT Frozen 40% Cirrhosis M 
1Y 
3M 
1460G>C Homozygous Arg487Pro DM Medium NO NO 
Single tumour; 
trabecular 
 
For each lesion reported are details on the sample, the histopathological description. All patients had non-remitting cholestasis of neonatal onset (PFIC). BSEP expression 
was assessed immunohistochemically in tumours and corresponding background livers. FFPE = formalin-fixed paraffin embedded; *Cholestasis was observed, unless 
otherwise stated. DM=disease-causing mutations, DFP=disease-associated polymorphism with additional supporting functional evidence and FP= in vitro/laboratory or in 
vivo functional polymorphism 
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2.1.2 Samples from mouse liver cancer  
Founders of the FVB.129P2-Abcb4tm1Bor/J (Mdr2-KO, stock number: 002539) 
and FVB/NJ (Mdr2 wild type, stock number:001800) mice were purchased from The 
Jackson Laboratory and colonies of both strains maintained under specific pathogen-free 
conditions. Mice were sacrificed at 10-16 months (Table 6).  
 
Table 6: Description of mouse samples 
ID Targeted region 
Tumour 
content 
Tumour size 
(cm) 
Age 
(months) 
Sex 
51509/1 Whole exome 20% 1.1 16 M 
60400/2 Whole exome 40% 1.4 13 F 
218/1 Whole exome 50% 1.0 15 M 
52686/1 Whole exome 50% 0.7 15 F 
58853/3 Whole exome 60% 1.7 15 M 
60400/1 Whole exome / whole genome 60% 0.6 13 F 
58163/3 Whole exome 70% 3.0 15 M 
58163/4 Whole exome 70% 3.0 15 M 
215/1 Whole exome 80% 1.8 14 M 
54913/10 866 genes ND 0.1 10 F 
54913/8 866 genes ND 0.5 10 F 
55481/10 866 genes ND 0.3 10 F 
55484/4 866 genes 30% 3.0 10 F 
218/3 Whole genome 70% 1.0 15 M 
 
2.2 Experimental procedure 
We performed all experiments in collaboration with Giacchino Natoli's group, 
Department of Experimental Oncology, European Institute of Oncology (IEO), Milan, 
Italy. Agnese Collino maintained the mouse colonies and performed the experiments. 
Federica Pisati prepared the sample for histology inspection. Histologpatholgy inspection 
on mouse and human samples was done by Enrico Radaelli from VIB Center for the 
Biology of Disease, KU Leuven Center for Human Genetics and A.S.Kinsely from 
Institute of Liver Studies, King’s College Hospital respectively. DNA sequencing, TaqMan 
copy number assay and gene expression experiments were performed by Consortium for 
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Genomic Technologies (Cogentech). SNP microarray experiments for human samples 
were conducted by Fondazione Filarete.     
 
2.2.1 DNA extraction  
For human BSEP-deficient HCCs, we obtained frozen or formalin-fixed paraffin-
embedded (FFPE) samples from seven patients during native-liver hepatectomy with 
parental written consent. We used non-neoplastic liver tissues from all the patients as 
matching background references. We extracted genomic DNA from each tumour and 
matched background liver tissue using the DNeasy Blood and Tissue Kit (Qiagen) for 
frozen samples and with the AllPrep DNA/RNA FFPE Mini Kit (Qiagen) for FFPE blocks. 
For mouse Mdr2-KO HCCs, we snap froze the adenoma and HCC nodules from 
Mdr2-KO mice for DNA/RNA extraction or fixed in formalin for histological analysis and 
performed the initial pathological stage (inflammation) DNA/RNA extraction on purified 
populations of hepatocytes obtained via collagenase liver perfusion, using a two-step 
protocol. We snap froze the normal livers or kidneys and used them as the reference. We 
homogenized all the frozen tissue samples with GentleMACS Dissociator (Miltenyi 
Biotec) before column extraction and extracted the genomic DNA using the DNeasy Blood 
and Tissue Kit (QIAGEN) according to the manufacturer’s protocol.  
Agnese Colino from Giacchino Natoli's group had performed the DNA extraction. 
 
2.2.2 DNA-sequencing 
2.2.2.1 Whole exome sequencing of human samples 
We performed target capture on six human tumours and matched normal samples 
(Table 7) using the SureSelect XT Human All Exon V4 kit (Agilent) targeting 20,965 
human genes, following the manufacturer’s protocol with minor modifications. We 
excluded sample UKT from whole exome sequencing because of the low tumour content. 
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We sheared around 3 ug of genomic DNA using Adaptive Focused Acoustics technology 
(Covaris) and selected 200 bp fragments after library preparation with Illumina DNA 
Sample Prep Kit using the Agencourt AMPure PCR Purification system (Beckman 
Coulter). We further amplified selected fragments with 5 to 7 cycles of PCR and 
hybridized 500 ng of DNA with the bait library followed by paired-read cluster generation 
on the Cluster Station (Illumina). We sequenced libraries of each sample using one half-
lane of Illumina HiSeq2000, with 76 bp or 101 bp paired-end protocol, except for the 
tumoral sample of patient 7860, where one entire lane was used due to high levels of DNA 
degradation (Table 7). 
DNA sequencing unit in Consortium for Genomic Technologies (Cogentech) had 
performed the DNA sequencing. 
 
 
Table 7: Whole exome sequencing setting of BSEP-HCCs 
ID Sequencing setting Samples per lane 
175 101 PE 2 
7860 76 PE 1 
23836 76 PE 2 
HB4R 101 PE 2 
1790 101 PE 2 
2896 101 PE 2 
 
For each lesion reported is the read length and number of lanes used for sequencing. All 
experiments were performed with a paired end setting. 
 
2.2.2.2 Targeted sequencing, whole exome sequencing and whole genome sequencing 
of mouse samples 
For targeted re-sequencing we designed SureSelect custom capture kit for mouse 
genes that are orthologs of known human cancer genes. In order to select genes for 
targeted re-sequencing, we first collected all human cancer genes from the Cancer Gene 
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Census (Futreal, et al. 2004), COSMIC 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) and high-throughput cancer 
mutational screenings (http://ncg.kcl.ac.uk/) that totalled to 2,061 genes. We next 
identified the mouse orthologs of these genes using eggNOG (Jensen, et al. 2008) and MGI 
(http://www.informatics.jax.org) that resulted in a total of 1,753 mouse orthologs, of which 
only 866 had RefSeq entries. We then designed the SureSelect Custom kit (Agilent) to 
capture 15,067 exons of these 866 genes, for a total of 2.7 Mbp of DNA. We also excluded 
exons that were shorter than 60 bp (except for those with mutations in COSMIC), sequence 
repeats, segmental duplications, PAR regions and gaps. Further, we selected regions with 
GC content ranging from 30 to 65% to optimize the capture efficiency. 
We performed target capture using SureSelect custom kit for the 866 selected genes 
(~2.7 Mb) and the SureSelect XT Mouse All Exon kit (Agilent) targeting 21,543 mouse 
genes (~50.4 Mb) following the manufacturer’s protocol with slight modifications (Table 
8). Briefly, we sheared around 3 ug of genomic DNA using an ultrasonic disruptor 
(Bioruptor, Diagenode) or using Adaptive Focused Acoustics technology (Covaris) and 
selected 200-250 bp fragments after library preparation with the Illumina DNA Sample 
Prep Kit. We then purified the genomic fragments by gel extraction, or using the minelute 
PCR purification kit (QIAGEN), or using the Agencourt AMPure PCR Purification system 
(Beckman Coulter). We further amplified the fragments with 10 cycles of PCR and 
hybridized 500 ng of DNA with each bait library followed by single- or paired-read cluster 
generation on the Cluster Station (Illumina). We sequenced the libraries obtained for the 
866 genes on the Genome Analyzer IIx with the 76 single end protocol, using one lane for 
each tumour sample or matching normal sample and the libraries obtained for the whole 
exomes using one-half lane of Illumina HiSeq2000 for each sample, with the 101 bp 
paired-end protocol (Table 8).  
We performed whole genome sequencing of HCCs (218/3 and 60400/1) and 
matched normal samples from two Mdr2-KO mice: 218 and 60400. For whole genome 
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sequencing, we sheared around 1 ug of mouse genomic DNA in 400-500 bp fragments 
using an ultrasonic disruptor (Bioruptor, Diagenode) and prepared the libraries using 
Illumina Paired-End DNA Sample Prep Kit. We sequenced the obtained libraries using one 
lane of Illumina HiSeq2000 and 101 bp paired-end protocols (Table 8). 
Fabio Iannelli from Francesca Ciccarelli’s group created the custom microarray 
using Agilent eArray services and the DNA sequencing unit in Cogentech performed the 
DNA sequencing. 
Table 8: Targeted and whole exome sequencing settings of Mdr2-KO HCC 
ID Target regions 
Targeted regions 
Mbps 
Sequencing 
setting 
Samples per lane 
51509/1 
Whole exome 50.4 101 PE 
2 
60400/2 2 
218/1 2 
52686/1 2 
58853/3 2 
60400/1 2 
58163/3 2 
58163/4 2 
215/1 2 
54913/10 
866 genes 2.7 76 SE 
1 
54913/8 1 
55481/10 1 
55484/4 1 
218/3 
Whole genome  101 PE 
1 
60400/1 1 
 
For each lesion reported are details on read length, number of lanes used and the length of targeted 
genome used for capture and sequencing. All experiments were performed with a paired end 
setting. 
 
2.2.3 Dilution experiment for assessments of variant calling  
We measured the specificity of the variant calling procedure by re-sequencing 16 
somatic non-silent SNVs in human tumours and 15 somatic non-silent SNVs mouse in 
mouse tumours with Sanger sequencing. For Sanger sequencing, we amplified genomic 
regions surrounding the somatic SNVs by PCR using the Taq DNA Polymerase (Qiagen) 
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and sequenced them in the tumour and corresponding reference in both directions on a 
3730xl DNA Analyzer (Applied Biosystems) using the dRhodamine chemistry. Of the 16 
SNVs in human, for two SNVs the PCR amplification failed and we confirmed 13 out of 
the 14 remaining SNVs (specificity = 92.9%). In mouse we also confirmed 14 out of the 15 
SNVs (specificity = 93.3%). 
In order to measure the sensitivity in calling somatic mutations in cancer samples 
with variable tumour contents due to contamination from normal tissue, we used eight 
dilutions of a homozygous germline mutation (CC) with the corresponding wild type 
genotype (TT). In this setting, the frequency of the variant allele mimics the decreased 
frequency of a somatic mutation in presence of normal tissue contamination.  
We performed the dilutions of the minor allele as follows. We amplified a 105 bp 
long region centred on the mouse SNP rs32609672 (dbSNP build 128, chr5:36209358) 
from the genomic DNA of two mice with CC and TT homozygous genotypes (FVB/NJ 
and C57BL/6J strains, respectively), using a nested PCR approach. We first, amplified and 
Sanger sequenced a 393 bp fragment from each genomic DNA for genotype confirmation. 
Subsequently, we performed nested PCR to generate a 105 bp long amplicon, centred on 
the nucleotide of interest. We next purified the two amplicons (CC and TT) using the 
MinElute PCR Purification Kit (Qiagen) and used for library preparation with Illumina 
Paired-End DNA Sample Prep Kit. We then pooled the two libraries in eight different 
molar ratios with C:T proportion ranging from 0.04 to 0.41. These dilutions corresponded 
to variant allele (C) frequencies ranging from ~4% to ~41% and simulated a normal 
contamination ranging from ~20% to ~90%. We then sequenced each pool on a different 
Illumina GAIIx lane together with other samples in a ~1:1000 molar ratio and aligned the 
reads obtained to mouse chromosome 5 (NCBI37/mm9) using the same alignment setting, 
duplicate removal and somatic variant calling as described in paragraph 2.3.1.2. The 
dilution of the variant at 4% frequency was used as the normal counterpart, to simulate the 
possible presence of tumour contaminant in the normal counterpart. 
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Our procedure correctly detected the mutated base down to 20% frequency. 
Therefore, our pipeline can correctly detect homozygous and heterozygous somatic 
variants within samples with ≥20% and ≥40% tumour content, respectively. Notably, all 
samples used for mutational screening had >50% tumour content (Table 9). 
DNA sequencing unit in Cogentech performed the DNA sequencing and Fabio 
Iannelli from Francesca Ciccarelli’s group analysed the data. 
 
Table 9: Variant frequency at different dilutions  
Dilution 
Variant 
frequency (%) 
Simulated 
contamination 
(homozygous 
variants) 
Simulated 
contamination 
(heterozygous 
variants) 
Total 
coverage 
Variant 
coverage 
Base 
Calling 
1 41.4 58.60% 17.20% 64 18 C 
2 36.6 63.40% 26.80% 35 18 C 
3 32 68.00% 36.00% 53 20 C 
4 27.2 72.80% 45.60% 63 17 C 
5 23.1 76.90% 53.80% 62 16 C 
6 19.1 80.90% 61.80% 65 19 C 
7 15 85.00% 70.00% 40 6 T 
8 (Normal) 3.6 NA NA 40 2 NA 
 
For each set of dilution reported is the corresponding variant frequency, simulated contamination 
for homozygous and heterozygous, coverage after sequencing and the base identified at the 
position 
 
2.2.4 SNP array for detecting copy number variations in human samples 
We extracted the genomic DNA from the seven human tumour and their matched 
normal samples and processed according to Infinium® HD assay ultra manual (Table 5). 
We restored the DNA from FFPE samples before SNP array processing according to 
Infinium HD FFPE restore protocol. We assayed all samples using Illumina 
HumanOmniExpress-12 v1.0 and scanned the image data using a BeadArray reader. We 
extracted the intensity and genotype data for copy number variation analysis after 
normalizing raw fluorescent signals using Illumina Genome Studio v2011.1.  
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Agnese Collino from Gioacchino Natoli’s group extracted the DNA and 
Microarray unit in Fondazione Filarete restored the FFPE DNA and processed the SNP 
array. 
 
2.2.5 TaqMan copy number assay for copy number variation validation 
We assessed copy number variation in Mdr2-KO HCCs by quantitative RT-PCR, 
using TaqMan Copy Number Assay, on a 7900HT Fast Real-Time PCR System (Applied 
Biosystems) with Sequence Detection Systems Software 2.2.2. We used TaqMan probes 
designed by the manufacturer for the experiment (Table 10) and Tert (Applied Biosystems, 
part number 4458373) as the reference. We plated all samples in quadruplicates with 
approximately 20 ng of DNA for each reaction. We analysed all TaqMan copy number 
assay experiments using CopyCaller v2.0 (Applied Biosystems). For each nodule, we used 
its matched normal tissue as the reference and considered a gene as amplified or deleted if 
the confidence scores associated with the copy number passed quality metrics as provided 
in the CopyCaller manual 
(http://www6.appliedbiosystems.com/support/software/copycaller/). 
Real Time PCR Unit in Cogentech performed the quantitative RT-PCR. 
 
 
Table 10: TaqMan probes used for validation of copy number amplification 
Gene Name TaqMan Coordinate Assay Id Amplicon size (bp) 
Map2k7 Chr8:4238961 Mm00251746_cn 86 
Irs2  Chr8:11005122 Mm00580766_cn 70 
Mapk8 Chr14:34203892 Mm00418304_cn  95 
ATF2 Chr2:73688980 Mm00046575_cn 101 
MYC Chr15:61821405 Mm00615587_cn 73 
St18 Chr1:6817977 Mm00040629_cn 83 
Hnf4a Chr2:163377436 Mm00060776_cn 70 
Gata1 ChrX:7539550 Mm00628417_cn 75 
Gdf3 Chr6:122559836 Mm00561648_cn 70 
Wnt10b Chr15:98604678 Mm00612962_cn 81 
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For each gene reported is the corresponding coordinate in the mouse genome (mm9), Applied 
Biosystems TaqMan copy number assay identification number and the size of the amplicon in bp. 
 
2.2.6 Fluorescence in situ hybridization 
We validated the amplification of chromosome 19 in the human sample 23836 by 
two-colour fluorescence in situ hybridization (FISH) using a Vysis LSI 19q13 
SpectrumOrange / 19p13 SpectrumGreen probe (Abbott), according to manufacturer’s 
instructions. We deparaffinised 2 mm FFPE slides from tumour and background liver of 
patient 23286 in xylene, washed in 100% ethanol, incubated in 1x SSC (0.3M sodium 
chloride, 0.03M sodium citrate) pH 6.0 at 80°C for 20 min for demasking, and digested 
with pepsin (0.5 mg/ml in 0.2N HCl, pH 1.0; Protease and Protease Buffer II, Abbott) for 
17 min at 37°C. We then washed samples in 2x SSC, dehydrated in 70, 95 and 100% 
ethanol, and directly applied air dried 10ul of probe onto each slide and topped with a 
coverglass that was then sealed with rubber cement. We placed the slides in a HYBrite 
(Abbott), and the probe was left to denature for 1 min at 85°C, followed by an overnight 
hybridization at 37°C. We then removed the coverglasses and washed the slides twice in 
2x SSC with 0.1% NP-40 at RT, once in 0.4x SSC with 0.3% NP-40 at 73°C, and once 
again in 2x SSC with 0.1% NP-40 at RT. After counterstaining with DAPI (Sigma), we 
scored the FISH signals with an Olympus BX61 upright microscope, using a 100x 
objective. 
Agnese Collino from Gioacchino Natoli’s group prepared the slides for FISH 
experiment and Luca Giorgetti performed the FISH analysis. 
 
2.2.7 Pathway enrichment analysis 
We performed pathway enrichment analysis using ConsensusPathDB (Kamburov, 
et al. 2013). We compared 935 human cancer genes amplified in at least 4 BSEP-HCCs 
 60 
and 27 genes that were amplified in the majority of human and mouse HCCs to the 
pathway-base gene set composed of 10,529 pathway-associated genes. ConsensusPathDB 
calculates p-values using the hypergeometric test based on the number of pathway 
components present in both the amplified cancer gene set and the pathway-base gene set. It 
then corrects the resulting p-values for multiple testing using false discovery rates. 
Fabio Iannelli from Francesca Ciccarelli’s group performed the pathway analysis. 
 
2.2.8 Expression quantification of Map2k7 in mouse liver cancer 
We extracted total RNA for q-RT-PCR experiments from Mdr2-KO tumours, 
Mdr2-KO inflamed livers, and age matched Mdr2-WT healthy livers in Trizol (Invitrogen) 
using the RNeasy Mini Kit (Qiagen) according to manufacturer’s instructions and used 0.5 
ug of total RNA for cDNA synthesis (using ImProm-II Reverse Transcriptase, Promega). 
We then performed RNA quantification using Nanodrop, and assessed their quality using 
Bioanalyzer (Agilent). We quantified the expression by qPCR on 1 μl of cDNA reverse-
transcribed from 0.5 μg of total RNA. We used Applied Biosystems 7500 Real-time PCR 
system to extract cycle threshold (Ct) values from qPCR (SYBR Green, Applied 
Biosystems). We then normalized the target gene Ct values with the nucleolin Ct values of 
the same sample to get delta Ct values for each gene in each samples. Next, we calculated 
the expression value as 2 to the power of negative delta Ct. For each gene with replicates; 
we then calculated the average expression for each gene. 
Real Time PCR Unit in Cogentech performed the quantitative RT-PCR. 
 
 
2.2.9 Treatment of Mdr2-KO mouse with SP600125 JNK inhibitor 
We randomly divided twenty-three Mdr2-KO mice into two groups at the age of 13 
to 14 months, when nodules are already formed (Pikarsky, et al. 2004). One group of 12 
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mice was treated with SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) (Calbiochem), and the 
other group of 11 mice with vehicle). Vehicle for SP600125 was 40% polyethylene glycol 
(PEG, Sigma) in PBS diluted in DMSO. We administered treatments of 60 mg per dose, 
intraperitoneally 3 times a week for a total of 3 weeks and sacrificed the mice one week 
after the end of the treatment. We counted all grossly detectable nodules and measured 
them with a calliper. We then collected them for DNA extraction and histological analysis. 
Agnese Collino and Paola Nicoli from Gioacchino Natoli’s group administered the 
drug, sacrificed the mice and extracted the DNA. 
 
2.3 Computational Procedure 
We performed all computational analysis in Francesca Ciccarelli's group, 
Department of Experimental Oncology, European Institute of Oncology (IEO), Milan, 
Italy. 
2.3.1 Alignment and variant calling from targeted re-sequencing data 
We mapped paired-end sequencing reads from each tumour and reference to the 
human genome (GRCh37/hg19) using Novoalign (http://novocraft.com). We allowed at 
most three mismatches per read and removed duplicated reads using rmdup of SAMtools 
(Li, et al. 2009). We considered all reads that uniquely mapped within 75-100 bp of the 
targeted regions as on target and retained them for further analysis (Table 11). We then 
identified single nucleotide variants (SNVs) and indels using SAMtools (Li, et al. 2009) 
and VarScan 2 (Koboldt, et al. 2012) and retained those variants that were covered by at 
least 10 reads and with frequency ≥20%. We next identified somatic mutations and indels 
as mutations with coverage ≥5x, frequency <10% in the reference, and not present in 
dbSNP build 137 (MAF >1%). All 44 SNVs and 8 indels were retained after manual 
inspection and 14 non-silent SNVs underwent orthogonal validation. 
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Table 11: Sequencing and alignment throughput of BSEP-HCCs  
ID 
Sequenced 
Gbps 
Aligned 
Gbps 
Aligned w/o 
duplicates 
Gbps 
On Target 
Gbps 
Mean 
coverage 
Mean coverage 
of matched 
normal 
175 17.15 15.38 11.62 8.17 160 157 
7860 30.30 25.42 3.93 2.57 50 33 
23836 13.46 11.96 8.27 5.52 108 110 
HB4R 16.82 12.27 5.76 2.67 52 150 
1790 8.70 5.99 5.45 4.73 92 146 
2896 9.70 6.46 5.93 5.16 101 239 
 
For each lesion of the human tumours reported are the sequenced bases, bases aligning to the 
mouse genome (mm9) before and after removing duplicates, bases aligning to the targeted regions 
of the genome, mean coverage in the tumour and the matched normal.  
 
 
We mapped single- and paired-end reads to the mouse genome (NCBI37/mm9) 
using Novoalign (http://novocraft.com) for the targeted sequencing and using Burrows-
Wheeler Aligner (BWA) (Li and Durbin 2009) for whole genome sequencing. We allowed 
a maximum of three mismatches per read and removed the duplicated reads generated 
during the PCR amplification using rmdup of SAMtools (Li, et al. 2009). In the targeted 
sequencing analyses, we considered all reads that uniquely mapped within 75-100 bp of 
the targeted regions as on target and retained these reads for further analysis (~80% of all 
aligned reads) (Table 12). For the whole genome sequencing, around 70% of raw reads 
aligned to the reference genome (Table 12). We identified mutations and indels using 
SAMtools (Li, et al. 2009) and VarScan 2 (Koboldt, et al. 2012) and retained variants 
covered by at least 10 reads with frequency ≥20%. We then identified somatic mutations 
and indels from the entire pool if they had frequency <5% in the reference sample and 
coverage of the mutation ≥10x. We used the same normal tissue as unique control because, 
in principle, mice from an inbred strain are genetically identical. We further manually 
inspected all the retained variants. 
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Fabio Iannelli from Francesca Ciccarelli’s group performed the alignment and 
variant calling and mutational analysis. 
  
Table 12: Sequencing and alignment throughput of Mdr2-KO HCCs 
ID 
Target 
regions 
Sequenced 
Gbps 
Aligned 
Gbps 
Aligned w/o 
duplicates 
Gbps 
On Target 
Gbps 
Mean 
coverage 
Mean coverage 
of matched 
normal 
51509/1 
Whole 
exome 
16.44 10.50 10.43 6.34 126 132 
60400/2 17.74 11.39 11.39 7.13 142 132 
218/1 15.40 9.92 11.20 6.94 138 132 
52686/1 21.05 13.47 12.54 7.78 154 132 
58853/3 17.65 11.24 12.02 7.34 146 132 
60400/1 17.72 11.54 10.06 6.26 124 132 
58163/3 19.16 12.22 12.74 7.82 155 132 
58163/4 15.52 9.99 9.61 5.31 105 132 
215/1 18.89 12.34 12.57 7.99 159 132 
54913/10 
866 
genes 
2.88 2.20 2.15 1.28 481 189 
54913/8 3.13 2.06 2.01 1.20 450 189 
55481/10 3.14 2.25 2.20 1.27 476 189 
55484/4 2.51 1.46 1.43 0.84 317 189 
218/3 Whole 
genome 
37.59 30.73 28.16 NA 11 13 
60400/1 48.03 35.30 32.78 NA 13 12 
 
For each lesion of the mouse tumours reported are the screening, sequenced bases, bases aligning 
to the mouse genome (mm9) before and after removing duplicates, bases aligning to the targeted 
regions of the genome, mean coverage in the tumour and the matched normal 
 
2.3.2 CNV analysis from SNP arrays  
We performed copy number variation (CNV) analysis using ASCAT (version 2.1), 
which takes into consideration ploidy and non-aberrant cell admixture present in each 
tumour sample (Van Loo, et al. 2010). For each genomic segment of the tumour, the 
software provides an aberration reliability score, which measures how well the predicted 
integer copy number matches the real data as compared to the null hypothesis of no 
aberration.  
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We ran ASCAT with default parameters of segment lengths for ASPCF 
Segmentation and homozygous probes (probes with 0.3>BAF>0.7 in matched reference) 
for all samples except two cases (1790 and 7860). For sample 1790, we masked the SNPs 
with BAF value difference <1.0 between tumour and reference to further reduce the noise 
and for sample 7860, we changed the segment length for ASPCF Segmentation from 25 to 
100 to avoid over-segmentation due to scattered values of log ratio and BAF. We analysed 
all tumour samples by comparing them with their matched reference, except for HB4R. We 
analysed HB4R without the matched reference because the SNP array for the background 
liver failed quality control. In this case, we ran ASCAT using the Illumina700k platform 
provided in ASCAT for somatic CNV detection in absence of matched reference.  
For six tumours with whole exome sequencing data, we integrated the frequency 
distributions of the germline heterozygous SNPs with the SNP array results to identify high 
confidence aberrant regions. In a diploid genome, heterozygous SNPs follow a unimodal 
distribution centred around 50% frequency because both alleles are present at equal 
frequency. In case of allelic imbalance leading to copy number variation, frequency 
distribution of heterozygous SNPs deviates from unimodality and their frequency will be 
different from 50%, because of the unbalanced ratio between mutated and wild type allele 
(Baca, et al. 2013). Hence, the distribution of heterozygous SNP frequencies can be used to 
identify genomic regions undergoing copy number variations. We identified high 
confidence aberrant regions as genomic segments with copy number different from 2 or 
with allelic imbalance leading to copy neutral loss of heterozygosity (CN-LOH) and with 
either an aberration reliability score higher than the average reliability score for that 
sample or present in regions with non-unimodal SNP frequency distribution. In the case of 
sample UKT, which did not undergo exome sequencing, we defined high confidence 
aberrant regions only on the basis of their aberration reliability score.  
To identify amplified, deleted, and CN-LOH genes, we intersected the genomic 
coordinates of the aberrant regions in each sample with those of 20,965 human genes of 
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the SureSelect XT Human All Exon V4 kit (Agilent) and considered genes as modified if ≥ 
80% of their length was contained in an aberrant region.  
We further assessed the copy numbers of aberrant regions (amplifications, 
deletions, and CN-LOH) using ASCAT and merged adjacent regions with the same copy 
number. We defined single amplification, deletion, or CN-LOH events spanning ≤ 50% of 
the chromosome arm length as focal as opposite to arm-level alterations that spanned 
≥98% of the chromosome arm length (Beroukhim, et al. 2010). We considered a minimum 
of ten consecutive copy number oscillations between two copy number states within the 
same chromosome as a possible indication of chromothripsis, according to its operational 
definition (Korbel and Campbell 2013). 
I had performed the CNV analysis from SNP arrays. 
 
2.3.3 CNV and structural rearrangement analysis from whole genome sequencing 
data 
We performed copy number analysis on whole genome sequencing using 
CNVnator v.0.2.5 (Abyzov, et al. 2011) with sequence bins of 300bp. We then removed 
CNV regions with low confidence (p-value <0.05), composed of ≥65% repeats and/or gap, 
or covered with ≤30% of high quality mapping reads. Furthermore, we retained CNVs only 
if their length spanning at least 3 consecutive bins was >1000bp. We next identified 
somatic CNVs if there was ≤ 5% overlap in length between tumour copy number regions 
and matched normal. To identify the CNV boundary, we merged the adjacent regions with 
the same copy number state. We estimated the copy number fold change of each region of 
the tumour genome by dividing the tumour coverage by the coverage of the normal 
counterpart, after coverage normalization. We normalized sequence coverage (1) to reduce 
the coverage variations within the sample using the trimmed mean method (Dillies, et al. 
2013) and (2) to scale the coverage of the tumour to its normal counterpart (Quackenbush 
 66 
2002). To estimate copy number state in the tumour, we multiplied the fold change by 2, 
which is the expected copy number of a diploid genome. We considered a minimum of ten 
consecutive copy number oscillations between two copy number states within the same 
chromosome as a possible indication of chromothripsis, according to its operational 
definition (Korbel and Campbell 2013). 
We inferred structural rearrangements using PEMer (Korbel, et al. 2009) with 
slight modifications to adapt the method to Illumina sequencing. We first calculated the 
paired-end insert size distribution to determine the expected insert size range and selected 
all mapped paired-end pairs with either an insert size greater/less than the expected insert 
size or with an unexpected orientation. Of these, we selected only discordant read pairs 
overlapping with or next to mapped CNV regions in the tumours for manual inspection. 
We identified rearrangements between chromosomes 8 and 14 (ID: 218/3) and 8 and 19 
(ID: 60400/1), which we also validated by PCR amplifications and Sanger sequencing. 
Fabio Iannelli from Francesca Ciccarelli’s group analysed the WGS data for 
structural rearrangements and I had performed the CNV analysis. 
 
2.3.4 GeneCNV 
We developed a novel method, GeneCNV that identifies genes undergoing 
genomic alterations from whole exome and targeted sequencing data. We applied 
GeneCNV to identify altered genes in Mdr2-KO HCCs that underwent whole exome re-
sequencing or targeted re-sequencing. In addition, we also assessed the performance of 
GeneCNV and compared its performance with three other state-of-the-art exome-based 
methods: ExomeCNV (Sathirapongsasuti, et al. 2011), EXCAVATOR (Magi, et al. 2013) 
and VarScan 2 (Koboldt, et al. 2012).  
I had designed and developed the method. Gennaro Gambardella and Matteo 
Cereda contributed in the development of the software and tested the software. Fabio 
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Iannelli supervised the method and tested the software. I had performed the CNV analysis 
from targeted re-sequencing data using the three exome-based methods (ExomeCNV, 
EXCAVATOR and VarScan 2) and SNP arrays used as the gold standard for the 
assessment of the exome-based methods. 
 
2.3.4.1 Workflow of the method 
GeneCNV uses as an input exome sequencing data from two samples: the test and 
the reference sample. Although, in principle, these samples may be of any kind, for clarity, 
we refer to them as tumour and normal exomes from here on. 
To detect altered genes from targeted and whole exome sequencing data, 
GeneCNV first calculates the coverage of targeted exons using BEDTools CoverageBed 
(Quinlan and Hall 2010) as: 
ExonCoveragee = d ´  bd
d=0
max(depth)
å
 
where d is the depth of coverage and bd is the number of bases at depth of coverage 
d in exon e.  
It next maps the exons to the corresponding gene using the targeted gene annotation 
file (i.e. the Agilent SureSelect bed files equivalent) and measures the gene coverage as the 
cumulative coverage of all exons divided by the length of the gene:  
GeneCoverageg=
ExonCoveragee  
e=1
no. of  exons
å
ExonLengthe  
e=1
no. of  exons
å
 
where e is the exon and g is the gene.  
To minimize the variability of capture and sequencing efficiency within the exome, 
GeneCNV then applies median scaling normalization (Ioannidis, et al. 2009; Dillies, et al. 
2013): 
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GeneCoverageg ' =
GeneCoverageg
median( GeneCoverageg )s
 
where g is the gene and s is the exome sample.  
Furthermore, it applies quantile normalization (Bolstad, et al. 2003) to correct for 
gene coverage variations between tumour and matched normal exomes. Genes in the 
tumour and in the matched normal samples are ranked according to their normalized gene 
coverage values (GeneCoverage'). The coverage of genes occupying equivalent positions 
in the two ranked lists is then reassigned as the average gene coverage between the two 
values (GeneCoverage").  
After normalization, GeneCNV calculates the log2ratio between the gene coverage 
in the tumour and in the matched normal exome (L2RGC) for each gene: 
L2RGC = Log2
GeneCoverage"g, tumor
GeneCoverage"g, normal
æ
è
çç
ö
ø
÷÷
 
In order to identify sample-specific thresholds of L2RGC for calling amplified and 
deleted genes, GeneCNV relies on the deviation from the expected 50% frequency of 
heterozygous SNPs in cases of allelic imbalance due to CNVs. GeneCNV first identifies 
heterozygous SNPs as germline mutations within 40-60% frequency interval in the normal 
sample. It then divides the tumour exome into non-overlapping regions with each region 
containing 100 such heterozygous SNPs and considers regions that host ≥80% of 
heterozygous SNPs within 40-60% frequency as allelic balanced regions. Some of these 
regions could however be polyploidy due to amplification of both the alleles. Since allelic 
balanced regions with polyploidy have high L2RGC values, GeneCNV considers regions 
with L2RGC values in the bottom 10% of the distribution of L2RGC values of all allelic 
balanced regions as diploid. It then finally calculates the thresholds for calling amplified 
and deleted genes from the distribution of L2RGC in the diploid regions as:  
L2RGCA = (L2RGC )10%+1SD(L2RGC )10%  
L2RGCD = (L2RGC )10%-1SD(L2RGC )10%  
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where SD represents standard deviation of the L2RGC values in the diploid regions. 
We empirically estimated the optimal numbers of SNPs to divide the exome (100 
SNPs), the L2RGC value to define diploid regions (10% of the distribution) and the number 
of standard deviations (SD). Though we have set theses as the default parameter values for 
running GeneCNV, the user can change these parameters values. 
GeneCNV next uses SNP frequency and L2RGC of genes to detect copy number 
change. In order to assess the allelic copy number change, it uses a minimum of five SNPs 
present in the gene region. For genes that do not contain SNPs, GeneCNV adds 500bp to 
the flanking regions iteratively till the new gene region contains five SNPs. Since the new 
gene region may include other genes, GeneCNV re-calculates the L2RGC value for the gene 
as the mean of L2RGC values of all genes contained within the new gene region.  
GeneCNV considers a gene to have allelic imbalance, if a minimum of two third of 
the SNPs do not have frequency between 40%-60%. It then identifies genes as amplified, 
deleted or LOH: 
f(Gene) =
Amplified if L2RGC ³ L2RGCA,
Deleted L2RGC £ L2RGCD & allelic imbalance
LOH L2RGCD < L2RGC < L2RGCA & allelic imbalance,
Wild type otherwise
ì
í
ï
ï
î
ï
ï
 
 
2.3.4.2 Dataset for exome-based method evaluation 
To evaluate the performance of the exome-based methods, we used the six BSEP-
HCCs for which the whole exome sequencing data and SNP array results were present for 
both tumour and matched normal samples. Furthermore, to increase the number of 
samples, we also included twenty-two samples from myelodysplasia (Yoshida, et al. 2011) 
for which whole exome sequencing data as well as SNP array data were publicly available 
for both tumour and their matched normal samples. We were thus able to do a 
comprehensive evaluation of the methods on a total of 28 tumour-normal pairs (Table 8). 
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Table 13: Exomes used for method comparisons 
ID 
Read 
Length 
(bp) 
Sequencing 
platform 
Agilent SureSelect 
Human Kit 
Targeted 
genes (n) 
Alignment 
software 
SNP array platform 
SNP call rate 
in tumour 
SNP call rate in 
matched normal 
Tumour type 
CMML-01 76 
Illumina GAIIx 
 
All Exon 38Mb kit 19,104 
BWA 
Affymetrix 250K 
SNP arrays 
 
99.13 98.86 
Myelodysplasia 
(Yoshida, et al. 
2011) 
CMML-03 108 All Exon 50Mb kit 20,965 98.70 98.64 
CMML-04 108 All Exon 50Mb kit 20,965 98.00 98.31 
MDS-03 101 / 76 All Exon 38Mb kit 19,104 99.07 99.48 
MDS-04 101 / 76 All Exon 38Mb kit 19,104 98.72 99.54 
MDS-06 101 All Exon 38Mb kit 19,104 97.94 98.11 
MDS-07 101 All Exon 38Mb kit 19,104 96.90 98.81 
MDS-08 101 / 76 All Exon 38Mb kit 19,104 99.58 98.85 
MDS-09 108 All Exon 50Mb kit 20,965 98.72 99.53 
MDS-10 108 All Exon 50Mb kit 20,965 99.34 98.41 
MDS-13 108 / 76 All Exon 38Mb kit 19,104 97.57 98.02 
MDS-14 108 / 76 All Exon 38Mb kit 19,104 97.76 99.36 
MDS-15 108 All Exon 50Mb kit 20,965 99.25 95.80 
MDS-18 76 All Exon 38Mb kit 19,104 99.55 99.20 
MDS-20 108 All Exon 38Mb kit 19,104 99.54 99.34 
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ID 
Read 
Length 
(bp) 
Sequencing 
platform 
Agilent SureSelect 
Human Kit 
Targeted 
genes (n) 
Alignment 
software 
SNP array platform 
SNP call rate 
in tumour 
SNP call rate in 
matched normal 
Tumour type 
tAML-01 101 
Illumina GAIIx 
 
All Exon 38Mb kit 19,104 
BWA 
Affymetrix 250K 
SNP arrays 
 
98.18 96.22 
Myelodysplasia 
(Yoshida, et al. 
2011) 
tAML-02 108 / 101 All Exon 38Mb kit 19,104 98.91 97.00 
tAML-03 108 / 76 All Exon 38Mb kit 19,104 97.29 98.24 
tAML-04 108 / 76 All Exon 38Mb kit 19,104 97.93 97.72 
tAML-05 108 All Exon 38Mb kit 19,104 99.18 99.52 
tAML-06 108 / 101 All Exon 50Mb kit 20,965 98.76 98.58 
tAML-07 108 All Exon 50Mb kit 20,965 97.65 96.79 
175 101 
Illumina HiSeq2000 
All Exon 50Mb kit 20,965 
Novoalign 
Illumina 
HumanOmniExpres
s-12 v1.0 
 
0.93 1.00 
BSEP-HCCs 
1790 101 All Exon 50Mb kit 20,965 1.00 1.00 
2896 101 All Exon 50Mb kit 20,965 1.00 0.99 
7860 76 All Exon 50Mb kit 20,965 0.73 0.86 
23836 76 All Exon 50Mb kit 20,965 0.95 0.98 
HB4R 101 All Exon 50Mb kit 20,965 0.84 0.87 
For each sample reported are the ID as in the original study; the length of sequenced reads (all experiments were performed with a paired end setting); the sequencing 
platform, the exome capture kit; the number of targeted genes, the software used for read alignment; the SNP array platform; the SNP call rate in the tumour and in the 
matched normal; and the tumour type. 
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2.3.4.3 Identification of altered genes from SNP array 
We downloaded the raw SNP array files for myelodysplasia from Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/, GSE31174) (Yoshida, et al. 2011) and 
analysed them using ASCAT (version 2.1) (Van Loo, et al. 2010) with default parameters 
(segment length = 25; homozygous probes with 0.3>B allele frequency (BAF) >0.7 in 
matched reference were masked). High confidence somatic CNVs and CN-LOHs were 
identified in each tumour sample as genomic segments with an aberration reliability score 
higher than the average reliability score for that sample. We then identified altered genes in 
each sample by intersecting the genomic coordinates of the aberrant regions in each sample 
with those of the human gene sets of the Agilent SureSelect Human All Exon 50Mb kit 
(20,965 genes) or 38Mb kit  (19,104 genes) depending on the kit used to capture the exome 
in the corresponding sample (Table 13). We considered genes as modified if ≥ 80% of 
their length was contained in an aberrant region. For the six samples from BSEP-HCCs, 
we used the SNP array results after processing the data as previously described. In total, 
we identified altered genes from SNP arrays of 28 samples (Table 13) that were then used 
as gold standard for comparison of exome-based methods.   
 
2.3.4.4 Identification of modified genes from exome sequencing data 
We downloaded the whole exome sequencing data for myelodysplasia from 
Sequence Read Archive  (SRA, http://www.ncbi.nlm.nih.gov/sra , DRA000433) (Yoshida, 
et al. 2011). We mapped the sequencing reads from each tumour and matched normal to 
the human genome (GRCh37/hg19) using BWA (Li and Durbin 2009) allowing at most 
three mismatches per read and removed the duplicated reads using rmdup of SAMtools 
(Li, et al. 2009). We considered all reads uniquely mapping within 75-100 bp of the 
targeted regions as on target and retained them for further analysis. For the six BSEP-
HCCs, we used the aligned files obtained after processing the reads as described. 
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We identified CNVs from exome sequencing data for each of the twenty-eight 
tumour exomes using GeneCNV, ExomeCNV (version 1.4), VarScan 2 (version 2.3.6) and 
EXCAVATOR (version 2.2). We ran all the methods using the default parameters 
(ExomeCNV: minimum sensitivity and specificity = 0.9999 and optimizing for specificity; 
VarScan 2: minimum coverage = 8, minimum size = 10 bases, log ratio threshold = 0.25 
for both the lower and upper bounds; EXCAVATOR: mode = somatic). Since 
ExomeCNV, VarScan 2 and EXCAVATOR identify CNV regions, to detect deleted and 
amplified genes in each tumour exome, we performed similar analysis as described before 
for the SNP arrays. CN-LOH genes could only be identified using ExomeCNV and 
GeneCNV. 
 
2.3.4.5 Comparison of GeneCNV with other methods  
We considered the amplified, deleted and CN-LOH genes from the SNP arrays as 
the true alterations occurring in the tumour samples and used these results to compare the 
performance of the four exome-based methods. For each exome-based method, we defined 
true positives as the genes with the same alterations as detected in the SNP arrays and true 
negatives as unaltered genes in both. We then calculated sensitivity as the number of true 
positives over the total number of altered genes in the SNP arrays and specificity as the 
number of true negatives over the total number of unaltered genes in the SNP arrays. We 
also measured accuracy as the number of correct calls (sum of true positives and true 
negatives) over the total number of targeted genes. We next measured the concordance 
between the results from exome-based methods and SNP arrays using the Jaccard index as 
the number of true positives over the sum of altered genes detected by the exome-based 
method and in SNP arrays.  
We also assessed the performance of the exome-based methods in detecting clonal 
events, where we identified clonal events using the BAF and the log R ratio (LRR) profile 
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from the SNP array. In particular, we considered altered regions with all SNPs in the 
tumour with the BAF value >0.6 or <0.4 or with the LRR value of >0.25 or <-0.25 as 
clonal events. 
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Results  
The aim of my project is to understand the alterations that occur during liver cancer 
progression in the absence of external mutagens. HCC is a multistep process and arises in 
response to various external factors such as virus infection, aflatoxin and alcohol, or as a 
consequence of metabolic diseases including obesity and diabetes (Block, et al. 2003; El-
Serag and Rudolph 2007). HCC is heterogeneous in terms of the genetic make up (Unsal, 
et al. 1994; Dragani 2010) and the acquired mutation signature depends on the initiating 
agent (Zhang 2012).  Irrespective of the causative agents, HCC develops in the background 
of cirrhosis, fibrosis and chronic inflammation as a result of liver injury and regeneration 
(Levrero 2006). The contribution of chronic inflammation and cirrhosis to liver injury 
resulting in cancer is not well understood. Hence we investigated to which extent liver 
injury due to inflammation, chemical damage, and fibrosis aids in the acquisition of cancer 
genomic instability.  
For the purpose of our study, we used human BSEP-HCCs, which have inherited 
inactivating mutations in the biliary transporter gene, ABCB11 (BSEP). BSEP-HCCs are 
generally deficient in BSEP expression and develop in response to chronic liver injury due 
to the accumulation of bile salts (Knisely, et al. 2006). To further investigate the role of the 
acquired alterations in the progression of the human tumours, we used a genetic mouse 
model Mdr2-KO, which is etiologically similar to BSEP-HCCs. Mdr2-KO mice, like 
human BSEP-HCC patients have inactivating mutations in a biliary transporter gene, 
ABCB4 and develop HCCs due to hepatocellular damage and inflammation (Smit, et al. 
1993; Mauad, et al. 1994).    
We profiled the genome of seven human and fourteen mouse liver tumours (Table 
5 and Table 6). To study the mutations and CNVs profiles in both human and mouse 
tumours, we used known methods for identifying mutations and CNVs from SNP arrays 
and WGS data. We in addition developed a new method, GeneCNV to detect CNVs from 
targeted re-sequencing data. We applied GeneCNV on WES screenings in mouse tumours. 
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In the following paragraphs I first describe the rationale, validation and salient 
features of GeneCNV, followed by the analytical observations on the genomic alterations 
in human BSEP-HCCs and mouse Mdr2-KO HCCs. 
 
3.1 GeneCNV: Rationale and performance evaluation 
3.1.1 Rationale of GeneCNV  
The detection of CNVs from NGS data is possible using read-depth or read-pair 
approach. Read-pair approach is based on mapping and orientation of reads at the 
breakpoints of the CNVs. This approach is not suitable for WES data because CNVs that 
have breakpoints in untargeted regions will be missed. Read-depth approach assumes that 
amplified regions have higher coverage and deleted regions have lower coverage in 
comparison to unaltered regions. This approach is widely used for detecting CNVs from 
WGS and WES data. The application of the read-depth approach to WES data is 
particularly challenging because of the sparse distribution of exons of variable length and 
sequence composition across the genome.  This further affects the sequence coverage. Few 
methods such as ExomeCNV, VarScan 2 and EXCAVATOR have been developed in 
recent times for detecting CNVs from WES data. ExomeCNV compares the read depth of 
exons between tumour and normal samples and employs CBS, a segmentation method to 
identify breakpoints of copy number change in the tumour. However it does not take into 
consideration the difference in the total sequencing coverage between the normal and the 
tumour samples that may lead to ambiguous CNV calls. Similar to ExomeCNV, VarScan 2 
exploits the coverage differences between tumour and normal samples and uses CBS to 
detect CNV breakpoints after normalizing for the coverage between the two samples. 
EXCAVATOR uses a new segmentation algorithm that exploits the distance between the 
adjacent exons, thus accounting for the sparseness of the exons in WES data. Though all 
the available methods use different normalization and CNV calling techniques, they 
 78 
invariably use segmentation to identify regions of copy number changes. Segmentation has 
been widely used in identifying CNVs in WGS and microarrays, where information across 
the whole genome is available. However, segmentation had reduced efficacy in detecting 
CNVs from WES data because of the non-contiguous distribution of exons. Additionally, 
these methods do not take into consideration the effect of large-scale rearrangements, 
which is a common feature in cancers.  
To address these issues, we developed a novel method that does not depend on 
segmentation and instead calls CNVs at the gene level. GeneCNV adopts a novel strategy 
to minimize the coverage variability because of exon length, composition, and discrete 
distribution along the genome that is different from those of other exome-based methods 
(Figure 19).  
 
 
 
Figure 19: Schematic representation of GeneCNV 
Shown is the schematic workflow of GeneCNV for detecting CNVs and CN-LOHs from whole 
exome sequencing data. It uses as inputs, aligned read files (BAM), genomic coordinates of regions 
targeted for re-sequencing (bed) and variant file (vcf or snp). It uses read aligned files of the 
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exomes to calculate the coverage of all targeted genes in test (e.g. tumour) and reference (e.g. 
matched normal) exomes independently. It normalizes the gene coverage within and between the 
samples using median normalization and quantile normalization, respectively. It then measures the 
log2ratio of gene coverage (L2RGC) between tumour and matched normal exomes for each targeted 
gene and identifies the regions of allelic balance in the tumour. Within the allelic balanced regions, 
GeneCNV further identifies regions that maintain a diploid status in the tumour and defines L2RGC 
thresholds for amplifications and deletions. This allows the detection of CNVs, CN-LOH and two 
copy genes along the whole exome.  
 
 
Exons of different length and sequence in the genome affect the sequencing 
efficiency, which leads to variability in exon coverage. In order to address this problem, 
GenCNV first merges all targeted exons of each gene to rebuild a contiguous region that 
spans the entire length of the gene. This is then used to calculate the average gene 
coverage, thus allowing uniformly captured and sequenced exons to compensate for the 
non-uniform coverage of other exons within the same gene (Figure 20).  
 
 
 
Figure 20: Gene coverage calculation 
Shown is the step for calculating gene coverage. The coverage of each gene is calculated as the 
sum of coverage of the exons over the length of gene defined as the sum total of the length of 
exons constituting the gene. Merging the exons for a gene reduces the effect of non-uniform 
converge of exons (exon 3). 
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Further, coverage variation may still exist between genes within the same exome 
due to the sequence composition. To remove this bias, GeneCNV normalizes the gene 
coverage within the same exome using global median normalization (Figure 21).  Next, it 
normalizes gene coverage across tumour and matched normal exomes using quantile 
normalization (Figure 21). Quantile normalization is an important step that accounts for the 
coverage variability between two samples due to different DNA quality, library 
preparation protocols, sequencing settings and performance.  
 
 
 
Figure 21: Distribution of gene coverage at each step of normalization 
Shown are distribution of gene coverage at each the steps of normalization to remove variations 
due to technical issues related to WES data: length and sequence composition of the targeted 
exons, DNA quality, library preparation protocol, sequencing settings and performances. Median 
normalization is used to remove the coverage variations present within the exome and quantile 
normalization is used to remove the coverage variability between the samples. 
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To detect changes in copy numbers, GeneCNV exploits the difference in 
sequencing coverage between tumours and normal counterparts. It uses the normalized 
gene coverage in the tumour and normal exomes to calculate the gene coverage log2ratio 
(L2RGC) between tumour and matched normal for each targeted gene (Figure 22). In 
principle, L2RGC values around zero are indicative of genes with the same copy number in 
the tumour and in the normal counterpart, while L2RGC values higher than 0.6 
(corresponding to ≥1.5 fold change) or lower than -1 (corresponding to ≤0.5 fold change) 
indicate tumour-specific gene amplifications and deletions, respectively (Figure 22A). 
However, such fixed thresholds can be used only in genomes where no widespread 
chromosomal rearrangements occur. Since most cancer genomes acquire significant 
chromosomal instability, they often show substantially modified L2RGC spectra (Figure 
22B). 
 
Figure 22: Gene coverage log2ratio measure (L2RGC) spectrum 
Shown is the log2ratio (L2RGC) of coverage for each gene targeted in the whole exome sequencing 
data, calculated as the log ratio value between the normalized coverage of tumour over the normal. 
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A) The L2RGC is calculated between a normal sample from male and tumour sample from female 
of Mdr2-KO mice. Genes not undergoing CNVs have same coverage in both tumour and normal 
(grey) and hence have L2RGC values around zero (black lines). L2RGC of 0.6 corresponds to ≥ 1.5 
fold change in copy number (green dashed line) and of -1.0 corresponds to ≤ 0.5 fold change in 
copy number (red dashed line). Additional copy of chromosome X in female compared to male 
corresponds to L2RGC >0.6. Genes are amplified (green) if L2RGC >0.5 and deleted (red) if L2RGC 
<-1.0  B) Substantially modified spectra of L2RGC in a human WES cancer sample, where L2RGC 
for unaltered genes is substantially shifted from expected zero value. Amplified (green), deleted 
(red), CN-LOH (yellow) and unaltered genes, two-copy (grey) are coloured according to results 
from SNP arrays.  
 
 
For this reason, GeneCNV does not apply fixed L2RGC thresholds and instead 
derives them for each tumour sample by identifying the distribution of L2RGC in the 
diploid regions of the tumour genome. It first identifies regions of the tumour genome that 
maintain their allelic balance. In a normal diploid genome, allelic balance is maintained 
and the expected frequency of heterozygous germline mutations (SNPs) is around 50%. In 
the case of an allelic imbalance with different numbers of copies of the alleles, the 
frequency of the heterozygous SNPs deviates from the expected 50% (Figure 23). Hence, 
GeneCNV identifies regions of the tumour genome where the frequency of heterozygous 
SNPs is around 50%, thus indicating that their allelic balance is maintained. 
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Figure 23: Identification of regions of allelic balance using SNP frequency 
A) SNP frequency in human tumour sample. Regions of chromosome 5, 8, 18 and 19 undergo 
allelic imbalance whereas in other regions (yellow) allelic balance is maintained. B) Regions of 
allelic imbalance chromosome 5 and allelic balance of chromosome 13. Histogram shows the 
observed SNP frequency in normal and tumour conditions. As expected, for diploid region, the 
SNP frequency is around 50%, while it deviates from 50% in case of allelic imbalance. 
 
 
GeneCNV then identifies diploid regions within these allelic balanced regions, as 
the ones with L2RGC values in the lower tail of the L2RGC distribution (Figure 24), because 
regions of allelic balance but with high L2RGC values may correspond to tumour-specific 
amplifications of both alleles. GeneCNV uses the distribution of L2RGC values in diploid 
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regions to identify sample-specific L2RGC thresholds for amplification (L2RGCA) and 
deletion (L2RGCD,) (Figure 24).  
 
 
 
Figure 24: Identification of diploid region and estimating sample-specific thresholds  
A) L2RGC distribution in allelic balanced regions. Lower 10% of the distribution corresponds to 
diploid region (grey) that have lower values of L2RGC when compared to regions with 
amplification of both alleles (yellow). B) Estimation of sample-specific thresholds for deletion 
(L2RGCD) and amplifications (L2RGCA), calculated as -1 SD and +1 SD from the mean of the L2RGC 
distribution in the diploid region respectively.  SD=standard deviation 
  
 
Genes in regions of allelic imbalance and with L2RGC values within the thresholds 
are considered as undergoing CN-LOH. All the other genes are regarded as maintaining a 
two-copy status (Figure 25).  
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Figure 25: CNV calling  
Shown is the result of GeneCNV in calling amplified (green), deleted (red) and CN-LOH (yellow) 
genes. Genes are identified as amplified if L2RGC ≥ L2RGCA, deleted if L2RGC ≤L2RGCD and CN-
LOH if L2RGCD<L2RGC<L2RGCA and present in allelic imbalanced region. 
 
3.1.2 Comparison of GeneCNV with other methods 
We assessed the performance of GeneCNV as compared to three widely used 
exome-based methods, namely ExomeCNV, VarScan 2, and EXCAVATOR. As a test 
dataset, we used tumour and their matched normal WES data from 22 myelodysplasias 
(Yoshida, et al. 2011) and the six BSEP-HCCs (). Tumour-specific amplified, deleted and 
CN-LOH genes detected from the SNP arrays on the same samples were used as the gold 
standard for assessment. For each of the four exome-based methods, we measured 
sensitivity, specificity, accuracy, and the Jaccard index, which estimates the concordance 
with the SNP array results. Overall, GeneCNV showed the highest sensitivity (51%), 
accuracy (78%), and Jaccard index (36%) as compared to the other three methods (Figure 
26). In addition, although it had the second best specificity (88%), it showed the best trade-
off between specificity and sensitivity (Figure 27).  
 86 
 
 
Figure 26: Comparison of GeneCNV with other exome-based methods for CNV 
detection in 28 tumour exomes 
Reported are sensitivity, specificity, accuracy and Jaccard index of the four exome-based methods 
(GeneCNV, ExomeCNV, VarScan 2, and EXCAVATOR) in detecting all CNVs in the 28 samples 
as compared to SNP array 
 
 
Figure 27: Trade-off between sensitivity and specificity for the four exome-based 
methods 
Reported are the trade-off between sensitivity and specificity of each exome-based method in 
detecting CNVs in the 28 tumour exomes 
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In general, all four exome-based methods and in particular GeneCNV, were more 
sensitive in detecting amplified genes (Figure 28A) than deleted genes (Figure 28B). 
GeneCNV again showed the highest concordance with the SNP array results in detecting 
deletions (Figure 28B) whereas ExomeCNV and VarScan 2 showed high sensitivity but 
poor specificity, thus suggesting that the higher sensitivity of the other methods was due to 
an overall overestimation of deletions. Of the four exome-based method, only GeneCNV 
and ExomeCNV can detect CN-LOHs, and GeneCNV showed the best performance in all 
comparisons (Figure 28C).  
 
 
Figure 28: Performance assessment of the four exome-based methods in detecting 
amplifications, deletions and CN-LOH 
Reported are sensitivity, specificity, accuracy and Jaccard index of the four exome-based methods 
(GeneCNV, ExomeCNV, VarScan 2, and EXCAVATOR) in detecting (A) amplified genes, (B) 
deleted genes and (C) CN-LOH.  
 
Overall, exome-based methods had poor concordance with somatic copy number 
events called by SNP arrays (Figure 26). In order to understand the reasons for this, we 
assessed the performances in each tumour exome individually and noticed that exome-
based methods consistently failed to detect any CNVs in some tumours (Figure 29).  
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Figure 29: Performance assessment of the four exome-based methods in detecting 
altered genes in each 28 samples 
Reported are sensitivity, specificity, accuracy and Jaccard index of the four exome-based methods 
(GeneCNV, ExomeCNV, VarScan 2, and EXCAVATOR) in detecting CNVs in each sample. 
Samples with at least one altered gene are shown. 
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There are multiple and probably concurrent reasons for the poor performance of 
exome-based methods. One possible reason could be the poor SNP call rate of some of the 
SNP arrays (e.g. MDS-15, tAML-07 and tAML-02, (Table 13)), thus suggesting the 
occurrence of possible false positive calls from the SNP arrays. Moreover, tumour somatic 
alterations are usually a mixture of clonal and subclonal events, depending on when they 
occur during cancer growth. Sensitivity of exome-based method is lower in detecting 
subclonal CNVs, because the differences in coverage between tumour and normal samples 
are not high enough to identify changes in copy number. This leads to false negative calls 
from exome-based methods. To understand whether this was the case, we defined clonal 
events based on the B allele frequency and log R ratio of heterozygous SNPs in the 28 
tumour SNP arrays and re-assessed the performances of exome-based methods only on 
clonal events. Indeed, we noticed substantial increase in sensitivity, while specificity 
remained unchanged (Figure 30 and Figure 31). 
 
 
 
Figure 30: Comparison of GeneCNV with other exome-based methods for detection 
of clonal events in the 28 tumour exomes 
Reported are sensitivity, specificity, accuracy and Jaccard index of the four exome-based methods 
(GeneCNV, ExomeCNV, VarScan 2, and EXCAVATOR) in detecting clonal variant genes in the 
28 samples as compared to SNP array. 
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Figure 31: Performance assessment of the four exome-based methods in detecting 
clonal variants in each 28 samples 
Reported are sensitivity, specificity, accuracy and Jaccard index of the four exome-based methods : 
GeneCNV, ExomeCNV, VarScan 2, and EXCAVATOR, in detecting clonal variant genes in each 
sample as compared to SNP array. Samples with at least one clonal variant are shown. 
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3.1.3 Analytical and graphical outputs 
GeneCNV, in addition to providing the list of amplified, deleted and CN-LOH 
genes, also generates a graphical output with an analytical report of the results for each 
sample. This report includes information on the variation of gene coverage in the tumour 
and matched normal before and after normalization, which can be used to evaluate the 
coverage differences between the two exomes (Figure 32).  
 
 
 
Figure 32: Distribution of genes coverage before and after normalization 
Shown are the plots of gene coverage in the tumour and the normal exomes before and after the 
two normalizations: median (within sample) and quantile (between samples). 
 
GeneCNV next provides the L2RGC spectrum of all targeted genes in the tumour 
exome, with amplified, deleted, and CN-LOH genes depicted in green, red, and yellow, 
respectively (Figure 33). 
 
 
Figure 33: Spectrum of L2RGC in the tumour exome 
Displayed are the tumour L2RGC spectrum with amplified, deleted and CN-LOH genes highlighted 
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 It then provides a quantification of tumour-altered genes and the cumulative 
density map of their distribution along the chromosomes useful for understanding the most 
prevalent type of alteration in the sample (Figure 34). Finally, it summarizes all results in a 
Circos plot where altered genes that play known (Futreal, et al. 2004) or candidate (An, et 
al. 2014) roles in cancer are shown (Figure 35).  
 
 
 
Figure 34: Distribution of altered genes in the sample 
Shown is the percentage of somatic amplified, deleted and CN-LOH genes in each chromosome 
and in regions representing 10% of chromosome arms of the tumour exome 
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Figure 35: Circos plot summarizing the CNVs analysis for the sample 
Shown is the Circos plot summarizing all alterations and reporting known and candidate cancer 
genes that undergo modifications in the tumour exome. 
 
 
Apart from analysing tumour-normal exome pairs for CNVs and CN-LOHs, 
GeneCNV can also be used to compare CNV profiles across multiple samples. Such 
analysis is particularly useful when a cohort of patients is screened. In this case, the 
analysis report summarizes the percentage of total altered genes in each tumour exome 
(Figure 36A) and highlights the frequently altered genes across all samples (Figure 36B). 
The later analysis is particularly useful to pinpoint possible cancer driver events. It also 
provides the corresponding Circos plot and reports the recurrently altered cancer genes 
(Figure 37).  
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Figure 36: Distribution of amplified, deleted and CN-LOH genes across a cohort of 
tumour samples 
Reported is (A) the percentage of amplified, deleted and CN-LOH genes in each tumour exome 
and (B) the number of genes whose modifications recur across samples present in the cohort 
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Figure 37: Circos plot with overview of the CNVs detected in the cohort of tumour 
samples 
Shown is the Circos plot reporting all genomic alterations in each sample and recurrently altered 
cancer genes. 
 
3.2 Genomic alterations in human BSEP-HCCs and mouse Mdr2-KO HCCs  
After the comprehensive evaluation of GeneCNV, we next analysed the genomic 
landscapes in liver cancers. 
Human BSEP-HCC arises in a background of fibrosis and chronic inflammation in 
the absence of other mutagenic factors. Thus, it provides an opportunity to understand the 
contribution of chronic inflammation, cirrhosis and fibrosis to the acquired genomic 
alterations that trigger liver cancer. Mdr2-KO mouse model is aetiologically similar to 
BSEP-HCCs patients. Mdr2-KO mice have inactivating mutation of bile transporter gene 
ABCB4. Impairment of ABCB4 causes cirrhosis, fibrosis and chronic inflammation in liver 
leading to cancer. Hence, Mdr2-KO mouse provides the opportunity to validate the 
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contribution of genomic modification in BSEP-HCCs. We profiled the genomes and the 
exomes. We then applied VarScan 2 to detect SNVs and indels in both human and mouse. 
To detect CNVs, we used ASCAT for analysing SNP arrays for BSEP-HCCs and 
CNVnator for analysing WGS data for Mdr2-KO HCCs. In addition, we applied 
GeneCNV on WES and targeted re-sequencing data of Mdr2-KO HCCs for detecting 
CNVs.  
In the following paragraphs I will describe the observations on the genomic 
alterations that occur in seven BSEP-HCCs and fourteen Mdr2-KO HCCs.  
 
3.2.1 Human BSEP-HCCs do not accumulate mutations in known cancer genes 
We performed somatic mutations analysis on the whole exomes of six BSEP-HCCs 
and corresponding background livers. We identified a total of 44 single nucleotide variants 
(SNVs) and 8 small insertions and deletions (indels) (Table 14) with no mutation shared 
between any two lesions.  
 
 
Table 14: Somatic mutations and copy number alterations in human BSEP-associated 
HCCs 
ID Sex 
Age 
(Years) 
Tumour 
content 
Somatic 
SNVs 
Non-silent 
SNVs 
Somatic 
Indels 
Amplified 
genes 
Deleted 
genes 
LOH 
genes 
175 M 1.6 90% 7 3 0 10,688 1 4,964 
7860 F 2.6 90% 5 2 0 13,594 1,248 891 
23836 M 1.3 90% 5 1 0 12,450 19 2,847 
HB4R F 8.6 70% 25 9 7 5,598 2,575 7,124 
1790 M 11.7 60% 1 0 0 8,601 0 158 
2896 F 1.3 50% 1 0 1 9,687 244 3,702 
UKT M 1.3 40% NA NA NA 3,801 258 0 
Total - - - 44 15 8 18,428 3,628 9,757 
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Shown are the SNVs and CNVs detected in the BSEP-HCCs along with tumour content. Non-silent 
SNVs indicate mutations leading to protein modifications. None of the identified indels introduced 
a frameshift. Total refers to modifications found in at least one sample. The higher number of 
mutations found in sample HB4R compared to other samples probably reflects that this was a 
relapse and that the patient had been treated with chemotherapy.  
 
Each exome showed on average 0.05 somatic mutations per Mbp (Table 14), which 
was lower than the average mutation frequency observed in other human HCCs and other 
paediatric cancers (Vogelstein, et al. 2013) (Figure 38). This is in contrast to the adult 
HCCs that have higher mutation frequency. To exclude the possibility that we did not 
detect mutations due to poor sensitivity, we also measured the false negative rate of the 
variant calling method at different percentages of tumour content. We estimated 100% 
sensitivity in detecting somatic variants in lesions with >40% tumour content (Table 9).  
 
 
 
Figure 38: Mutation frequency in BSEP-HCCs, other liver cancer and paediatric 
cancers 
Reported are the average non-silent mutations frequencies in the six BSEP-HCCs as paediatrics 
adult HCC and paediatric cancers (Vogelstein, et al. 2013). 
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We detected a total of 15 non-silent modifications in 15 genes (Table 15). These 
mutated genes were not known driver gene in HCC or in any other human cancers (Futreal, 
et al. 2004; Zhang 2012) for example TP53, CTNNB1, and chromatin regulators as 
mentioned previously (Figure 3). Also some were known passengers that recurrently 
mutate in several cancer types ((Lawrence, et al. 2013) and http://ncg.kcl.ac.uk/). 
Moreover, most of them were usually either poorly or not expressed in human liver thus 
indicating that they are probably not functional in this tissue (Table 15).  
Overall, our results showed that BSEP-HCCs have low levels of mutational 
instability. The absence of mutations in known cancer driver genes suggests that the 
acquisition of mutational instability is not the driving force for the development of this 
type of liver cancer.  
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Table 15: Non-silent mutations in the seven human BSEP-HCCs 
Chromosome Position Reference Variant ID 
Gene 
Name 
RefSeq ID 
Modification 
on cDNA 
Modification 
on protein 
Sanger 
validation 
Expression 
in human 
liver 
Recurrent 
passenger 
gene 
chr11 55541019 G A 7860 OR5D13 NM_001001967 c.G106A p.V36I NA - YES 
chr8 106815605 G A 7860 ZFPM2 NM_012082 c.G3295A p.E1099K TRUE No No 
chr6 152755062 C G 23836 SYNE1 NM_182961 c.G4329C p.M1443I TRUE No YES 
chr2 27354663 C T 175 PREB NM_013388 c.G1036A p.V346M TRUE High No 
chr4 38051398 C G 175 TBC1D1 NM_015173 c.A1789G p.I597V TRUE Low No 
chr17 80391669 G A 175 HEXDC NM_173620 c.G418A p.A140T TRUE - No 
chr5 140589586 G C HB4R PCDHB12 NM_018932 c.G1107C p.R369S TRUE No No 
chr6 138725657 C T HB4R HEBP2 NM_014320 c.C25T p.P9S TRUE High No 
chr7 17838695 C G HB4R SNX13 NM_015132 c.G2381C p.R794P TRUE Low No 
chr8 28574094 C T HB4R EXTL3 NM_001440 c.C518T p.A173V TRUE Low No 
 
  
 100 
Chromosome Position Reference Variant ID 
Gene 
Name 
RefSeq ID 
Modification 
on cDNA 
Modification 
on protein 
Sanger 
validation 
Expression 
in human 
liver 
Recurrent 
passenger 
gene 
chr9 71491651 G A HB4R PIP5K1B NM_003558 c.G259A p.A87T TRUE Low No 
chr10 119134186 C A HB4R PDZD8 NM_173791 c.G553T p.A185S TRUE - No 
chr12 47629532 G A HB4R FAM113B NM_138371 c.G686A p.G229E TRUE - No 
chr15 43531430 G A HB4R TGM5 NM_004245 c.C790T p.R264W TRUE Low No 
chr20 60942292 G C HB4R LAMA5 NM_005560 c.C10G p.R4G NA No No 
 
Shown are for each non-silent mutation shown are chromosome; genomic coordinate on the human genome (GRCh37/hg19); reference and variant base; number of reads 
for the position (total coverage) and for the variant base (variant coverage); lesion where the variant was found; gene name and RefSeq accession number; mutation effect 
at the nucleotide and protein level; outcome of Sanger validation. NA = the region could not be PCR amplified; expression levels in human liver; and if the gene has been 
reported as frequently mutated in other tumours. For the methodology used to assess expression levels and recurrent mutation see the Methods. - = data not available. 
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3.2.2 Massive gene amplification occurs in human BSEP-HCCs 
We used genome-wide SNP arrays to investigate the occurrence of CNVs in seven 
BSEP-HCCs, including all tumours screened for point mutations and one additional lesion 
(Table 14). We detected a total of 18,428 and 3,628 genes that were amplified or deleted, 
respectively in at least one of the seven samples (Table 14 and Figure 39) with CNV 
frequency higher than that observed in adult HCCs (Figure 40). We also detected 9,757 
genes with CN-LOH in at least one of the seven samples that recurrently affected 
chromosome 11 and to a lesser extent chromosome 16 (Figure 39).  
 
 
 
Figure 39: Copy number alterations in the 7 BSEP-HCCs 
Circos plot reporting amplifications, deletions, and CN-LOH in all chromosomes of the seven 
BSEP-HCCs 
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Figure 40: CNV frequency in BSEP-HCCs and adult HCCs 
Shown is the frequency of amplifications (green) and deletions (red) in this study and other studies 
on adult HCCs. Above panel shows the CNV frequency in the seven BSEP-HCCs as compared to 
each adult HCCs (Totoki, et al. 2011; Fujimoto, et al. 2012; Guichard, et al. 2012). Below panel 
shows the average CNV frequency in the BSEP-HCCs and all adult HCCs take together. Frequency 
was measured as percentage of altered genes among total human genes and as CNVs per 100 base 
pairs. Bars indicate the minimum and maximum altered fractions across samples. 
 
 
We found low-level copy number gains (on average 4 copies per aberrant region) 
as the most pervasive alterations, with around 38% of the total genome amplified in each 
sample (Figure 41A). We further analysed these samples for focal and arm-level CNV 
events (Beroukhim, et al. 2010) and observed that deletions were mostly focal and sample-
specific with the exception of sample HB4R that had three arm-level deletions in 
chromosomes 1p, 4q and 17q (Figure 41). Instead copy number gains were arm-level or 
multiple focal events that led to the amplification of entire chromosomes, most notably in 
chromosomes 8, 19, and 20 in the majority of lesions (Figure 41B).  
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Figure 41: Distribution of genomic alterations in the 7 BSEP-HCCs 
A) Percentage of chromosomes that undergo CN-LOH, deletions and amplifications in each 
samples. "all" refers to the average percentage of altered chromosomes for each sample and the 
percentage (red) is the average percentage across the seven samples. B) Arm-level CN-LOH 
events, deletions, and amplifications for each chromosome in each sample. Arm-level alterations 
were identified as single CNVs spanning ≥98% of the chromosome arm length. 
 
 
 104 
To validate these results, we performed fluorescence in situ hybridization (FISH) 
on sample 23836 with probes located on both arms of chromosome 19 and confirmed the 
amplification of this chromosome (Figure 42).  
 
Figure 42: Amplification of chromosome 19 in the sample 23836 as validated by FISH 
Shown are four representative hepatocyte nuclei (blue, DAPI staining) from a paraffin-embedded 
tumour sample 23836 confirming the amplification of chromosome 19 in patient 23836 as 
validated by FISH. Probes on chr19p13 (green) and on chr19q13 (orange) were used and nuclei in 
a-b-c show additional copies of chromosome 19, while the nucleus in d has only two. Scale bars = 
20 um  
 
 
Multiple amplifications likely occurred via step-wise DNA rearrangements rather 
than through one-shot catastrophic events, because we did not detect any sign of 
chromothripsis in most of the samples. The only exception was sample UKT (Figure 43), 
where we detected several consecutive oscillations between two copy number states in 
chromosomes 4 and 6, which may suggest the occurrence of catastrophic rearrangement 
events in this sample (Stephens, et al. 2011; Korbel and Campbell 2013). 
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Figure 43: Oscillations of copy number alterations in sample UKT 
Shown are the regions with at least ten oscillations between two copy number states are highlighted 
in pink for chromosomes 4 (A) and 6 (B) of human sample UKT Copy numbers were derived from 
ASCAT and adjacent regions with same copy number were merged before counting oscillations. 
Only the chromosome portion where ten consecutive changes between the same copy number 
states were observed is reported (Korbel and Campbell 2013). 
  
 
To find possible cancer drivers we focussed on genes that were recurrently altered 
in the majority of samples and in particular on 935 known cancer genes that were 
amplified in the genome of at least four of the seven lesions (Figure 44). Pathway 
enrichment analysis of these genes highlighted three top-scoring pathways, namely the 
MAPK, the ErbB, and the PI3K/Akt pathways (corrected p-value =3x10-06, 9x10-06, and 
2x10-05, respectively, hypergeometric test).  These pathways form a complex and 
interconnected signalling network (Manning and Cantley 2007; Raman, et al. 2007) and 
their activation is a known driver event in some types of liver cancer (Calvisi, et al. 2006; 
Yea, et al. 2008; Calvisi, et al. 2011).  
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Figure 44: Recurrently altered genes in the 7 BSEP-HCCs 
Reported are the amplified (green) and deleted (red) genes in the seven BSEP-HCCs, grouped 
according to the number of samples in which they were altered. 
 
 
The results of CNV analysis showed that BSEP-HCCs are characterized by a 
pervasive occurrence of chromosomal rearrangements that lead to massive gene 
amplification. Recurrent events involve the amplifications of signalling genes, thus 
suggesting that the alteration of signalling pathways may be involved in the development 
and progression of HCC. 
 
3.2.3 The genomic landscape of Mdr2-KO HCCs resembles that of BSEP-HCCs 
To validate the potential contribution of the genomic alterations in BSEP-HCC, we 
profiled the cancer genomes of Mdr2-KO mice, which, like human BSEP-deficient 
patients, develop HCC due to impairment of bile formation (Smit, et al. 1993; Pikarsky, et 
al. 2004). We sequenced the exomes of nine HCCs extracted from the liver of seven Mdr2-
KO mice using the kidney of one of them as a reference (Table 16) and identified a total of 
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118 somatic SNVs and no indels (Table 16). Also in this case, we confirmed >93% 
specificity of the variant calling. None of the 118 SNVs was shared between any two 
tumours, and 60 of them led to modifications in 60 proteins. As with BSEP-HCCs, no 
mutated gene was a known driver of HCC or of other cancers (Futreal, et al. 2004; Zhang 
2012) and only a few were expressed in the liver (Su, et al. 2004) (Figure 45). We further 
sequenced the coding exons of 866 mouse orthologs of human cancer genes in four 
additional Mdr2-KO HCCs, using the normal liver as a reference. In this case, we 
increased the depth of sequencing coverage to further exclude that mutations might have 
been missed because of high intratumoral heterogeneity. Again we found no somatic 
mutations and no small indels in any cancer genes in any of the four samples.  
 
Table 16: Somatic mutations and copy number alterations in Mdr2-KO HCCs 
ID Sex 
Age 
(Months) 
Size 
(cm) 
Tumour 
content 
Sequenced 
regions 
Somatic 
SNVs 
Non-silent 
SNVs 
Amplified 
genes 
Deleted 
genes 
51509/1 M 16 1.1 20%  
Whole 
exome 
8 5 59 0 
60400/2 F 13 1.4 40%  8 3 113 0 
218/1 M 15 1 50%  5 2 298 1 
52686/1 F 15 0.7 50%  8 4 15* 2 
58853/3 M 15 1.7 60%  20 8 631 0 
60400/1 F 13 0.9 60%  9 3 455 0 
58163/3 M 15 3 70%  17 6 333 1 
58163/4 M 15 3 70%  39 27 625 0 
215/1 M 14 1.8 80%  4 2 562 0 
54913/10 F 10 0.1 NA 
866 cancer 
genes 
0 0 49 0 
54913/8 F 10 0.5 NA  0 0 10 0 
55481/10 F 10 0.3 NA  0 0 17 0 
55484/4 F 10 3 30%  0 0 41 0 
Total - - - - - 118 60 2,507 4 
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Shown are the SNVs and CNVs detected in Mdr2-KO HCCs. Nodules with insufficient amount of 
tissue for histology inspection where defined as NA (not available). Non-silent SNVs indicate 
mutations leading to protein modifications. Total refers to modifications found in at least one 
sample. *TaqMan copy number assay assessed a high number of false negatives for this sample, 
thus suggesting an overall underestimation. 
 
 
 
Figure 45: Expression levels of the mutated genes in normal liver of mouse  
Shown are the expression levels of the mutated genes in normal liver (Su, et al. 2004) in the two 
replicates (Exp.1 and Exp.2) and in the average expression over the replicates (Union). Normalized 
gene expression (Nexp) was calculated as the gene expression level over the median expression of 
all genes in liver. Values above and below zero indicate gene expression higher and lower than the 
median. -1 indicates no expression in liver 
 
 
To assess whether the massive copy number alteration observed in BSEP-HCC also 
occurred in mouse tumours, we used, GeneCNV, a novel method developed in our group. 
GeneCNV integrates frequency of heterozygous SNPs together with difference in the 
normalized gene coverage between the tumour and the reference; to detect CNVs directly 
from targeted sequencing data. In the 13 mouse HCCs, we identified a total of 2,510 
altered genes, almost all of which were amplified (2,507, Table 16). We validated 10 
randomly selected amplified genes with TaqMan copy number assay and estimated 70% 
sensitivity, 93% specificity and 84% accuracy of the method. To exclude the possibility 
that we did not detect deletions due to poor sensitivity, we compared the copy numbers of 
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genes on the male X chromosome with those of female samples in mouse and estimated 
100% sensitivity and accuracy in calling deletions (Table 17). We further sequenced the 
whole genomes of two late stage Mdr2-KO HCCs from two different mice, using the 
corresponding kidneys as matched references. We again observed an overall higher 
occurrence of amplifications than deletions, with a total of 1,074 amplified and 117 deleted 
genes in the two genomes. For one of the two tumours (ID: 60400/1), which had been also 
used for exome sequencing, we observed that by far most of the amplified genes detected 
in the whole exome were also found in the whole genome (85%), thus further confirming 
the reliability of the method.  
 
Table 17: Sensitivity assessment of the method in detecting deletions in Mdr2-KO 
HCCs 
ID Sex 
Reference 
ID 
Sex 
Genes on 
Chr X 
Genes detected 
as deleted 
Sensitivity (%) Accuracy (%) 
218/1 M 52686/1 F 926 925 100 100 
218/1 M 60400/1 F 926 926 100 100 
218/1 M 60400/2 F 926 926 100 100 
 
Shown are the sensitivity and accuracy in detecting deletions by comparing genes in chromosome 
X between male and female samples. Female samples are used as the reference sample. Reported 
are the sample ID and sex of the test and reference samples, genes present and deleted in 
chromosome X, sensitivity and accuracy. Sensitivity estimated as the number of genes detected as 
deleted in chromosome X over the total number of genes present in chromosome X. 
 
 
The results of the genomic profiling of Mdr2-KO HCCs showed that, similarly to 
human BSEP-HCCs, these tumours are not prone to accumulate somatic point mutations 
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and small indels. Instead, they show pervasive chromosomal instability with overwhelming 
recurrence of gene amplification. 
 
3.2.4 Somatic CNVs accumulate during Mdr2-KO HCC progression 
Since BSEP-HCCs with high tumour content (90%) accumulated higher numbers 
of gene amplifications than those with low tumour content (Table 14), we used mouse 
HCCs to verify and quantify this signal. Interestingly, a positive correlation between 
tumour size and fold change of the amplified regions was already reported in HCCs from 
Mdr2-KO mice that underwent partial hepatectomy (Barash, et al. 2010). We confirmed a 
positive correlation between the number of amplified genes and the HCC content (Pearson 
correlation coefficient = 0.78, Figure 46). Moreover, bigger lesions showed significantly 
more amplified genes than smaller lesions (p = 0.03, Wilcoxon test, N = 10, Figure 46). 
This result suggests that amplifications tend to occur at later stages of tumour 
development. Furthermore, we also observed that amplifications accumulated 
preferentially near the centromeres (Figure 47) of mouse chromosomes, which are known 
hotspots for mitotic recombination (Jaco, et al. 2008). 
 
 
Figure 46: Accumulation of amplifications during tumour progression 
Reported is the correlation between the number of amplified genes and HCC content in mouse 
tumours that underwent whole exome and whole genome sequencing (A) and the comparison 
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between number of altered genes in small (<15mm) and big (>15mm) lesions with minimum and 
maximum number of altered genes in the two groups are shown as bar (B). Correlation coefficients 
were measured using Pearson correlation testing. * = p <0.05, Wilcoxon test, N=10.  
 
 
 
Figure 47: Preferential accumulation of amplifications near centromere 
Shown are the cumulative fractions of gene amplifications (amplified genes/total genes) in regions 
representing 10% of the q arm length in all mouse chromosomes. In case of exome re-sequencing, 
the chromosome length was calculated as the region from the first to the last targeted base in the 
SureSelect XT Mouse All Exon kit (Agilent). Pearson correlation coefficients were calculated 
between the fraction of amplified genes in each region and the proximity to the centromere of each 
chromosome. *52686/1 was the only tumour with a negative correlation, likely due to overall 
underestimation of CNVs in this sample. 
 
 
In both the Mdr2-KO HCC genomes we identified inverted translocations 
involving chromosomes 8 and 14 in one tumour (ID: 218/3, Figure 48A) and chromosomes 
8 and 19 in the other (ID: 60400/1, Figure 48B). Interestingly, mouse chromosome 8 is the 
ortholog of human chromosomes 8 and 19, which are the most recurrently amplified 
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chromosomes in the human BSEP-HCCs. Through the analysis of discordantly aligned 
read pairs, we were able to map the two breakpoints at base pair resolution and both 
rearrangements were confirmed with PCR amplification and Sanger sequencing (Figure 
48A and B). In one of the two tumours (ID: 60400/1), we counted ten consecutive disomic 
and trisomic copy number states in the region of chromosome 19 involved in the inverted 
translocation (Figure 48B and Figure 49). Therefore, again similarly to the human samples, 
we found possible indications that one-off catastrophic events could be responsible for the 
acquisition of at least some of the genomic rearrangements in this liver cancer type.  
 
Figure 48: Inverted translocations in mouse samples 218/3 and 60400/1 
Shown are the breakpoint locations at base resolution for inverted translocations between (A) 
chromosomes 8 and 14 of lesion 218/3 and (B) between chromosomes 8 and 19 of lesion 60400/1. 
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Through the analysis of discordant sequencing read pairs, breakpoints of both rearrangements were 
mapped at base pair resolutions and confirmed by PCR amplification and Sanger sequencing of 
breakpoint regions. In sample 60400/1, 10 consecutive copy number oscillations at chromosome 19 
were detected in proximity of the rearrangement with chromosome 8. The genomic coordinates of 
amplified regions in each chromosome are shown in brackets. 
 
 
 
Figure 49: Oscillations of copy number alterations in Mdr2-KO HCC sample 60400/1 
Shown is the region with at least ten oscillations between two copy number states is highlighted in 
pink for chromosomes 19 in mouse sample 60400/1. Copy number ratio for each region was 
calculated by dividing its normalized coverage by the normalized coverage of the normal 
counterpart over 300bp long regions. It should be noted that in case of the mouse sample 60400/1 
the region of oscillation is probably longer, as shown by the whole chromosome diagram. We 
however reported only the chromosome portion where ten consecutive changes between the same 
copy number states were observed (Korbel and Campbell 2013). 
 
 
In summary, the CNV analysis of Mdr2-KO HCCs showed that they undergo 
frequent genomic rearrangements that lead to gene amplifications. CNVs mostly occur at 
late stages of cancer development, thus suggesting a possible driver role in tumour 
progression. 
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3.2.5 JNK is deregulated in Mdr2-KO HCCs 
Given the similarities in genomics landscape of acquired alterations between 
BSEP- and Mdr2-KO HCCs, we performed pathway enrichment analysis on 27 genes that 
were amplified in most human and mouse cancers (Figure 50). Again we found the MAPK 
signalling cascade among the top scoring pathways (corrected p = 2x10-02, 
hypergeometric test) (Table 18). In particular Map2k7 was amplified in >70% human and 
mouse HCCs (5 out of 7 and 10 out of 14, respectively) (Figure 50).  
 
 
Figure 50: Recurrently altered genes in Mdr2-KO HCCs 
Reported are the amplified (green) and deleted (red) genes in all the sequenced Mdr2-KO HCCs, 
grouped according to the number of samples in which they were altered. No gene was modified in 
more than seven tumours. Circos plot reporting amplifications and deletions in the 10 whole exome 
or whole genome sequenced samples with the 27 recurrently altered genes in both human and 
mouse. Map2k7 was amplified in majority of the human and mouse HCCs (> 70%). 
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Table 18: List of enriched pathways in the 27 recurrently amplified genes in human 
and mouse tumours 
Pathway Source p-value Corrected p-value Amplified components  
Insulin Signalling Wikipathways 0.0003 0.0115 
KIF5B; MAP3K8; 
MAP2K7; INSR 
MAPK signalling 
pathway 
Biocarta/PID 0.0064 0.0230 MAP3K8; MAP2K7 
Signalling by TGF-beta 
Receptor Complex 
Reactome 0.0073 0.0230 ARHGEF18; BAMBI 
 
Reported are the pathways found to be enriched in the 27 genes that are recurrently amplified in 
both human and mouse tumours (ConsensusPathDB (Kamburov, et al. 2013)), source from where 
the pathways information is taken, hypergeometric p-value, p-value after false discovery rate 
correction and amplified genes present in the pathway.  
 
 
Since Map2k7 was the most frequently amplified gene in Mdr2-KO HCCs, we 
screened 35 additional tumours from 16 distinct mice by TaqMan copy number assay to 
better quantify the frequency of its amplification. Altogether, Map2k7 was amplified in 14 
of the 49 Mdr2-KO nodules that were analysed overall (29%). This frequency was 
significantly higher than expected by chance (p=6x10-04, binomial test), but lower than 
the one we found previously in the exome sequenced samples. The difference was likely 
due to the presence of many adenomas among the screened samples. Indeed, 7 of the 12 
nodules (58%) with high HCC content (≥40%) showed Map2k7 amplification, a fraction 
significantly higher than expected by chance (p=9x10-05, binomial test) (Figure 51). This 
result further supports the general observation that gene amplification tends to occur 
preferentially in lesions with high tumour content. 
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Figure 51: Map2k7 amplification in 12 Mdr2-KO samples with >40% HCC 
Shown is the percentage of nodules with Map2k7 amplification in the 12 Mdr2-KO tumour 
samples with >40% tumour content. * = p 9x10-05, Binomial test,  N=12. 
 
 
To investigate whether additional copies of Map2k7 directly impinge on gene 
expression, we measured Map2k7 mRNA levels in age-matched Mdr2-KO normal, 
inflamed, and tumoral liver samples. Significant overexpression was found in tumours with 
Map2k7 amplifications compared to normal and inflamed Mdr2-KO liver (Figure 52) thus 
indicating that gene amplification led to increased expression.  
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Figure 52: Map2k7 expressions in Mdr2-KO HCCs, inflamed and in normal samples 
Shown is the Map2k7 expression measured by qPCR in Mdr2-KO nodules where the gene is 
amplified, in nodules with no amplification, in Mdr2-KO inflamed livers, and in age-matched 
Mdr2-WT livers. Dots represent the different samples in each group. * = p <0.05, ** = p<0.005, 
Wilcoxon test,  N=71. Maximum, minimum, and median are shown for each distribution. 
 
 
Map2k7 is an upstream regulator of the c-Jun NH(2)-terminal kinase (JNK) (Davis 
2000; Tournier, et al. 2001; Wada, et al. 2004), which is activated mainly by pro-
inflammatory cytokines and environmental stress (Weston and Davis 2007). JNK 
deregulation has been already associated with liver cancer, where it plays cell- and stage-
dependent roles during HCC development (Sakurai, et al. 2006; Hui, et al. 2007; Hui, et al. 
2008; Beroukhim, et al. 2010; Nikolaou, et al. 2012). Interestingly, upstream and 
downstream direct JNK interactors, as well as JNK itself, were altered in several human 
and mouse samples (Figure 53). 
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Figure 53: Frequent alteration of upstream and downstream direct JNK interactors 
in human and mouse HCCs  
Shown are the 13 primary and two secondary JNK interactors that are frequently altered in Mdr2-
KO and BSEP-HCCs. Numbers of lesions with the amplified gene are reported for mouse (light 
blue) and human (deep blue).  
 
 
These data showed that gene amplifications occurring in Mdr2-KO tumours 
preferentially hit signalling genes, most notably JNK direct interactors, which may have a 
driver role in triggering liver tumour progression.  
 
3.2.6 JNK inhibition arrests carcinoma progression in Mdr2-KO mice 
We next investigated whether JNK inhibition might interfere with liver cancer 
progression by treating Mdr2-KO mice with SP600125, a synthetic polyaromatic chemical 
that directly inhibits the JNK kinases (Bennett, et al. 2001; Nikolaou, et al. 2012; Shibata, 
et al. 2012; Ye, et al. 2012; Lan, et al. 2013; Tan, et al. 2013). We randomized 23 Mdr2-
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KO mice to receive either SP600125 or vehicle only (12 and 11 mice, respectively). We 
sacrificed mice after three weeks of treatment and compared the tumours from the two 
cohorts in terms of Map2k7 amplification, nodule number, size, histology, and tumour 
content. We found a significantly lower proportion of lesions with Map2k7 amplification 
in the treated mice (5 out of 36, 14%) in comparison to the untreated cohort (13 out of 35, 
37%, p = 0.03, Fisher’s exact test) (Figure 54). Thus, tumours with Map2k7 amplification 
were more sensitive to JNK inhibition than those without Map2k7 amplification, which 
explains their relative depletion after treatment. Indirectly, this result also indicated that the 
effects of SP600125 were mainly caused by its on-target activity on JNK. Despite of the 
two groups showing a comparable number of tumours per mouse, no mouse treated with 
the JNK inhibitor had nodules bigger than 20 mm, which instead represented ~20% of all 
lesions in the untreated group (Figure 55). In a reciprocal fashion, the proportion of 
nodules with diameters between 10 and 20 mm was significantly higher in treated mice 
than in the untreated group (Figure 55).  
 
Figure 54: Nodules with Map2k7 amplification  
Reported is the percentage of nodules amplified in treated and untreated Mdr2-KO mouse groups. 
Map2k7 is significantly amplified in less number of nodules in treated mouse group (p-value=0.03, 
Fisher's exact test) 
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Figure 55: Nodule size in treated and untreated Mdr2-KO mouse groups 
Reported are the size differences in nodules from treated and untreated Mdr2-KO mouse groups 
along with representative images of livers from a treated and an untreated mouse. Nodules from 
treated mice were significantly enriched in 10-20 mm lesions, but had no lesions >20 mm. The 
latter represented ~20% of nodules in untreated mice. Arrows indicate the nodules. Scale bar = 1cm 
 
 
We then compared the histological composition of nodules in the treated and 
untreated groups and observed that nodules bigger than 10 mm showed significantly higher 
proportion of adenoma and lower proportion of adenocarcinoma in treated than in 
untreated mice (Figure 56). We did not detect any difference in the histological 
composition of small lesions (diameter <10 mm) between the two groups. Similarly, we 
compared the tumour content per mouse in the two cohorts, and again found that treated 
mice showed an overall significant depletion in HCC, while purely adenomatous nodules 
were over-represented (Figure 57) 
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Figure 56: Histological composition of nodules in the cohort of treated and untreated 
mice 
Reported is histological composition of nodules from treated and untreated mice along with 
representative photomicrograph histologic sections of HCC and adenoma from treated and 
untreated livers, respectively (hematoxylin / eosin). Nodules in the two cohorts of mice were 
divided into two groups by size (<10 mm and >10 mm) and the Scale bar = 150um. 
 
 
Figure 57: Tumour content in the treated and untreated mice 
Shown is the cumulative tumour content in treated and untreated mice. Tumour content was 
measured as a percentage of HCC in each nodule. Nodules with HCC fraction >10%, <10%, and 
with no HCC were compared between treated and untreated mice. 
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Altogether, these data suggested that the drug blocks tumour progression towards 
bigger lesions with higher HCC content, thus supporting the role of JNK deregulation in 
progression more than in initiation of Mdr2-KO tumours. They were also consistent with 
the results of the CNV analysis, and specifically with the tendency of gene amplification, 
and of Map2k7 amplification in particular, to occur in large lesions with high HCC 
content. 
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Discussion 
HCC has a complex pathogenesis in which external factors such as virus infection, 
exposure to aflatoxin and alcohol all cooperate with inflammation to promote cancer. 
Recent studies have highlighted recurrent mutations in key cancer genes such as TP53, 
CTNNB1, and chromatin regulators and genomic regions that frequently undergoing CNVs 
(Li, Zhao, et al. 2011; Totoki, et al. 2011; Fujimoto, et al. 2012; Guichard, et al. 2012; 
Huang, et al. 2012; Jiang, et al. 2012; Sung, et al. 2012). Nevertheless, considerable 
differences in the acquired genomic alterations have been observed in these studies that 
suggest genetic heterogeneity of HCC depending on the initiating agents (Zhang 2012). So 
far, all the genomic re-sequencing studies in HCC have been mostly focussed on HCV- 
and HBV-associated HCCs (Li, Zhao, et al. 2011; Totoki, et al. 2011; Fujimoto, et al. 
2012; Guichard, et al. 2012; Huang, et al. 2012; Jiang, et al. 2012; Sung, et al. 2012). 
However, HCCs invariably arise in the background of chronic inflammation, cirrhosis and 
fibrosis resulting from sustained liver injury. Currently, a clear understanding of how 
combination of chemical damage, inflammation and cirrhosis directly contribute to the 
acquisition of critical genomic changes that lead to cancer is lacking. Hence, we 
investigated the genomic landscapes of genomes of etiologically related human and mouse 
HCCs that develop cancer in response to chronic exposure to non-neutralized bile acids 
and in the absence of exogenous direct (viruses) or indirect (alcohol) mutagens. We 
studied the mutational and CNVs landscapes in both human and mouse HCCs. To this aim, 
we also developed a novel method, GeneCNV, for the detecting CNVs from WES data. In 
the successive paragraphs, I will first explain the rationale of GeneCNV and review its 
performance followed by detailed discussion on the identification and characterization of 
the genomic alterations in the human and mouse HCCs. 
WES is one of the extensively used next generation sequencing technology for 
genotyping and identification of putative pathogenic mutations because it is time and cost 
effective. In addition, WES gives insights into the genomic alterations of protein coding 
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genes, which are often the most interesting to follow up. Although, a few methods have 
been developed to call CNVs from exome re-sequencing data in recent years, they all have 
some limitations (Liu, et al. 2013; Zhao, et al. 2013). First, all these methods use 
segmentation to identify CNVs. Ideally, segmentation will merge exons with same copy 
number into one segment such that the coverage variance is minimized within the same 
segment but maximized between adjacent segments (Figure 58). Segmentation has been 
successfully used in detection of CNVs from WGS and microarrays where information 
along the whole genome is available. However, its efficiency may be reduced when 
applied to WES data because of the scattered distribution of the exons in the genome. In 
particular, segmentations may lead to overestimation of CNVs in some cases (Figure 58). 
Second, none of the developed methods take into consideration the effect of normalization 
on samples undergoing large-scale rearrangement, which is a common feature of cancer. 
The distribution of L2RGC in such samples is skewed and the expected L2RGC for a diploid 
gene is shifted from the expected zero value. This may lead to ambiguous calls in methods 
such as VarScan 2 and EXCAVATOR that use fixed L2RGC values to define the thresholds 
for detecting altered genes. Another limitation of many methods is that they are unable to 
detect CN-LOH events from WES data. GeneCNV uses a novel approach to address these 
issues. First GeneCNV does not rely on segmentation of the genome to detect genomic 
alterations and instead calls copy number changes at the gene level by merging the targeted 
exons within a gene to form a contiguous representative gene. GeneCNV, then removes the 
bias in coverage due to sequence composition, DNA quality, library preparation protocols, 
and sequencing settings (Harismendy and Frazer 2009; Knierim, et al. 2011; Sims, et al. 
2014) and make the gene coverages between the test and the reference samples comparable 
using normalization techniques. It next integrates the frequency of germline mutations 
(SNPs) with L2RGC to identify sample-specific thresholds for amplifications and deletions. 
Thus, the CNV calls made by GeneCNV are not affected by the modified spectrum of 
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L2RGC in samples with large-scale CNVs. In addition, GeneCNV is able to detect CN-
LOH events by integrating SNP frequency with L2RGC. 
 
 
 
Figure 58: Segmentation approach for calling CNVs  
Shown are the steps during segmentation and copy number call where calls at each exon are 
sequentially merged together with adjacent exons. Exons 1 and 2 (copy number=3) and exon 3 are 
amplified (copy number > 3). Exons 5 and 7 are deleted while exons 4 and 6 are copy-neutral. In 
the final CNV calls, copy neutral exons 4 and 6 are merged with deletion segments, which may or 
may not be true. In the situation that these are true, segmentation may lead to overestimation of 
deletions. Taken from (Sathirapongsasuti, et al. 2011) 
 
 
We evaluated the performance of GeneCNV and compared with three other exome-
based methods: ExomeCNV, VarScan2 and EXCAVATOR. In general, all exome-based 
methods showed low sensitivity in detecting CNVs. Nonetheless, GeneCNV performed 
better than the other existing methods and showed the highest concordance with the SNP 
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arrays (Figure 26). The poor sensitivity of all exome-based methods in majority of the 
samples were due to the subclonal genomic alterations that arise late in the cancer 
progression. We observed an increase in the sensitivity for all exome-based methods when 
only clonal variants were considered for the evaluation (Figure 30). Subclonal variants 
may be difficult to detect due to inappreciable differences in the coverage between tumour 
and normal samples, which may be further affected due to the non-contiguous nature of the 
exons. Though the current exome-based methods are limited to detecting clonal variants 
from WES data, GeneCNV performed better than other exome-based methods and had the 
highest sensitivity and concordance with SNP-derived CNV results.  In addition, 
GeneCNV showed the highest sensitivity in detecting CN-LOHs (Figure 28). Altogether, 
GeneCNV provided the best solution in detecting CNVs and CN-LOHs among the exome-
based methods studied here, thus highlighting the advantage of GeneCNV over other 
exome-based methods in detecting altered genes. Further improvements in GeneCNV can 
be anticipated by including information on tumour purity using a combinatorial approach 
integrating SNP frequency and L2RGC values.  Since only limited combinations of 
mutation frequency and L2RGC values are possible for a given copy number state, any 
deviation from the expected values could be due to tumour heterogeneity or tumour purity 
(Liu, et al. 2013). This approach has been successfully applied in SNP arrays, where it has 
been shown to correctly identify the tumour purity and call copy number states (Attiyeh, et 
al. 2009; Popova, et al. 2009; Greenman, et al. 2010; Van Loo, et al. 2010; Yau, et al. 
2010; Li, Liu, et al. 2011). After assessing the performance of GeneCNV in detecting 
altered genes, we next applied it to detect CNVs from exome of mouse HCCs. 
We studied the landscape of somatic mutations and CNVs in seven human and 
fourteen mouse tumours. Despite the small number of samples in our study, the genomic 
profiling of both human and mouse showed a consistent genomic signature within and 
between species. The results of our screenings showed that this particular type of liver 
tumours accumulate a surprisingly low number of somatic SNVs and small indels. None of 
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the mutations detected were found in cancer genes such as TP53, CTNNB1, and chromatin 
regulators that were previously reported to play a driver role in HCCs (Li, Zhao, et al. 
2011; Totoki, et al. 2011; Fujimoto, et al. 2012; Guichard, et al. 2012; Huang, et al. 2012; 
Jiang, et al. 2012; Sung, et al. 2012). Instead, these HCCs acquired massive CNVs with 
preferential accumulation of copy number gains (Figure 40). Our findings on Mdr2-KO 
tumours are in agreement with previous studies that have shown high degrees of 
chromosomal instability in Mdr2-KO HCCs with pervasive amplifications, no detectable 
deletions, and recurrent amplifications in chromosomes 5, 8, and 18 after partial 
hepatectomy (Barash, et al. 2010). In both human and mouse, we found possible 
indications that one-off catastrophic events could be responsible for the acquisition of at 
least some of the genomic rearrangements in this liver cancer type. The remarkable 
similarity in the genomic alterations between human and mouse HCCs suggests that Mdr2-
KO mimics the molecular basis of this type of human liver cancer. Interestingly, none of 
analysed tumours showed a level of mutation and chromosomal instability that is 
comparable with other HCCs reported in recent studies (Li, Zhao, et al. 2011; Totoki, et al. 
2011; Fujimoto, et al. 2012; Guichard, et al. 2012; Huang, et al. 2012; Jiang, et al. 2012; 
Sung, et al. 2012). These studies have mostly sequenced virus (HBV or HCV) or alcohol 
induced HCCs that acquire mutational instability and tend to accumulate gene deletions 
rather than amplifications (Guichard, et al. 2012). The genomic signature of HCC induced 
by bile acids and inflammation is unique and greatly differs from that of the other HCCs 
previously sequenced. These findings confirm the genetic heterogeneity of liver cancers 
caused by different etiological agents and, at the same time, the remarkable analogy among 
human and mouse tumours with similar etiopathogenesis.  
We observed that both human BSEP-HCCs and mouse Mdr2-KO HCCs 
accumulate CNVs at late stages of cancer development. This may suggest a possible driver 
role of CNVs in tumour progression rather than initiation. The detailed analysis of CNVs 
in Mdr2-KO mouse cancer genomes revealed that copy number gains tend to cluster in 
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genomic regions with high mitotic recombination rates, such as centromeres and telomeres 
(Figure 47). Significant association has been observed for both CNVs and chromosomal 
rearrangements with increased recombination rate, hence making these regions as fragile 
sites in the genome (Volker, et al. 2010).  Furthermore, these regions have been associated 
with LOH events (Gupta, et al. 1997) and replication stress (Dereli-Oz, et al. 2011; Burrell, 
McClelland, et al. 2013; Burrell, McGranahan, et al. 2013). Studies have shown that 
chronic inflammation induces the production of reactive oxygen species that may lead to 
oxidative DNA damage and reduced DNA repair causing genomic instability (Carter, et al. 
2006; Barash, et al. 2010) (Figure 59). Moreover there is preliminary evidence for 
increased oxidative stress in the chronic inflammatory stages in Mdr2-KO mice 
(Katzenellenbogen, et al. 2006), which may explain the up-regulation of genes associated 
with chromosomal instability in the liver of Mdr2-KO mice (Carter, et al. 2006). It is 
therefore tempting to speculate that recombination hotspots are directly involved in cancer 
genomic instability in this tumour type, in the absence of external causes of DNA damage. 
This is also compatible with the role of inflammation in inducing a hypoxic 
microenvironment that favours chromosomal instability (Coquelle, et al. 1998; Eltzschig 
and Carmeliet 2011; Kumareswaran, et al. 2012). Inflammation induces hypoxia by 
increasing the metabolic demands of cells and reducing the metabolic substrates (Eltzschig 
and Carmeliet 2011). Hypoxia in turn induces breaks in fragile sites leading to gene 
amplifications (Coquelle, et al. 1998) through aberrant DNA double strand break repair 
(Kumareswaran, et al. 2012).  
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Figure 59: Chronic inflammation causes genomic instability leading to cancer 
Chronic liver inflammation induces many afflictions, including DSBs, by oxidative damage. All 
these ailments, together and apart, contribute to the progress of HCC. The DNA damage response 
leads to cell cycle arrest, DNA repair, and apoptosis (dashed-line arrows). Accumulation of DNA 
damage results in genomic instability (solid-line arrow). Under the replicative stress, some of the 
impaired cells containing DSBs were salvaged from the DNA damage response and replicated, thus 
increasing genomic instability and facilitating tumour progression (solid-line arrow). Taken from 
(Barash, et al. 2010). 
 
 
The analysis of recurrent copy number alterations in human and mouse HCCs was 
essential to pinpoint the similarities among tumours in the two species. In particular, we 
observed higher occurrence of amplifications than deletions. We observed MAPK 
signalling cascade among the top scoring pathways and identified recurrent amplifications 
of JNK activators. At least, one direct interactor of JNK or JNK itself was altered in all the 
samples and most notably Map2k7 was amplified recurrently in both human and mouse 
HCCs. Map2k7 are activated mainly by pro-inflammatory cytokines and environmental 
stress (Weston and Davis 2007). Map2k7 were also overexpressed in mouse HCCs with 
Map2k7 amplifications, thus suggesting the role of CNVs in its deregulation. Our findings 
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are also supported by previous studies in Mdr2-KO HCCs that have reported up-regulation 
of genes in the 20Mbps around the centromere of chromosome 8 where Map2k7 is present 
(Katzenellenbogen, et al. 2007). These findings suggest that JNK pathway is deregulated 
and its modification may play a driver role in this liver cancer type. Since amplifications of 
JNK activators preferentially occur in the late stages of HCC development, the 
deregulation of this pathway is likely to favour cancer progression rather than initiation. 
JNK is involved in several physiological and pathological processes including cell 
proliferation, differentiation, apoptosis, and tumorigenesis (Weston and Davis 2007). 
Deregulation of JNKs has already been reported to play cell- and stage-dependent roles 
during HCC development and its activation has been implicated in the progression of liver 
cancer (Sakurai, et al. 2006; Hui, et al. 2007; Hui, et al. 2008; He, et al. 2010; Nikolaou, et 
al. 2012). For example, liver-specific deletion of Mapk14, a negative regulator of Map2k7, 
leads to JNK hyper-activation and HCC development in the mouse (Hui, et al. 2007). In 
addition, mice deficient in either c-Jun or JNK1 do not develop HCC after being exposed 
to mutagens (Eferl and Wagner 2003; Sakurai, et al. 2006; Hui, et al. 2008; He, et al. 
2010). Interestingly, JNK deficiency when present in both hepatocytes and non-
parenchymal cells reduces the onset of inflammation and tumorigenesis. However its 
deficiency when limited to hepatocytes is linked to increased tumour size (Das, et al. 
2011). This hints at an oncogenic role of JNK in non-parenchymal cells where it likely 
promotes an inflammatory environment that favours transformation and/or tumour 
progression. Our data support such a scenario, suggesting that JNK amplification leads to 
its deregulation and favours tumour progression in BSEP- and Mdr2-KO HCCs. In 
contrast, the JNK pathway is not recurrently amplified in virus-, alcohol- and other risk 
factor-associated HCCs (Li, Zhao, et al. 2011; Totoki, et al. 2011; Fujimoto, et al. 2012; 
Guichard, et al. 2012; Huang, et al. 2012; Jiang, et al. 2012). This further highlights that 
different disease aetiologies have distinct impacts on tumour genome, which in turn may 
lead to different molecular mechanisms of tumour initiation and progression.  
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In order to ascertain the role of JNK in HCC development, we inhibited JNK using 
the drug SP600125. Although SP600125 has been reported to exert secondary effects on 
targets other than JNKs (Dvorak, et al. 2008; Marozin, et al. 2012), we observed that 
tumours with Map2k7 amplification were significantly depleted upon treatment indicating 
that the effects of SP600125 were mainly accounted for by the ability to inhibit JNK. No 
tumours from mice treated with the drug were of more than 20 mm in size, which instead 
represented ~20% of all lesions in the untreated mice. Moreover, tumours from treated 
mice showed significant depletion in HCCs and enrichment in adenomas when compared 
to tumours from untreated mice, thus suggesting that pharmacological inhibition of JNK 
impairs the adenoma-to-carcinoma progression in vivo. These finding pinpoint JNK as a 
potential target for therapy in this type of liver cancer and its inhibition may be useful to 
block HCC onset in BSEP deficiency patients waiting for liver transplantation.  
In conclusion, the analysis of copy number alterations in liver cancers induced by 
chronic inflammation as a result of exposure of hepatocytes to bile acids, highlighted key 
genes and pathways that may play driver role in tumour progression. They also provide 
evidence that these tumours are associated with chromosomal instability rather than 
mutational instability. They demonstrate that these HCCs generate a unique and distinctive 
genomic signature that can be clearly distinguished from those caused by viruses and other 
external mutagens. They further confirm aetiology-dependent genetic heterogeneity in 
liver cancers. In the future, a comparative study of genomic features with tumours arising 
from other chronically inflamed tissues will be useful to determine the extent of similarity 
in the genomic changes as a characteristic of inflammation. 
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Appendix: Published papers 
 
The two published papers and the manuscript under revision are attached at the end 
of the thesis. My contribution in each publication is reported below. 
 
 Iannelli F*, Collino A*, Sinha S*, Radaelli E, Nicoli P, D'Antiga L, 
Sonzogni A, Faivre J, Buendia MA, Sturm E, et al: Massive gene 
amplification drives paediatric hepatocellular carcinoma caused by bile 
salt export pump deficiency. Nat Commun 2014, 5:3850. 
*
 These authors 
contributed equally to this work. 
Contribution: I had performed the CNV analysis from whole genome 
sequencing data and SNP array data for mouse and human samples 
respectively. In addition, I developed a novel method for detecting CNVs 
from targeted re-sequencing data, which was used in the identification of 
altered genes from whole exome sequencing data in the mouse samples. I 
had analysed the data from TaqMan copy number assay and quantification 
of Map2k7 expression I had contributed in the writing of the manuscript. 
 
 D'Antonio M, Pendino V, Sinha S, Ciccarelli FD: Network of Cancer 
Genes (NCG 3.0): integration and analysis of genetic and network 
properties of cancer genes. Nucleic Acids Res 2012, 40:D978-983.  
Contribution: I had collected the human genes from Gencode and RefSeq 
and created a unique human gene set that was used in the protein network. I 
had helped in developing the web interface and contributed in the writing of 
the manuscript. 
 
 Sinha S, Iannelli F, Gambardella G, Cereda M, Ciccarelli FD: GeneCNV: 
detection of gene copy number variations and loss of heterozygosity 
from whole exome sequencing data. (Manuscript under revision).  
Contribution: I had designed and developed the method. I had performed 
the CNV analysis from targeted re-sequencing data using the three exome-
based methods (ExomeCNV, EXCAVATOR and VarScan 2) and SNP 
arrays, which is used as the gold standard for the assessment of the exome-
based methods. I had contributed in the writing of the manuscript.  
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defects in hepatocyte biliary transporters, which expose hepatocytes to bile salts and cause
chronic inﬂammation that develops into cancer. In both human and mouse cancer genomes,
we ﬁnd few somatic point mutations with no impairment of cancer genes, but massive gene
ampliﬁcation and rearrangements. This genomic landscape differs from that of virus- and
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cancer development and frequently target the MAPK signalling pathway, and in particular
direct regulators of JNK. The pharmacological inhibition of JNK retards cancer progression in
the mouse. Our study demonstrates that intrahepatic cholestasis leading to hepatocyte
exposure to bile acids and inﬂammation promotes cancer through genomic modiﬁcations that
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H
uman hepatocellular carcinoma (HCC) arises in response
to identiﬁable causes that in most patients show little or
no overlap, including hepatitis C virus (HCV) or hepatitis
B virus (HBV) infection, alcohol, exposure to aﬂatoxin and non-
alcoholic steato-hepatitis associated with metabolic diseases1,2.
Because of these distinct aetiologies, the characterization of
different types of HCCs allows a basic question in cancer biology
to be addressed, namely the speciﬁcity of the tumour genomic
landscape relative to the disease causative factors. Recent data
already suggested that the high genetic heterogeneity of liver
cancer depends on the initiating agents. For example, genomic
re-sequencing of human liver cancers highlighted recurrent
mutations in key cancer genes, such as TP53 and CTNNB1, and
chromatin regulators, but also substantial differences3–8. Genes
encoding components of the chromatin-remodelling complexes
are frequently mutated in hepatitis HCV- but not in HBV-
associated HCC5. Also the tumour mutational signature (that is,
number and type of acquired mutations) strongly depends on the
underlying mutagenic mechanism and exposure to different
genotoxic chemicals leads to distinct mutation patterns3,4,6. In
addition, integration of HBV DNA into the host genome induces
genomic instability but may also directly modify cancer driver
genes6,8,9, thus triggering oncogenic events. These data clearly
show that HCC has a complex pathogenesis in which exogenous
factors, inﬂammation and sustained regeneration cooperate to
promote cancer.
To understand how liver injury due to a combination of
chemical damage, inﬂammation and ﬁbrosis contributes to the
acquired cancer genomic instability, we proﬁled the genome of
human HCCs associated with bile salt export pump (BSEP)
deﬁciency, also known as progressive familial intrahepatic
cholestasis type 2. Progressive familial intrahepatic cholestasis
designates a heterogeneous group of rare autosomal recessive
disorders caused by inherited inactivating mutations in the
hepatocyte membrane transporter genes ATP8B1, ABCB11 and
ABCB4 (ref. 10). The disease usually appears in infancy or early
childhood and manifests with hepatocellular damage and
cholestasis due to defects in bile formation10. In BSEP
deﬁciency, inherited mutations in the ABCB11 gene cause
impairment of bile salt export from hepatocytes into bile,
leading to liver chronic inﬂammation and to the early onset of
hepatocellular carcinoma11. Thus, this liver cancer type, which we
refer to as BSEP-HCC, provides the opportunity to map the
acquired genomic modiﬁcations that trigger liver cancer in the
absence of external mutagenic factors.
The genomic proﬁling of BSEP-HCCs revealed a scenario
different from all other HCCs sequenced to date. Exome
sequencing showed only very few somatic mutations that did
not affect known cancer genes. In contrast, BSEP-HCC genomes
acquired massive gene ampliﬁcation that affected components of
signal transduction pathways, such as the ErbB, the PI3K/Akt and
the mitogen-activated protein kinase (MAPK) signalling path-
ways. To further examine the role of these aberrations in cancer
onset and progression, we re-sequenced exomes and genomes of
HCCs from Mdr2-KO mice. The Mdr2-encoded P-glycoprotein
belongs to the ABC family of membrane transporters and its
absence impairs the secretion of phosphatidylcholine into biliary
canaliculi12. The resulting high concentration of monomeric bile
salts induces hepatocellular damage, inﬂammation and eventually
HCC with high penetrance13–16. It has been suggested that this
sequence of events recapitulates to some extent the development
of the most common types of human HCCs. In fact, HCCs
arisen in chronic liver disease in Mdr2-KO mice have an
aetiopathogenesis similar to that of BSEP-HCCs, while it is clearly
distinct from that of viral and metabolic disease-associated
human HCCs. Consistent with this notion, in Mdr2-KO HCC we
identiﬁed very few somatic point mutations, instead we detected a
progressive accumulation of gene ampliﬁcations affecting the
MAPK signalling pathways, and in particular activators of the
cJun-N terminal kinases (JNK). Pharmacological inhibition of
JNK in the mouse dampened cancer progression.
Altogether, our data suggest that the genetic heterogeneity of
liver cancers correlates with their distinct pathogenesis and leads
to different mechanisms of tumour progression that can be at
least partially recapitulated in the mouse. They also provide
evidence that solid tumours are not necessarily associated with
mutational instability and that, in the speciﬁc case of liver cancer,
this instability is mostly due to exposure to external mutagens.
Results
Human BSEP-HCCs do not accumulate mutations in cancer
genes. To map the somatic mutations acquired in BSEP-HCC, we
sequenced the whole exomes of six HCCs and corresponding
background livers (Table 1 and Supplementary Data 1). After
exome capture, Illumina sequencing and alignment of sequence
reads (Supplementary Data 1), we identiﬁed a total of 44 single-
nucleotide variants (SNVs) and 8 small insertions and deletions
(indels) that were present in the six cancer exomes but not in the
corresponding background livers (see Methods, and Table 1). The
orthogonal validation of representative mutations assessed 93%
speciﬁcity of our variant calling strategy (see Supplementary
Methods). No mutation was shared between any two lesions, and
each exome contained on average 0.05 somatic mutations per
Mbp (Table 1). This mutation frequency was lower than the
average mutation frequency of other human HCCs and of other
Table 1 | Somatic mutations and copy-number alterations in human BSEP-associated liver cancers.
Lesion
ID
Gender Age
(years)
Tumour content
(%)
Somatic
SNVs
Non-silent
SNVs
Somatic
indels
Ampliﬁed
genes
Deleted
genes
LOH
genes
175 M 1.6 90 7 3 0 10,688 1 4,964
7860 F 2.6 90 5 2 0 13,594 1,248 891
23836 M 1.3 90 5 1 0 12,450 19 2,847
HB4R F 8.6 70 25 9 7 5,598 2,575 7,124
1790 M 11.7 60 1 0 0 8,601 0 158
2896 F 1.3 50 1 0 1 9,687 244 3,702
UKT M 1.3 40 NA NA NA 3,801 258 0
Total — — — 44 15 8 18,428 3,628 9,757
F, female; LOH, loss of heterozygosity; M, male; NA, not available; SNV, single-nucleotide variation.
Tumour content is expressed as percentage of tumour tissue in the inspected sample on histological analysis. Non-silent SNVs indicate mutations leading to protein modiﬁcations. None of the identiﬁed
indels introduced a frameshift. Total refers to modiﬁcations found in at least one sample. The higher number of mutations found in sample HB4R compared with other samples probably reﬂects that this
was a relapse and that the patient had been treated with chemotherapy.
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paediatric cancers17 (Fig. 1a). To exclude the possibility that
we did not detect mutations due to poor sensitivity, we measured
the false negative rate of the variant calling method at different
percentages of tumour content (see Supplementary Methods
and Supplementary Table 1). We estimated 100% sensitivity
in detecting somatic variants in lesions with 440% tumour
content.
Of the 44 somatic SNVs, 15 led to non-silent modiﬁcations in
15 genes (Supplementary Data 2). Inspection of these genes
pinpointed no strong candidates as drivers of BSEP-HCC. First,
none of the mutated genes was a known driver gene in HCC or in
any other human cancers18,19. Second, some of them were known
passengers that recurrently mutate in several cancer types20,21.
Finally, most of these genes are either poorly or not expressed in
the human liver (Supplementary Data 2), thus indicating that
they are probably not functional in this tissue.
Overall, our results showed low levels of mutational instability
in BSEP-HCC, thus suggesting that the acquisition of mutational
instability is not the driving force for the development of this type
of liver cancer.
Massive gene ampliﬁcation occurs in human BSEP-HCCs. We
used genome-wide SNP arrays to investigate the occurrence of
copy-number variations (CNVs) in seven BSEP-HCCs, including
all tumours screened for point mutations and one additional
lesion (Table 1). Compared with adult HCCs, BSEP-HCCs
showed higher frequency of CNVs (Fig. 1b and Supplementary
Fig. 1), with a total of 18,428, 3,628 and 9,757 genes that
underwent ampliﬁcation, deletion or loss of heterozygosity,
respectively, in at least one of the seven samples (Table 1 and
Supplementary Data 3). Low-level copy-number gains (on aver-
age four copies per aberrant region, Supplementary Fig. 2,
Supplementary Data 3) were the most pervasive alterations, with
around 38% of the total genome ampliﬁed in each sample
(Supplementary Fig. 3A). We further analysed whether copy-
number alterations were focal or arm-level events22 and observed
that deletions were mostly focal and sample speciﬁc, except for
sample HB4R that had three arm-level deletions involving
chromosomes 1p, 4q and 17p (Supplementary Fig. 3B). Copy-
number gains were instead either arm-level (Supplementary
Fig. 3B) or multiple focal events that led to the ampliﬁcation of
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Figure 1 | Somatic genomic alterations occurring in BSEP-HCCs. (a) Average non-silent mutations frequency in the six BSEP-HCCs as compared with
adult HCC and paediatric cancers17. (b) Average CNV frequency in the seven BSEP-HCCs as compared with adult HCC3,6,7. Frequency was measured
as CNVs per 100 base pairs and as percentage of altered genes among total human genes. Detailed comparison with each adult HCC screening is reported
as Supplementary Fig. 1. (c) Circos plot reporting ampliﬁcations, deletions and LOH in all chromosomes of the seven BSEP-HCCs. (d) Copy-number proﬁle
of sample 175, as detected from genome wide SNP array. The upper and lower panels show the log ratio of intensity and the B-allele frequency (BAF) of
germline heterozygous SNPs, respectively. Ampliﬁed, deleted and LOH segments are shown in each chromosome. Dotted lines identify centromeres.
(e) Ampliﬁcation of chromosome 19 in patient 23836 as validated by FISH. Shown are four representative hepatocyte nuclei (blue, DAPI staining) from a
parafﬁn-embedded tumour sample. Probes for chr19p13 (green) and for chr19q13 (orange) were used. Scale bars¼ 20mm. (f) Ampliﬁed (green) and
deleted (red) genes in the seven BSEP-HCCs, grouped according to the number of samples in which they were altered.
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entire chromosomes, most notably chromosomes 8, 19 and 20 in
the majority of lesions (Fig. 1c,d and Supplementary Fig. 3A). To
validate these results, we performed ﬂuorescence in situ
hybridization (FISH) with probes located on both arms of
chromosome 19 and conﬁrmed the ampliﬁcation of this
chromosome in sample 23836 (Fig. 1e). Multiple ampliﬁcations
likely occurred via step-wise DNA rearrangements rather than
through one-shot catastrophic events, because in most samples
we did not detect any sign of chromothripsis. The only exception
was sample UKT where several consecutive oscillations between
two copy-number states in chromosomes 4 and 6 (Supplementary
Fig. 4A,B, Supplementary Data 3) may suggest the occurrence of a
one-shot catastrophic rearrangement event23,24.
To ﬁnd possible cancer drivers, we focused on genes that were
recurrently altered in the majority of samples and in particular on
935 known cancer genes that were ampliﬁed in the genome of at
least four of the seven lesions (Fig. 1f). Pathway enrichment
analysis of these genes highlighted three top-scoring pathways,
namely the MAPK, the ErbB and the PI3K/Akt pathways
(corrected P¼ 3 10 06, 9 10 06 and 2 10 05, respec-
tively, hypergeometric test, Supplementary Data 4). These
pathways form a complex and interconnected signalling net-
work25,26, and their activation is a known driver event in some
types of liver cancer27–29.
The results of the copy-number analysis showed that
BSEP-HCCs are characterized by a pervasive occurrence of
chromosomal rearrangements that lead to massive gene ampli-
ﬁcation. Recurrent events involve the ampliﬁcations of signalling
genes, thus suggesting that the alteration of signalling pathways
may be involved in the development and progression of this type
of HCC.
Mdr2-KO HCCs resemble the genomic landscape of BSEP-
HCCs. To validate the potential contribution of the genomic
modiﬁcations in BSEP-HCC, we proﬁled the cancer genomes of
Mdr2-KO mice, which, similarly to human BSEP-deﬁcient
patients, develop HCC due to impairment of bile secretion12,15.
We sequenced the exomes of nine HCCs extracted from the livers
of seven Mdr2-KO mice using the kidney of one of them as a
reference (Table 2). We applied the same procedures as those
used with human samples for target enrichment, Illumina
sequencing and variant calling (Supplementary Data 5) and
identiﬁed a total of 118 somatic SNVs and no indels (Table 2).
Also in this case, we conﬁrmed 493% speciﬁcity by orthogonal
validation of randomly selected variants (see Supplementary
Methods). None of the 118 SNVs was shared between any two
tumours, and 60 of them led to modiﬁcations in 60 proteins
(Supplementary Data 6). As with BSEP-HCCs, no mutated gene
was a known driver of HCC or of other cancers18,19, and only a
few of them were expressed in the liver (Supplementary Data 6).
We further sequenced the coding exons of 866 mouse orthologues
of human cancer genes (Supplementary Data 7) in four additional
Mdr2-KO HCCs, using the normal liver as a reference. In this
case, we increased the depth of sequencing coverage to further
exclude that mutations might have been missed because of high
intratumoral heterogeneity (Supplementary Data 5). Again we
found no somatic mutations and no small indels in any cancer
genes in any of the four samples (Table 2).
To assess whether the massive copy-number alteration
observed in BSEP-HCC also occurred in mouse tumours, we
developed a novel method to investigate CNVs directly from
targeted re-sequencing data. Our procedure was based on the
comparison of normalized gene coverage between tumour and
reference that led to the identiﬁcation of tumour-speciﬁc copy-
number gains and losses (see Supplementary Methods). In the 13
mouse HCCs, we identiﬁed a total of 2,510 altered genes, almost
all of which (2,507) were ampliﬁed (Table 2 and Supplementary
Data 8). Validation of 10 randomly selected ampliﬁed genes using
TaqMan copy-number assay estimated 70% sensitivity, 93%
speciﬁcity and 84% accuracy of the method to call ampliﬁcations
(Supplementary Table 2). We used genes on chromosome X to
assess the performances of our method to detect deletions and
estimated 91% sensitivity and 85% accuracy (see Supplementary
Methods and Supplementary Table 3). We further sequenced the
whole genomes of two late-stage Mdr2-KO HCCs from two
different mice, using the corresponding kidneys as matched
references. We again observed an overall higher occurrence of
ampliﬁcations than deletions, with a total of 1,074 ampliﬁed and
117 deleted genes in the two genomes (Supplementary Data 8).
Since one of the two tumours (ID: 60400/1) had been also used
for exome sequencing, we further assessed the performance of
CNV detection from targeted re-sequencing data. By far most of
the ampliﬁed genes detected in the whole exome were also found
in the whole genome (85%, Supplementary Data 8), thus
conﬁrming the reliability of the method.
Mdr2-KO tumours have already been shown to have high
degrees of chromosomal instability. In agreement with our
results, HCCs from Mdr2-KO mice that underwent partial
Table 2 | Somatic mutations and copy-number alterations in Mdr2-KO mice.
Lesion ID Gender Age
(months)
Size
(cm)
Tumour
content
Sequenced
regions
Somatic
SNVs
Non-silent
SNVs
Ampliﬁed
genes
Deleted
genes
51509/1 M 16 1.1 20% Whole exome 8 5 59 0
60400/2 F 13 1.4 40% 8 3 113 0
218/1 M 15 1 50% 5 2 298 1
52686/1 F 15 0.7 50% 8 4 15* 2
58853/3 M 15 1.7 60% 20 8 631 0
60400/1 F 13 0.9 60% 9 3 455 0
58163/3 M 15 3 70% 17 6 333 1
58163/4 M 15 3 70% 39 27 625 0
215/1 M 14 1.8 80% 4 2 562 0
54913/10 F 10 0.1 NA 866 Cancer genes 0 0 49 0
54913/8 F 10 0.5 NA 0 0 10 0
55481/10 F 10 0.3 NA 0 0 17 0
55484/4 F 10 3 30% 0 0 41 0
Total — — — — — 118 60 2,507 4
F, female; M, male; NA, not available; SNV, single-nucleotide variation.
Nodules with insufﬁcient amount of tissue for histologic inspection where deﬁned as NA.
*TaqMan copy-number assay assessed a high number of false negatives for this sample, thus suggesting an overall underestimation of gene ampliﬁcations.
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hepatectomy show pervasive ampliﬁcations, no detectable
deletions and recurrent ampliﬁcations in chromosomes 5, 8 and
18 (ref. 30). Moreover, genes in the 20Mbps around the
centromere of chromosome 8 are upregulated in Mdr2-KO
HCCs16. Interestingly, genes in this region were among the
most recurrently ampliﬁed in our samples (see below and
Supplementary Data 8).
The results of the genomic proﬁling of Mdr2-KO HCCs
showed that, similarly to human BSEP-HCCs, these tumours are
not prone to accumulate somatic point mutations and small
indels. Instead, they show pervasive chromosomal instability with
overwhelming prevalence of gene ampliﬁcation.
Somatic CNVs accumulate duringMdr2-KO HCC progression.
We noticed that human BSEP-HCCs with high tumour content
(90%) accumulated more ampliﬁcations than those with lower
tumour content (Table 1). Interestingly, a positive correlation
between tumour size and fold change of the ampliﬁed regions was
already reported in HCCs from Mdr2-KO mice that underwent
partial hepatectomy30. We therefore checked whether a similar
signal was detectable in Mdr2-KO HCCs of our cohort. We
indeed conﬁrmed a positive correlation between the number of
ampliﬁed genes and the HCC content (Pearson’s correlation
coefﬁcient¼ 0.78, N¼ 10, Fig. 2a). Moreover, bigger lesions
showed signiﬁcantly more ampliﬁed genes than smaller lesions
(P¼ 0.03, Wilcoxon test, N¼ 10, Fig. 2b). These results suggested
that ampliﬁcations tend to occur in larger and more advanced
lesions. Furthermore, ampliﬁcations preferentially accumulated
near the centromeres (Fig. 2c) of mouse chromosomes, which are
known hotspots for mitotic recombination31.
In the two Mdr2-KO HCC genomes, we identiﬁed inverted
translocations involving chromosomes 8 and 14 in one tumour
(ID: 218/3, Fig. 2d) and chromosomes 8 and 19 in the other (ID:
60400/1, Fig. 2e). Interestingly, mouse chromosome 8 is the
ortholog of human chromosomes 8 and 19, which are the most
recurrently ampliﬁed chromosomes in human BSEP-HCCs
(Supplementary Fig. 3A). Through the analysis of discordantly
aligned read pairs, we were able to map the two breakpoints at
base pair resolution and both rearrangements were conﬁrmed
with PCR ampliﬁcation and Sanger sequencing (Fig. 2d,e). In one
of the two tumours (ID: 60400/1), we counted 10 consecutive
disomic and trisomic copy-number states in the region of
chromosome 19 involved in the inverted translocation (Fig. 2e
and Supplementary Fig. 3C). Therefore, again similarly to the
human samples, we found possible indications that one-off
catastrophic events could be responsible for the acquisition of
at least some of the genomic rearrangements in this liver
cancer type.
In summary, the CNV analysis ofMdr2-KO HCCs showed that
they undergo frequent genomic rearrangements that lead to gene
ampliﬁcations. Moreover, the observation that CNVs tend to
accumulate in large lesions with high HCC content suggests that
their putative driver role is exerted in tumour progression rather
than in tumour initiation.
JNK is deregulated in Mdr2-KO HCCs. Given the similarities in
genomic landscapes of acquired alterations between BSEP-HCCs
andMdr2-KO HCCs, we performed pathway enrichment analysis
on 27 genes that were recurrently ampliﬁed in both human
and mouse cancers (Fig. 3a, Supplementary Data 8 and
Supplementary Table 4). Again we found that the MAPK
signalling cascade was among the top scoring pathways (corrected
P¼ 2 10 02, hypergeometric test, see Supplementary Methods).
In particular, Map2k7, encoding the mitogen-activated protein-
kinase kinase, was ampliﬁed in 470% human and mouse HCCs
(5 out of 7 and 10 out of 14, respectively). To better quantify the
frequency of Map2k7 ampliﬁcation, we screened 35 additional
tumours from 16 distinct mice using TaqMan copy-number assay.
Map2k7 was ampliﬁed in 14 of the 49Mdr2-KO nodules that were
analysed overall (29%, Supplementary Data 9), which was a signiﬁ-
cantly higher proportion than expected by chance (P¼ 6 10 04,
binomial test). When only nodules with high HCC content were
considered, the enrichment became even stronger, with 58% of
nodules with Z40% HCC showing Map2k7 ampliﬁcation (P¼ 9
 10 05, binomial test). This result further supports the general
observation that gene ampliﬁcation tends to occur preferentially in
lesions with high tumour content (Fig. 2a). To investigate whether
the additional copies of Map2k7 directly impinge on gene
expression, we measured the mRNA levels in tumours where the
gene was ampliﬁed as compared with tumours where it was not
ampliﬁed, with Mdr2-KO inﬂamed livers and with age-matched
healthy livers from Mdr2-wild type mice. Tumours with Map2k7
ampliﬁcations showed signiﬁcant Map2k7 overexpression com-
pared with all other groups (Fig. 3b), thus indicating that gene
ampliﬁcation led to increased expression. Map2k7 speciﬁcally
regulates the c-Jun NH(2)-terminal kinases (JNKs)32–34, which are
mainly activated mainly by pro-inﬂammatory cytokines and
environmental stress35. Deregulation of JNKs has been already
reported to play cell- and stage-dependent roles during HCC
development36–40. Interestingly, upstream and downstream direct
JNK interactors, as well as JNKs themselves, were altered in several
human and mouse samples (Fig. 3c).
These data showed that gene ampliﬁcations occurring in
Mdr2-KO tumours preferentially hit signalling genes, most
notably JNK direct interactors or upstream activators, which
may have a driver role in triggering liver tumour progression.
JNK inhibition arrests carcinoma progression in Mdr2-KO
mice. We set out to investigate whether JNK inhibition might
interfere with liver cancer progression by treating Mdr2-KO mice
with SP600125, a synthetic polyaromatic chemical that directly
inhibits the JNK kinases41–46. We randomized 23 Mdr2-KO mice
to receive either SP600125 or vehicle only (12 and 11 mice,
respectively, Supplementary Data 10). After 3 weeks of treatment,
mice were killed and the tumours from the two cohorts were
compared in terms of Map2k7 ampliﬁcation, nodule number,
size, histology and tumour content. We found a signiﬁcantly
lower proportion of lesions from treated mice (5 out of 36, 14%)
with Map2k7 ampliﬁcation when compared with lesions from the
untreated cohort (13 out of 35, 37%, P¼ 0.03, Fisher’s exact test,
Supplementary Data 10). Thus, tumours with Map2k7
ampliﬁcation were more sensitive to JNK inhibition than those
without Map2k7 ampliﬁcation, which explains their relative
depletion after treatment. Indirectly, this result also indicated that
the effects of SP600125 were mainly caused by its on-target
activity on JNK. Moreover, although treated and untreated
animals showed a comparable number of tumours per mouse, no
mouse treated with the JNK inhibitor had nodules bigger than
20mm, which instead represented B20% of all lesions in the
untreated group (Fig. 4a,b Supplementary Data 10). In a
reciprocal manner, the proportion of nodules with diameters
between 10 and 20mm was signiﬁcantly higher in treated mice
than in the untreated group (Fig. 4a). Finally, nodules bigger than
10mm showed signiﬁcantly higher proportion of adenoma and
lower proportion of adenocarcinoma in treated than in untreated
mice (Fig. 4c,d). No difference was detectable in the histological
composition of small lesions (diameter o10mm). Similarly,
treated mice showed an overall signiﬁcant depletion in HCC,
while purely adenomatous nodules were over-represented
(Fig. 4e). Altogether, these data suggested that the drug blocks
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tumour progression towards bigger lesions with higher HCC
content, thus supporting the role of JNK deregulation in
progression more than in initiation of Mdr2-KO tumours. They
were also consistent with the results of the CNV analysis, and
speciﬁcally with the tendency of gene ampliﬁcation, and of
Map2k7 ampliﬁcation in particular, to occur in large lesions with
high HCC content.
Discussion
In this study, we proﬁled the genomes of aetiologically related
mouse and human HCCs to identify the genomic changes
acquired in response to chronic exposure to non-neutralized bile
acids and in the absence of exogenous direct (viruses) or indirect
(alcohol) mutagens. Despite the small sample size that we
analysed, our screenings showed a consistent genomic signature
within and between species. In both human and mouse, cancer
genomes accumulated massive copy-number gain in contrast to
very few somatic SNVs or small indels. Such a genomic signature
is remarkably different from that of the other HCCs previously
sequenced, which acquire mutational instability and tend to
accumulate gene deletions rather than ampliﬁcations3. These
ﬁndings conﬁrm the genetic heterogeneity of liver cancers caused
by different aetiological agents and, at the same time, the
ba c
d
Normal HCCC
hr8-C
hr14
C
hr8
C
hr14
C
hr8-C
hr14
C
hr8
C
hr14
Chr.8 Chr.14
(0–32.1 Mbp) (26.7–0 Mbp)
10 Mbp
Lesion 218/3
Chr.8 Chr.14
A A C C T T A T G A A A A G T A T G A G T T G T A T C C
Breakpoint
20 40 60 80
100
300
500
HCC content (%)
Am
pl
ifie
d 
ge
ne
s 
(n)
700
Corr. coeff. = 0.78
P = 0.008
Pr
ox
im
ity
 to
 c
en
tro
m
er
es
–10+1
W
hole exom
e
W
hole
genom
e
60400/1
218/3
q arm
0% 100%
52686/1*
51509/1
60400/2
218/1
58853/3
215/1
58163/4
58163/3
60400/1
Correlation
coefficient
50%
Normal HCCC
hr8-C
hr19
C
hr8
C
hr19
C
hr8-C
hr19
C
hr8
C
hr19
Lesion 60400/1 Copy-number 
oscillationsChr.8 Chr.19
(0–7.3 Mbp)
2 Mbp
C A A T T G A A A A C A T G T T T T A A T T A A T T A G
Chr.8 Chr.19
Breakpoint
Extra copy Normal copy number 0 15
Amplified genes (%)
e
<
15
 
m
m
>
15
 m
m
100
300
500
Am
pl
ifie
d 
ge
ne
s 
(n)
700 *
0.5
1.0
1.5
2.0
3.0
0.5
1.0
1.5
2.0
3.0
Kbp
Kbp
(31.1–15.4 Mbp)
Figure 2 | Copy-number variations and complex structural rearrangements in Mdr2-KO HCCs. (a) Correlation between the number of ampliﬁed genes
and HCC content in mouse tumours that underwent whole-exome and whole-genome sequencing. Correlation coefﬁcients were measured using the
Pearson correlation testing. (b) Comparison between number of altered genes in small (o15mm) and big (415mm) lesions. *¼ Po0.05, Wilcoxon
test, N¼ 10. Minimum and maximum number of altered genes in the two groups are shown. (c) Cumulative fractions of gene ampliﬁcations (ampliﬁed
genes/total genes) in regions representing 10% of the q arm-length in all mouse chromosomes. In case of exome re-sequencing, the chromosome
length was calculated as the region from the ﬁrst to the last targeted base in the SureSelect XT Mouse All Exon kit (Agilent). Pearson correlation
coefﬁcients were calculated between the fraction of ampliﬁed genes in each region and the proximity to the centromere of each chromosome.
*52686/1 was the only tumour with a negative correlation, likely due to overall CNV underestimation in this sample (see also Table 2). (d) Inverted
translocations between chromosomes 8 and 14 of lesion 218/3 and (e) chromosomes 8 and 19 of lesion 60400/1. Through the analysis of discordant
sequencing read pairs, breakpoints of both rearrangements were mapped at base pair resolutions and conﬁrmed by PCR ampliﬁcation and Sanger
sequencing of breakpoint regions. In sample 60400/1, 10 consecutive copy-number oscillations at chromosome 19 were detected in proximity of the
rearrangement with chromosome 8. The genomic coordinates of ampliﬁed regions in each chromosome are shown in parentheses.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4850
6 NATURE COMMUNICATIONS | 5:3850 | DOI: 10.1038/ncomms4850 |www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
remarkable analogy among human and mouse tumours with
similar aetiopathogenesis.
The detailed analysis of Mdr2-KO mouse cancer genomes
revealed that copy-number gains tend to cluster in genomic
regions with high mitotic recombination rates, such as centro-
meres and telomeres (Fig. 2c). These regions are fragile
sites prone to rearrangements47 and are associated with
loss of heterozygosity48 and replication stress49–51. Chronic
inﬂammation induces the production of reactive oxygen species
that may lead to oxidative DNA damage, thus possibly explaining
why genes associated with chromosomal instability are
upregulated in the liver of Mdr2-KO mice30,52. It is therefore
tempting to speculate that recombination hotspots are directly
involved in cancer genomic instability in this tumour type, in the
absence of external causes of DNA damage. This is also
compatible with the role of inﬂammation in inducing a hypoxic
microenvironment that favours chromosomal instability53–55.
Frequent ampliﬁcations of JNK activators, most notably the
recurrent ampliﬁcation of Map2k7, were found in the majority of
mouse and human cancers, suggesting that these modiﬁcations
may be the driver events in this liver cancer type. Since
ampliﬁcations of JNK activators preferentially occur at late
stages of HCC development, the deregulation of this pathway is
likely to favour cancer progression rather than disease initiation.
JNK is involved in several physiological and pathological
processes including cell proliferation, differentiation, apoptosis
and tumorigenesis35. Its activation has already been implicated
in the development of liver cancer. For example, neither c-Jun
nor JNK1-deﬁcient mice develop HCC after exposure
to mutagens37,39,40,56. In addition, liver-speciﬁc deletion of
Mapk14, a negative regulator of Map2k7, leads to JNK hyper-
activation and HCC development in the mouse38. Interestingly,
JNK deﬁciency reduces the onset of inﬂammation and
tumorigenesis when occurring in both hepatocytes and non-
parenchymal cells, but it is linked only to increased tumour size
when limited to hepatocytes57. This hints at an oncogenic role of
JNK in non-parenchymal cells where it likely promotes an
inﬂammatory environment that favours transformation and/or
tumour progression. Our data support such a scenario, indicating
that JNK ampliﬁcation leads to its deregulation and favours
tumour progression in BSEP- and Mdr2-KO HCCs. In contrast,
the JNK pathway is not recurrently ampliﬁed in virus-,
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alcohol- and other risk factor-associated HCCs3–8. This further
highlights that different disease aetiologies have distinct impacts
on tumour genomics, which in turn may lead to different
molecular mechanisms of tumour initiation and progression.
Since we observed that pharmacological inhibition of JNK
impairs the adenoma-to-carcinoma progression in vivo, JNK
inhibition may be useful to block HCC onset in BSEP deﬁciency
patients waiting for liver transplantation. In this regard, it is
important to notice that the drug used to block JNK (SP600125)
has been reported to exert secondary effects on targets other
than JNKs58,59. However, the fact that tumours with Map2k7
ampliﬁcation were signiﬁcantly depleted on treatment suggests
that the effects of SP600125 were mainly accounted for by the
ability to inhibit JNK.
In conclusion, this study demonstrates that intrahepatic
cholestasis leading to hepatocyte exposure to bile acids and
chronic inﬂammation generates a unique and distinctive
signature of genomic changes that can be clearly distinguished
from those caused by viruses and other external factors. It will be
interesting to determine whether and to what extent similar
genomic changes represent a general feature of tumours arising
from other chronically inﬂamed tissues.
Methods
Human sample description and DNA extraction. Samples used in the study were
obtained from frozen or formalin-ﬁxed parafﬁn-embedded (FFPE) material from
seven children diagnosed with BSEP-HCC, with parental written consent
(Supplementary Data 1). The protocol for use of human tissues was approved by
the review board of the corresponding hospital of provenience (French Institute of
Medical Research and Health IRB Number 11-047; UK Integrated Research
Application System ID: 103273, REC reference:12/WA/0282; Italian Ministry of
Health, statement 61, 19/12/1986 N.900.2/ Ag 464/260; Ethical Review Board of the
University Hospital Tu¨bingen, Ref.no, 27/2008B01). All specimens were obtained
at native-liver hepatectomy during transplantation. The background liver in all
patients exhibited parenchymal rather than portal-tract cholestasis, with BSEP
expression detectable in none. Some patients had frank cirrhosis, others only
ﬁbrosis, which varied in degree from patient to patient (Supplementary Data 1).
Samples 7860 175, 1790, 2896 and UKT came from single-unencapsulated masses,
while sample 23836 derived from one of several HCC within a single liver. Sample
HB4R was a relapse that developed within allograft liver 6 years after transplan-
tation. The patient was treated with chemotherapy before relapse and surgical
resection. In all samples, non-neoplastic liver tissues from the same patients were
used as matching background references.
Genomic DNA was extracted from each tumour from matched background
liver tissue using the DNeasy Blood and Tissue Kit (Qiagen) for frozen samples and
with the AllPrep DNA/RNA FFPE Mini Kit (Qiagen) for FFPE blocks.
Exome sequencing, variant calling and mutation validation. Target capture was
done on six human tumour and reference samples (Supplementary Data 1) using
the SureSelect XT Human All Exon V4 kit (Agilent) targeting 20,965 human genes,
following the manufacturer’s protocol with minor modiﬁcations. Sample UKT was
excluded from whole-exome sequencing because of the low tumour content (see
Supplementary Methods). Around 3 mg of genomic DNA was sheared using an
Adaptive Focused Acoustics technology (Covaris). After library preparation with
an Illumina DNA Sample Prep Kit, 200 bp fragments were selected using the
Agencourt AMPure PCR Puriﬁcation system (Beckman Coulter). Fragments were
further ampliﬁed with 5 to 7 cycles of PCR and 500 ng was hybridized with the bait
library. DNA capture was followed by paired-read cluster generation on the Cluster
Station (Illumina). Libraries were sequenced using one-half lane of Illumina
HiSeq2000 per sample, with 76 bp or 101 bp paired-end protocol, except for the
tumoral sample of patient 7860, where one entire lane was used due to high levels
of DNA degradation (Supplementary Data 1).
Paired-end sequencing reads from each tumour and reference were mapped to
the human genome (GRCh37/hg19) using Novoalign (http://novocraft.com). At
most three mismatches per read were allowed and duplicated reads were removed
using rmdup of SAMtools60. All reads uniquely mapping within 75–100 bp of the
targeted regions were considered on target and retained for further analysis
(Supplementary Data 1). SNVs and indels were identiﬁed using SAMtools60 and
VarScan 2 (ref. 61) and retained if covered by at least 10 reads and with frequency
Z20%. Somatic mutations and indels were identiﬁed as tumour-speciﬁc mutations
with coverage Z5x, frequency o10% in the reference, and not present in dbSNP
build 137 (MAF 41%). All 44 SNVs and 8 indels were retained after manual
inspection, and 14 non-silent SNVs underwent orthogonal validation (see
Supplementary Methods).
Functional annotation of mutated genes. The list of genes affected by mutations
was intersected with the genes known to be recurrently mutated in HCC (TP53,
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CTNNB1, ARID1A, ARID2, AXIN1, RPS6KA3, VCAM1, CDK14, TERT, MLL4,
CCNE1)18 and with the list of 537 genes known to have a causative role in human
cancer19.
Expression levels of mutated genes in the normal liver were inferred from
publicly available data62,63. Starting from the raw CEL ﬁles of the two experiments,
data were normalized and analysed using the MAS5 algorithm. The expression
level for each gene in the liver was calculated as the mean value among all gene
probes with detection P-valueo0.05. If all probes of a gene had P-value40.05, the
gene was considered not expressed. The normalized expression level was then
measured as the gene expression level over the median expression of all genes in
the liver. Genes with expression higher than the median were considered to be high
expressed, while all genes with expression lower than the median were deﬁned as
low expressed.
Recurrently mutated passenger genes were retrieved from literature (refs 20,21
and http://bio.ieo.eu/ncg/).
SNP array and copy-number calling in the human samples. Genomic DNA
extracted from FFPE samples and from frozen samples was processed according to
the Inﬁnium HD assay ultra manual. DNA from FFPE samples was restored before
SNP array processing according to the Inﬁnium HD FFPE restore protocol. All
seven human tumours and matched background livers were assayed using Illumina
HumanOmniExpress-12 v1.0, and image data were scanned using a BeadArray
reader. Intensity and genotype data were extracted for CNV analysis after nor-
malizing raw ﬂuorescence signals using Illumina Genome Studio v2011.1. CNV
analysis was performed using ASCAT (version 2.1), which takes into consideration
aneuploidy and non-aberrant cell admixture present in each tumour sample64
(see Supplementary Methods).
For six tumours with whole-exome sequencing data, frequency distributions of
the germline heterozygous SNPs were integrated with the SNP array results to
identify high conﬁdence CNV regions (see Supplementary Methods). To identify
altered genes, the genomic coordinates of the aberrant regions in each sample were
intersected with those of 20,965 human genes of the SureSelect XT Human All
Exon V4 kit (Agilent). A gene was considered as modiﬁed if Z80% of its length
was contained in an aberrant region.
Fluorescence in situ hybridization. Validation of ampliﬁcation of chromosome
19 in sample 23836 was performed by two-colour ﬂuorescence in situ hybridization
(FISH) using a Vysis LSI 19q13 SpectrumOrange/19p13 SpectrumGreen probe
(Abbott), according to the manufacturer’s instructions. Two-micrometre FFPE
slides from the tumour and background liver of patient 23286 were deparafﬁnized
in xylene, washed in 100% ethanol, incubated in 1 SSC (0.3M sodium chloride,
0.03M sodium citrate) pH 6.0 at 80 C for 20min for demasking and digested with
pepsin (0.5mgml 1 in 0.2N HCl, pH 1.0; Protease and Protease Buffer II, Abbott)
for 17 min at 37 C. Samples were then washed in 2 SSC, dehydrated in 70, 95
and 100% ethanol and air dried. Ten microlitres of probe was directly applied onto
each slide and topped with a coverglass that was then sealed with rubber cement.
Slides were placed in a HYBrite (Abbott), and the probe was left to denature 1min
at 85 C, followed by an overnight hybridization at 37C. Coverglasses were then
removed and slides were washed twice in 2 SSC with 0.1% NP-40 at RT, once in
0.4 SSC with 0.3% NP-40 at 73 C and once again in 2 SSC with 0.1% NP-40
at RT. After counterstaining with DAPI (Sigma), FISH signals were scored with an
Olympus BX61 upright microscope, using a  100 objective.
Gene enrichment and pathway analysis. Pathway enrichment was done with
ConsensusPathDB65. A total of 935 human cancer genes ampliﬁed in at least four
BSEP-HCCs, and 27 genes that were ampliﬁed in the majority of human and
mouse HCCs, were compared with the pathway-base gene set composed of 10,529
pathway-associated genes. P-values were calculated with the hypergeometric test
based on the number of pathway components present in both the ampliﬁed cancer
gene set and the pathway-base gene set. The resulting P-values were then corrected
for multiple testing using false discovery rate.
Mouse description and DNA extraction. Experiments involving mice have been
done in accordance with the Italian Laws (D.L.vo 116/92) and mice have been
housed according to the guidelines of the European Commission Recommendation
2007/526/EC—June 18, 2007. The project has been notiﬁed to the Italian Ministry
of Health (project n. 106/11). Founders of the FVB.129P2-Abcb4tm1Bor/J
(Mdr2-KO, stock number: 002539) and FVB/NJ (Mdr2 wild type, stock
number:001800) mice were purchased from The Jackson Laboratory. Colonies of
both strains were maintained under speciﬁc pathogen-free conditions. Adenoma
and HCC nodules from Mdr2-KO mice were snap frozen for DNA/RNA
extraction or ﬁxed in formalin for histological analysis. Initial pathological stage
(inﬂammation) DNA/RNA extraction was carried out on puriﬁed populations of
hepatocytes obtained via collagenase liver perfusion, using a two-step protocol66.
The normal livers or kidneys were collected and frozen to be used as reference.
Frozen tissue samples were homogenized with a GentleMACS Dissociator
(Miltenyi Biotec) before column extraction. Genomic DNA was extracted using the
DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer’s protocol
for all samples and matching wild-type tissue.
Mouse histology. All analysed samples were inspected by a mouse pathologist.
Tumour growth in Mdr2-KO livers is multicentric; grossly detectable masses are
often very heterogeneous resulting from the collision of multiple contiguous
hepatocellular proliferations with different histologic features and grades. In
addition, there is a tendency for hepatocellular carcinoma to develop within an
adenoma (as foci of tumour progression). In this context, local invasion (one of the
most reliable indicators of tumour malignancy) is difﬁcult to assess and carcinoma
diagnosis relies entirely on the recognition of clear features of architectural or
cytologic atypia. Given these peculiar characteristics of tumour growth in
Mdr2-KO mice, the histological composition of grossly detectable hepatic nodules
was semiquantitatively determined based on reported classiﬁcation criteria67.
Selection of the 866 mouse orthologues of human cancer genes. A collection
of 2,061 human cancer genes was selected from the Cancer Gene Census19,
COSMIC (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) and high-
throughput cancer mutational screenings (http://bio.ieo.eu/ncg/). The 1,753 mouse
orthologues of these genes were identiﬁed using eggNOG68 and MGI (http://
www.informatics.jax.org), and only the 866 with RefSeq entries were selected
(Supplementary Data 7). The SureSelect Custom kit (Agilent) was designed to
capture 15,067 exons of the 866 genes, for a total of 2.7Mbp of DNA. Exons shorter
than 60 bp (except for those with mutations in COSMIC), sequence repeats,
segmental duplications, PAR regions and gaps were excluded. Finally, only regions
with GC content ranging from 30 to 65% were selected to optimize the capture
efﬁciency.
Whole-exome and whole-genome sequencing of mouse samples. The
SureSelect custom kit was used for the 866 selected genes and the SureSelect XT
Mouse All Exon kit (Agilent) was used to target 21,543 mouse genes following the
manufacturer’s protocol with slight modiﬁcations. In brief, around 3 mg of genomic
DNA was sheared using an ultrasonic disruptor (Bioruptor, Diagenode) or using an
Adaptive Focused Acoustics technology (Covaris). After library preparation with
the Illumina DNA Sample Prep Kit, 200–250 bp fragments were selected and
puriﬁed by gel extraction, or using the minelute PCR puriﬁcation kit (Qiagen),
or using the Agencourt AMPure PCR Puriﬁcation system (Beckman Coulter).
Fragments were further ampliﬁed with 10 cycles of PCR and 500 ng was hybridized
with each bait library. DNA capture was followed by single- or paired-read cluster
generation on the Cluster Station (Illumina). The libraries obtained for the 866
genes were sequenced on the Genome Analyzer IIx with the 76 single-end protocol,
using one lane for each tumour sample or matching normal sample. The libraries
obtained for the whole exomes were sequenced using one-half lane of Illumina
HiSeq2000 per sample, with the 101 bp paired-end protocol (Supplementary Data
5). For whole-genome sequencing, around 1 mg of mouse genomic DNA was
sheared in 400–500 bp fragments using an ultrasonic disruptor (Bioruptor,
Diagenode). Libraries were prepared with Illumina Paired-End DNA Sample Prep
Kit. The libraries obtained were sequenced using one lane of Illumina HiSeq2000
per sample, with the 101 bp paired-end protocol (Supplementary Data 5).
CNVs and structural rearrangements in mouse samples. To detect CNVs on
targeted re-sequencing data, we developed an in-house pipeline based on the
difference in sequencing coverage between tumours and normal counterparts (see
Supplementary Methods). Copy-number analysis on the whole-genome sequencing
data was performed using CNVnator v. 0.2.5 (ref. 69) (see Supplementary
Methods).
Structural rearrangements were inferred using PEMer70 with slight
modiﬁcations to adapt the method to Illumina sequencing. Paired-end insert size
distribution was calculated to determine the expected insert size range. All mapped
paired-end pairs that displayed either an insert size greater than expected or an
unexpected orientation were selected. Of these, only discordant read pairs
overlapping with or next to mapped CNV regions in the tumour were selected
for manual inspection. Identiﬁed rearrangements between chromosomes 8 and 14
(ID: 218/3) and 8 and 19 (ID: 60400/1) were conﬁrmed with PCR ampliﬁcations
and Sanger sequencing.
Expression quantitation of Map2k7. Total RNA for qRT-PCR experiments was
extracted from Mdr2-KO tumours, Mdr2-KO inﬂamed livers and age-matched
Mdr2-WT healthy livers in Trizol (Invitrogen) using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. Total RNA (0.5 mg) was used
for cDNA synthesis (using ImProm-II Reverse Transcriptase, Promega).
Quantiﬁcation was performed on Nanodrop, and quality was assessed on
Bioanalyzer (Agilent). Expression analysis was carried out by qPCR on 1 ml of
cDNA reverse-transcribed from 0.5 mg of total RNA. qPCR (SYBR Green, Applied
Biosystems) analysis was performed on an Applied Biosystems 7500 Real-time PCR
system. Values were normalized for nucleolin content.
Treatment with SP600125 JNK inhibitor. Twenty-three Mdr2-KO mice were
randomly divided into two groups at the age of 13 to 14 months, when nodules are
already formed15. One group of 12 mice was treated with an SP600125 (anthra[1,9-
cd]pyrazol-6(2H)-one) (Calbiochem), and the other group of 11 mice with vehicle
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Supplementary Data 10). Vehicle for SP600125, diluted in DMSO, was 40%
polyethylene glycol (PEG, Sigma) in PBS. Treatments (60mg per dose) were
administered intraperitoneally three times a week for a total of 3 weeks. Mice were
killed 1 week after the end of the treatment, and all grossly detectable nodules were
counted, measured with a caliper and collected for DNA extraction and histological
analysis.
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ABSTRACT
The identification of a constantly increasing number
of genes whose mutations are causally implicated in
tumor initiation and progression (cancer genes)
requires the development of tools to store and
analyze them. The Network of Cancer Genes (NCG
3.0) collects information on 1494 cancer genes that
have been found mutated in 16 different cancer
types. These genes were collected from the
Cancer Gene Census as well as from 18 whole
exome and 11 whole-genome screenings of cancer
samples. For each cancer gene, NCG 3.0 provides a
summary of the gene features and the cross-
reference to other databases. In addition, it de-
scribes duplicability, evolutionary origin, orthology,
network properties, interaction partners, microRNA
regulation and functional roles of cancer genes
and of all genes that are related to them. This
integrated network of information can be used to
better characterize cancer genes in the context
of the system in which they act. The data can
also be used to identify novel candidates that
share the same properties of known cancer genes
and may therefore play a similar role in cancer. NCG
3.0 is freely available at http://bio.ifom-ieo-campus.
it/ncg.
INTRODUCTION
The pivotal role of genomic instability in causing human
cancer is an old concept that dates back to the ﬁrst cyto-
genetic studies on cancer cells (1,2). Until very recently,
however, the number of genes whose somatic mutations
are causally implicated in cancer initiation and progres-
sion was very low. This was mainly due to the difﬁcult and
lengthy process of identifying genetic modiﬁcations
through traditional sequencing methods. The recent
development of next-generation sequencing techniques
has boosted the discovery of novel cancer genes. In the
last 5 years, high-throughput mutational screenings were
performed on several cancer types and led to the identiﬁ-
cation of mutations in both coding and non-coding
regions of the cancer genome. So far, around 30
high-throughput and whole genome sequencing experi-
ments on cancer samples have been published, which
identiﬁed around 1500 mutated genes that are potentially
actively involved in cancer development (3–30). This
constant delivery of new sequencing data is radically
changing our understanding of cancer genetics, showing
that the genomic landscape of cancer is complex and
varies among and within cancer types (31). One way to
reduce the complexity implies the identiﬁcation of
properties that are shared among cancer genes and distin-
guish them from the rest of human genes (32). For
example, cancer genes tend to be singletons, i.e. they
preserve one gene copy in the genome, and to encode
hubs, i.e. proteins that engage numerous physical connec-
tions with other proteins (33). Moreover, recessive cancer
genes appeared early in evolution and are involved in basic
cellular processes, while oncogenes originated later and
mainly act as regulators and signal transducers (34).
Thus, the identiﬁcation of speciﬁc properties of cancer
genes may help in better rationalizing their role in
cancer. While several databases collect mutational and
functional information on cancer genes, no description
of their systems-level properties is currently available.
The Network of Cancer Genes (NCG) was originally
created to collect information on duplicability and
network properties of cancer genes (35).
Information on duplicability and network properties of
cancer genes (35). In the current version of the database
(NCG 3.0), we included 1494 cancer genes that have been
identiﬁed so far, and provide an update of the human gene
set and the protein interactome. We also added novel
features, such as the functional description of cancer
genes as well as information about their interaction with
microRNAs (miRNAs). Finally, we developed a new web
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interface to allow more intuitive and ﬂexible queries of the
database. Since properties of cancer genes can be also
exploited to identify new candidates that may be
involved in cancer (36), we present a case study that
involves two paralogs, the DNA methyltransferase
alpha (DNMT3A) and beta (DNMT3B). On the basis
of the information that can be retrieved in NCG 3.0,
we hypothesize that, upon the acquisition of somatic mu-
tations, these genes may play an active role in cancer
development.
UPDATES OF DATA SOURCES
Cancer genes
NCG 3.0 includes information on 1494 cancer genes that
were extracted from 30 distinct studies (Table 1). The
genes were divided into three groups, according to the
experimental evidence that supported their involvement
in cancer. The ﬁrst group includes 498 genes from the
latest release of the Cancer Gene Census (CGC, 444
genes, 31 March 2011) (37) and from the census of
ampliﬁed cancer genes (77 genes) (38). Both these re-
sources are literature-based collections of genes whose
mutations and/or ampliﬁcations have been proven to be
causally implicated in tumorigenesis. Among the 444
genes from CGC, 346 are deﬁned as dominant (i.e. het-
erozygous mutations are sufﬁcient to cause tumorigenesis)
and 96 as recessive (i.e. homozygous mutations are
required to initiate tumorigenesis) (37). The second
group is formed of 698 candidate cancer genes from 18
high-throughput mutational screenings (HTMS) on 16
distinct cancer types, such as breast (15,30), colorectal
(30), pancreatic (13–15), lung (10,15), renal (8), prostatic
(15), bladder (12), and ovarian (15) cancers, glioblastoma
(20,21), leukemia (11), lymphoma (23), sarcoma (4),
myeloma (6), medulloblastoma (22), head and neck
squamous cell carcinoma (3,27), and melanoma (29).
These genes represent the subsets of mutated genes that
were identiﬁed as bearing driver mutations, i.e. mutations
that confer growth advantage and are actively involved in
tumor development (31). The third group of cancer genes
contains 457 genes that have been identiﬁed in eleven
whole genome sequencing (WGS) screenings of cancer
genomes, such as breast (26), lung (16,25), prostatic (5),
liver cancer (28), glioblastoma (7), leukemia (17,19),
myeloma (6) and melanoma (24).
Human gene set and orthology information
We gathered information on the human gene set from the
combination of Gencode v.7.0 (39) and RefSeq v. 46 (40).
Gencode is an initiative that aims at identifying and
mapping all human protein coding genes (41). It has
been used as the reference gene set for the Encode
project, for the 1000 Genomes Project and for the design
of the capture baits for whole exome sequencing (39). This
gene set is therefore likely to include all genes present in
current and future mutational screenings of whole cancer
exomes. Starting from 20 700 genes in Gencode v.7.0 (cor-
responding to 84 408 protein sequences), we removed
multiple isoforms that map to the same gene locus by
aligning all protein sequences to the reference human
genome (hg18) and retaining only the longest isoform
(33). At the end of this pipeline, we were able to
retrieve 19 560 unique genes. The 1140 missing genes
corresponded to transcripts that spanned more than
one gene. To recover them, we repeated the same
pipeline with 20 750 genes in RefSeq (corresponding to
34 571 protein sequences). The union of these two gene
lists led to the ﬁnal dataset of 20 531 unique human
genes.
To measure the duplicability of each gene, we identiﬁed
all additional hits on the genome that span at least 60% of
the gene length (33), and found that 4311 human genes
(21% of the total) have at least one additional copy.
Consistently with previous reports (33,34), we found that
cancer genes duplicate signiﬁcantly less than the rest of
human genes (15.7% of the total, p-value=3.0 107,
Pearson’s Chi-squared Test), and dominant genes are
more duplicated than recessive genes (Figure 1A and
Table 1).
We updated the information on orthology relationships
between human and other species to eggNOG v. 2.0 (42).
Orthologs were used to identify the evolutionary origin of
1,466 cancer genes (98% of the total), deﬁned as the
deepest internal node of the tree of life where an
ortholog could be found (34). We conﬁrmed that recessive
cancer genes are mostly ancient genes that have orthologs
in prokaryotes, plants and fungi, while a higher fraction of
Table 1. Primary data correspond to the list of cancer genes as they were extracted from the original papers. Five genes are not present in NCG
3.0 because they could not be mapped to current version of Entrez IDs. Dominant and recessive genes refer to the deﬁnition reported in the
cancer gene census (37). Ancient and recent genes refer to genes that originated between the last universal common ancestor and opisthokonts
and with metazoans or later, respectively. HTMS, high-throughput mutation screening; WGS, whole genome sequencing
Cancer genes Dominant Recessive Ampliﬁed HTMS WGS Total
Primary data 348 98 77 699 457 1,499
Present in NCG 3 346 96 77 698 454 1,494
Duplicated (%) 58 (17.7) 10 (10.5) 23 (29.9) 102 (14.8) 64 (14.3) 230 (15.7)
Ancient (%) 184 (55.6) 63 (66.3) 53 (69.9) 377 (54.6) 273 (61.2) 837 (57.1)
Recent (%) 147 (44.4) 32 (33.7) 24 (31.1) 313 (45.4) 173 (38.8) 629 (42.9)
Hubs (%) 185 (58.6) 71 (75.5) 50 (70.4) 231 (42.6) 116 (34.6) 532 (44.7)
miRNA targets (%) 53 (15.3) 14 (14.6) 17 (22.1) 53 (7.6) 28 (6.2) 118 (7.9)
miRNA hosts (%) 12 (3.5) 6 (6.3) 2 (2.6) 28 (4.0) 17 (3.7) 55 (3.7)
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dominant cancer genes appeared with metazoans or later
(Figure 1B and Table 1).
Human interaction network
We rebuilt the human interactome by integrating the latest
releases of ﬁve sources of protein–protein interactions,
such as HPRD (43), BioGRID (44), IntAct (45), MINT
(46) and DIP (47). Only primary interactions were used
while putative interactions inferred from orthology rela-
tionships were discarded. The ﬁnal dataset comprised
98 492 binary interactions between 13 531 proteins, sup-
ported by 25 915 independent publications. The resulting
human interactome contains 13% more proteins and 44%
more interactions than the previous version of NCG, and
reports interaction data for 1189 cancer genes (79% of the
total). We conﬁrmed that cancer genes are enriched in
hubs, deﬁned as top 25% most connected proteins (at
least 15 interactions) (34), and are therefore more con-
nected than the rest of human genes (Figure 1C and
Table 1).
NEW FEATURES OF NCG 3.0
Interactions between cancer gene and miRNAs
miRNAs are endogenous short nucleotide sequences that
interfere with RNA transcripts in the cytoplasm, thus
regulating protein synthesis (48). Alterations in miRNA
expression have been reported during cancer initiation,
progression and metastasis (49). In addition, miRNAs
regulate well-known cancer genes, such as PTEN,
NRAS, KRAS, (48). Because of this involvement in
cancer, we included information about the interactions
between miRNAs and their target cancer genes. Primary
data were extracted from TarBase v.5.0 (50) and
miRecords v.1.0 (51), which collect experimentally sup-
ported interactions between miRNAs and their targets.
The non-redundant integration of the two databases
returned a list of 54 miRNAs that regulate 118 cancer
genes (8% of the total, Table 1). This fraction is signiﬁ-
cantly higher compared to the rest of human genes (4%,
p-value=1011, Pearson’s Chi-squared Test), and
becomes even higher when only recessive or dominant
Figure 1. Properties of cancer genes. Circles represent the fraction of cancer, dominant, and recessive genes that are (A) singleton or duplicated, (B)
ancient or recent, (C) hubs or non-hubs. Ancient genes originated between the last universal common ancestor and opisthokonts; recent genes
originated with metazoans or later. (D) miRNA targets were derived from TarBase (50) and miRecords (51). Approximately 15% of dominant and
recessive cancer genes are targets of miRNAs, compared with 8% of all cancer genes. (E) Cancer genes were associated to one of the 12 functional
categories based on the corresponding GO terms (34).
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cancer genes are considered (15%, Figure 1D and Table
1). This enrichment reﬂects at least partly the fact that
cancer genes are heavily studied and therefore more infor-
mation are available for them compared to other genes. In
addition to miRNA targets, we also retrieved information
on 55 cancer genes that host miRNAs within their
genomic locus (Table 1).
Functional classiﬁcation of cancer genes
To derive the gene functional classiﬁcation, we ﬁrst ex-
tracted 1108 cancer genes (74% of all the total) that
have at least one term at levels 5 and 6 of the biological
process branch of the Gene Ontology (GO) tree (52). We
then grouped all these terms into 12 functional categories,
in order to provide a more general description of the gene
function (34). Dominant and recessive cancer genes have
different functional distributions. In particular, while
dominant genes are mostly involved in the regulation of
transcription, recessive genes are associated with basic
cellular functions such as cell cycle, cell response to
stimuli, cellular and DNA/RNA metabolism (Figure 1E).
Network representation
We developed a novel web interface and added several
new possibilities of querying the database, thus allowing
the user to search for speciﬁc cancer genes, for lists of
genes and miRNAs related to cancer, and for the
presence of cancer genes in genomic regions of interest.
In addition, it is now possible to retrieve the interactions
between a certain miRNA and the cancer genes that are
associated to it, as well as all cancer genes that are miRNA
targets or that host miRNAs within their genomic locus.
Finally, we adopted CytoscapeWeb (53) for the visualiza-
tion of protein–protein and miRNA–target interaction
networks, and for displaying the evolutionary origin of
cancer genes and their orthologs in other species.
IDENTIFICATION OF CANDIDATE CANCER GENES
USING NCG
In addition to providing a comprehensive description of
the properties of cancer genes, NCG can be used to
identify new possible candidates, based on the hypothesis
that genes with systems-level properties similar to known
cancer genes may also play similar roles in cancer (36).
Following this idea, two almost identical paralogs,
GNAQ GNA11, have recently been associated to the
same tumor type (54). Here, we hypothesize that a
similar association can be drawn for DNMT3A and its
paralog DNMT3B. Both these methyltransferases cause
Figure 2. Functional redundancy of DNMT3A and DNMT3B. (A) Protein-protein interaction network of DNMT3A and DNMT3B. The two
proteins share 14 interactors, which are mostly involved in the epigenetic control of chromatin and in the regulation of gene expression. Primary
interactions are physical interactions of a protein directly with DNMT3A or DNMT3B, while secondary interactions are physical interactions
between their primary interactors. (B) Interaction network between DNMT3A and DNMT3B and target miRNAs. Both genes are regulated by
members of the miR-29 family, whose expression is altered in cancer and is inversely correlated with the gene expression (57). CGC, cancer gene
census; HTMS, high-throughput mutational screenings; WGS, whole genome sequencing.
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de novo methylation during the differentiation of hemato-
poietic cells and are involved in hematopoietic stem-cell
renewal (55). DNMT3A is an already known cancer gene,
part of the cancer gene census and frequently mutated in
leukemia (56). Although its role in tumorigenesis is still
unclear, it has been hypothesized that mutations in
DNMT3A either induce altered gene expression or affect
genome stability (56). To date there is no evidence that
also DNMT3B is mutated in cancer, although NCG 3.0
provides several indications that this might be indeed the
case. First, both DNMT3A and DNMT3B originated with
eukaryotes and are associated with the same GO terms,
thus indicating functional redundancy. Second, the
encoded proteins DNMT3A and DNMT3B share 14
interactors, which, in turn, are connected through second-
ary interactions (Figure 2A). The resulting highly inter-
connected module involves key players in epigenetic
changes of chromatin, and consequent regulation of
gene expression. Third, both genes are targets of three
miRNAs of the miR-29 family (Figure 2B). The
downregulation of these miRNAs induces aberrant ex-
pression of both DNMT3A and DNMT3B in
non-small-cell lung cancer (57) and the upregulation of
both paralogs has been observed in several tumor types
(58). We hypothesize that the aberrant expression can be
related to the acquisition of mutations in the sequence of
these genes.
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Abstract 
Background: The detection of copy number variations (CNVs) and copy neutral loss 
of heterozygosity (CN-LOH) events from exome sequencing data is challenging 
because of the small size and sparse distribution of exons in the genome. As a result, 
available methods often fail to detect alterations of single genes. Here we present 
GeneCNV, a novel method suited at identifying CNVs and CN-LOHs at the gene 
level. 
Methods: GeneCNV concatenates targeted exons to rebuild full-length genes, 
measures the normalized coverage of each gene independently, and finally derives 
sample-specific thresholds to identify amplified, deleted, and CN-LOH genes as 
compared to a reference sequence.  
Results and Conclusions: GeneCNV shows the best performance among exome-
based methods and the highest concordance with SNP array results. It also provides a 
graphical summary that allows a comparative and analytical assessment of results. 
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Background  
Copy number variations (CNVs) are genomic alterations that lead to quantitative 
changes of the genomic content and account for ~12% of human genomic variability 
[1]. Several inherited CNVs have been associated with the onset of genetic disorders, 
including glomerulonephritis, autism, and rheumatoid arthritis [2-5]. Somatically 
acquired CNVs and copy neutral loss of heterozygosity (CN-LOH) events frequently 
occur in cancer [6, 7], where they can drive tumor progression [8-12]. Because of 
their primary roles in genome evolution and in disease onset, several technologies 
have been developed to identify CNVs, including single nucleotide polymorphism 
(SNP) array, array comparative genomic hybridizations (aCGH), and, more recently, 
next generation sequencing (NGS). Although whole genome sequencing (WGS) 
provides the most comprehensive CNV profile, whole exome sequencing (WES) 
remains the most widely used NGS approach because it is still time and cost effective. 
In addition, WES gives insights into the genomic alterations of protein coding genes, 
which are often the most interesting to follow up. CNV detection from WES data is 
however challenging due to the different size and sequence composition of exons, 
which result in non-uniform sequence coverage [13-15]. In addition, since exons are 
located at variable distances from each other, the detection of CNVs at breakpoint 
resolution is challenging [16, 17]. Several methods have been developed in recent 
years to circumvent these issues, including ExomeCNV [18], VarScan2 [19], 
ControlFreeC [20], ADTEx [21], and EXCAVATOR [22]. Although using different 
technical solutions, the majority of these methods identify CNV regions between two 
or more samples after segmenting the genome sequence into portions. Segmentation 
works by merging adjacent genomic regions into longer segments in the attempt to 
minimize coverage variability within the individual segments while maximizing it 
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between them. Segmentation has been widely applied to aCGH [23, 24] and WGS 
[25, 26] data, where information is available for long and contiguous regions. 
Although it has been adapted also to detect CNVs from exome data, the scattered 
nature of the data and the high variability in exon coverage reduce its efficacy in this 
context. 
Here we present GeneCNV, a novel method that detects CNVs and CN-LOHs without 
relying on segmentation. GeneCNV starts by rebuilding full-length targeted genes. It 
then calculates the coverage of each gene individually and normalizes it to reduce the 
variability within and between samples. Finally, it uses the frequency of germline 
heterozygous mutations to identify sample-specific thresholds for calling amplified, 
deleted, and CN-LOH genes at the sample level. When compared to other exome-
based methods, GeneCNV shows the highest concordance with SNP array-derived 
CNVs and provides the best trade-off between sensitivity and specificity. 
 
Methods 
The input data for GeneCNV are WES data from test and reference samples. 
Although test and reference may be of any kind, hereon we refer to them as tumor and 
normal exomes for the sake of clarity. 
 
Gene coverage calculation and normalization 
The coverage of each targeted exon is calculated using CoverageBed from BEDTool 
[27] as: 
 ExonCoveragee = d ×  bd
d=0
max(depth)
∑
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where d is the depth of coverage and bd is the number of bases at depth of coverage d 
in exon e. Exons of each gene are merged using the targeted gene annotation file (e.g. 
the Agilent SureSelect bed files or equivalent) to rebuild the full-length gene. Gene 
coverage is measured as the cumulative coverage of all exons divided by the gene 
length:  
 
where e is the exon and g is the gene.  
To minimize the variability of capture and sequencing efficiency within the exome, 
median scaling normalization [28, 29] is applied: 
 
where g is the gene and s is the sample.  
To correct for gene coverage variations between tumor and matched normal exomes, 
quantile normalization [30] is applied. Genes in the tumor and in the matched normal 
exomes are ranked according to their normalized gene coverage values. The coverage 
of genes occupying equivalent positions in the two ranked lists is then reassigned as 
the average gene coverage between the two values (GeneCoverageg"). For each gene 
the log2ratio between the gene coverage in the tumor and in the matched normal 
exome (L2RGC) is finally calculated as: 
 
 
GeneCoverageg=
ExonCoveragee  
e=1
no. of  exons
∑
ExonLengthe  
e=1
no. of  exons
∑
GeneCoverageg ' = GeneCoverageg
median( GeneCoverageg )s
L2RGC = Log2
GeneCoverage"g, tumor
GeneCoverage"g, normal
!
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Identification of diploid copy number regions and sample specific L2RGC 
thresholds 
In order to identify sample-specific thresholds of L2RGC for calling amplified and 
deleted genes, GeneCNV relies on the deviation from the expected frequency of 
heterozygous SNPs (frequency = 50%) in cases of allelic imbalance due to CNVs. 
Heterozygous SNPs are first identified as germline mutations with frequency within 
40-60% interval in the normal sample. Tumor exome is then divided into non-
overlapping regions each containing 100 such heterozygous SNPs. Regions hosting 
≥80% of heterozygous SNPs within 40-60% frequency are considered to maintain the 
allelic balance. Since high L2RGC values often indicate balanced amplifications of 
both the alleles, regions with L2RGC values in the lower tail (<10%) of the distribution 
of L2RGC values of all allelic balanced regions are considered as diploid. The 
thresholds for calling amplified and deleted genes are finally calculated from the 
distribution of L2RGC in the diploid regions as: 
L2RGCA = (L2RGC )10%+1SD(L2RGC )10%  
L2RGCD = (L2RGC )10%−1SD(L2RGC )10%  
where 1SD represents one standard deviation from the L2RGC value. 
The optimal numbers of SNPs to divide the exome (100 SNPs), the L2RGC value to 
define diploid regions (10% of the distribution) and the number of standard deviations 
(1SDL2RGC) have been empirically estimated and are given as the default parameters. 
They can be however modified by the user.  
 
Identification of altered genes from SNP array  
SNP arrays of 28 tumors and matched normal samples were downloaded from the 
Gene Expression Omnibus (GEO, GSE31174) [31, 32] and from the European 
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Genome-phenome Archive (EGA, EGAS00001000749) [33, 34] databases. All data 
were analyzed using ASCAT (version 2.1) [35] with default parameters (segment 
length = 25; homozygous probes with 0.3>B allele frequency>0.7 in the normal were 
masked). High confidence somatic CNVs and CN-LOHs were identified as genomic 
segments with an aberration reliability score higher than the ASCAT average 
reliability score in each tumor sample. The genomic coordinates of CNV and CN-
LOH regions were intersected with those of the human gene sets of the Agilent 
SureSelect Human All Exon 50Mb kit (20,965 genes) or 38Mb kit  (19,104 genes) 
depending on the kit used to capture the exome in the corresponding sample. A gene 
was considered as altered if ≥80% of its length was contained in a CNV or CN-LOH 
region. 
 
Identification of altered genes from exome sequencing data  
Exome sequencing data for the 28 tumors and matched normal samples were 
downloaded from Sequence Read Archive (SRA, DRA000433) [32, 36] and from 
EGA (EGAS00001000749) [34] databases. Sequencing reads from each tumor and 
matched normal were mapped to the human genome (GRCh37/hg19) using Novoalign 
[37] or BWA [38]. At most three mismatches per read were allowed and duplicated 
reads were removed using rmdup of SAMtools [39]. Only reads uniquely mapping 
within 75-100 bp of the targeted regions were considered on target and retained for 
further analysis. CNVs from exome sequencing data were identified in each of the 28 
tumor exomes using GeneCNV, ExomeCNV (version 1.4), VarScan 2 (version 2.3.6) 
and EXCAVATOR (version 2.2). All methods were run using default parameters 
(ExomeCNV: minimum sensitivity and specificity = 0.9999 and optimizing for 
specificity; VarScan 2: minimum coverage = 8, minimum size = 10 bases, log ratio 
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threshold = 0.25 for both the lower and upper bounds; EXCAVATOR: mode = 
somatic). Since ExomeCNV, VarScan 2 and EXCAVATOR identify CNV regions, to 
detect deleted and amplified genes in each tumor exome similar analysis was done as 
previously described for the SNP arrays. CN-LOH genes could only be identified 
using ExomeCNV and GeneCNV. 
 
Performance comparison among exome-based methods 
To compare the performance of the four exome-based methods, CNV and CN-LOH 
genes from the SNP arrays occurring in the tumor samples were considered as the true 
alterations. Sensitivity, specificity, accuracy and Jaccard index was then calculated for 
each exome-based method as compared to SNP array results. True positives were 
defined as genes with the same alterations as detected in the SNP arrays and true 
negatives were considered as unaltered genes in both. Sensitivity was calculated as 
the number of true positives over the total number of altered genes in the SNP arrays. 
Specificity was estimated as the number of true negatives over the total number of 
unaltered genes in the SNP arrays. Accuracy was measured as the number of correct 
calls (sum of true positives and true negatives) over the total number of targeted 
genes. The concordance between the results from exome-based methods and SNP 
arrays was measured using the Jaccard index as the number of true positives over the 
sum of altered genes detected by the exome-based method and in SNP arrays. B-allele 
frequency (BAF) and log R ratio (LRR) were used to identify clonal events. Namely, 
tumor alterations hosting SNPs with 0.4>BAF >0.6 or with -0.25>LRR>0.25 were 
considered as clonal events [40, 41].  
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Results and Discussion 
 GeneCNV rationale and workflow  
To minimize coverage variability due to exon length, composition, and discrete 
distribution along the genome, GeneCNV adopts a novel strategy that differs from 
those of other exome-based methods (Figure 1). First, it merges all targeted exons of 
each gene to rebuild a contiguous region that spans the entire gene length. This is then 
used to calculate the average gene coverage, thus allowing uniformly captured and 
sequenced exons to compensate for the non-uniform coverage of other exons within 
the same gene (Figure 1A). Second, it normalizes the gene coverage between genes 
within the same exome using global median normalization and across tumor and 
matched normal exomes using quantile normalization (Figure 1B). The two 
normalizations minimize the coverage variability due to sequence composition, DNA 
quality, library preparation protocols, and sequencing settings and performance. Using 
the normalized gene coverage in the tumor and normal exomes, GeneCNV calculates 
the gene coverage log2ratio (L2RGC) between tumor and matched normal for each 
targeted gene (Figure 1C). In principle, L2RGC values around zero indicate genes with 
the same copy number in the tumor and in the normal counterpart, while L2RGC 
values higher than 0.6 (corresponding to ≥1.5 fold change) or lower than -1 
(corresponding to ≤0.5 fold change) indicate tumor-specific gene amplifications and 
deletions, respectively. Such fixed thresholds, however, can be used only in genomes 
where no widespread chromosomal rearrangements occur. Since most cancer 
genomes acquire significant chromosomal instability, they often show substantially 
modified L2RGC spectra. For this reason, GeneCNV does not apply fixed L2RGC 
thresholds but derives them for each tumor sample. To this aim, it identifies regions of 
the tumor genome where the frequency of heterozygous SNPs is around 50%, thus 
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indicating that their allelic balance is maintained (see Methods and Figure 1D). 
Within these allelic balanced regions, GeneCNV identifies diploid regions as the ones 
with L2RGC values in the lower tail of the L2RGC distribution (Figure 1E), because 
regions of allelic balance but with high L2RGC values correspond to tumor-specific 
amplifications of both alleles. GeneCNV then uses the distribution of L2RGC values in 
diploid regions to identify sample-specific L2RGC thresholds for amplification 
(L2RGCA) and deletion (L2RGCD, Figure 1F). Genes in region of allelic imbalance and 
with L2RGC values within the thresholds are considered as undergoing CN-LOH. All 
the other genes are regarded as maintaining a two-copy status (Figure 1G).  
 
Comparison of GeneCNV with other methods 
We assessed the performance of GeneCNV as compared to three other widely used 
exome-based methods (ExomeCNV, VarScan 2, and EXCAVATOR). As a test 
dataset, we used tumor and matched normal WES data from 22 myelodysplasias [32] 
and six pediatric hepatocellular carcinomas [34] (Additional file 1). Tumor-specific 
amplified, deleted and CN-LOH genes detected from the SNP arrays on the same 
samples were used as the gold standard for comparison (Additional file 2). For each 
of the four exome-based methods, we measured sensitivity, specificity, accuracy, and 
the Jaccard index, which estimates the concordance with the SNP array results. 
Overall, GeneCNV showed the highest sensitivity (51%), accuracy (78%), and 
Jaccard index (36%) as compared to the other three methods (Figure 2A and 
Additional File 3). In addition, although it had the second best specificity (88%), it 
showed the best trade-off between specificity and sensitivity (Figure 2B). All four 
exome-based methods in general, and GeneCNV in particular, were more sensitive in 
detecting amplified genes (Figure 2C) than deleted genes (Figure 2D). GeneCNV 
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again showed the highest concordance with the SNP array results in detecting 
deletions (Figure 2D), thus suggesting that the higher sensitivity of the other methods 
was due to an overall overestimation of deletions. Of the four exome-based method, 
only GeneCNV and ExomeCNV can detect CN-LOHs, and GeneCNV showed the 
best performance in all comparisons (Figure 2E). Overall, exome-based methods had 
poor concordance with somatic copy number events called by SNP arrays (Figure 
2A). In order to understand the reasons for this, we assessed the performances in each 
tumor exome individually and noticed that exome-based methods consistently failed 
to detect any CNVs in some tumors (Additional file 4). Since the SNP call rate of 
some of them (e.g. MDS-15, tAML-07 and tAML-02, Additional file 1) was low, this 
suggested the occurrence of possible false positives in the SNP arrays. Moreover, 
tumor somatic alterations are usually a mixture of clonal and subclonal events, 
depending on when they occur during cancer growth. Sensitivity of exome-based 
method is lower in detecting subclonal CNVs, because the differences in coverage 
between tumor and normal samples are not high enough to identify changes in copy 
number. This in principle leads to false negative calls from exome-based methods. To 
understand whether this was the case, we defined clonal events on the basis of the B 
allele frequency and log R ratio of heterozygous SNPs in the 28 tumor exomes and re-
assessed the performances of exome-based methods only on clonal events (see 
Methods and Additional file 5). We noticed substantial increase in sensitivity, while 
specificity remained unchanged (Figure 2F and Additional file 6). 
 
GeneCNV graphical output  
In addition to the list of amplified, deleted and CN-LOH genes, GeneCNV also 
generates a graphical output that provides an analytical report of the results (Figure 3). 
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This report includes the variation of gene coverage in the tumor and matched normal 
before and after normalization, which can be used to evaluate the coverage 
differences between the two exomes (Figure 3A). It also shows the L2RGC spectrum 
of all targeted genes in the tumor exome, with amplified, deleted, and CN-LOH genes 
depicted in green, red, and yellow, respectively (Figure 3B). It then provides a 
quantification of tumor-altered genes and the cumulative density map of their 
distribution along the chromosomes (Figure 3C). Finally, it summarizes all results in a 
circos plot where altered genes that play known [42] or candidate [43] roles in cancer 
are shown (Figure 3D). GeneCNV can also be used to compare CNV profiles across 
multiple samples, which is useful when a cohort of patients is screened. In this case, 
the report summarizes the percentage of total altered genes in each tumor exome 
(Figure 3E), highlights frequently altered genes across all samples (Figure 3F) and 
provides the corresponding circos plot (Figure 3G). This is particularly useful to 
pinpoint possible cancer driver events.  
 
Conclusions  
In this study, we present GeneCNV, a novel method that detects gene-specific CNVs 
and CN-LOHs from WES data, based on normalized gene coverage and sample-
specific thresholds. GeneCNV does not rely on segmentation of the genome to detect 
genomic alterations and this leads to better performances as compared to other 
exome-based methods. GeneCNV is suited to analyse tumor-normal exome pairs as 
well as larger cohorts of samples.  
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Figures 
Figure 1  - GeneCNV workflow. 
GeneCNV uses whole exome sequencing to calculate the coverage of all targeted 
genes in test (e.g tumor) and reference (e.g matched normal) exomes independently 
(A). It normalizes the gene coverage within and between exomes using median 
normalization and quantile normalization, respectively (B). It then measures the 
log2ratio of gene coverage (L2RGC) between tumor and matched normal exomes for 
each targeted gene (C) and identifies the regions of allelic balance in the tumor (D). 
Within allelic balanced regions, GeneCNV further identifies regions that maintain a 
diploid status in the tumor (E) and defines L2RGC thresholds for amplifications and 
deletions from them (F). This allows the detection of amplified (green), deleted (red), 
CN-LOH (yellow) and two copy (grey) genes along the whole exome (G). The 
parameters to define diploid regions and the sample-specific thresholds are empirical 
and can be all modified by the user. 
 
Figure 2  - Performance comparison of GeneCNV with other exome-based 
methods. 
Reported are sensitivity, specificity, accuracy and Jaccard index of the four exome-
based methods (GeneCNV, ExomeCNV, VarScan 2, and EXCAVATOR) in detecting 
all CNVs in the 28 samples as compared to SNP array (A); the trade-off between 
sensitivity and specificity of each method (B); performance of the four methods in 
detecting amplified genes (C), deleted genes (D), CN-LOH genes and clonal variant 
genes (E). For CN-LOHs assessment, only GeneCNV and ExomeCNV are compared 
because VarScan 2, and EXCAVATOR cannot detect CN-LOHs.  
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Figure 3  - GeneCNV graphical output. 
Shown are exemplar graphical outputs of GeneCNV on a single tumor (sample MDS-
09, A-D) and on a cohort of tumors (all 22 myleodysplasia exomes, E-G, see also 
Additional File 1). In the case of the single sample analysis, provided are the plots of 
gene coverage in the tumor and the normal exomes before and after normalizations 
(A); the tumor L2RGC spectrum with amplified, deleted and CN-LOH genes 
highlighted in colors (B); the percentage of somatically amplified, deleted and CN-
LOH genes in each tumor chromosome and in regions representing 10% of 
chromosome arms (C); and the circos plot summarizing all alterations and reporting 
known [42] and candidate [43] altered cancer genes (D). In the case of multiple 
sample comparison, shown are the percentage of amplified, deleted and CN-LOH 
genes in each tumor exome (E); the number of genes whose modifications recur 
across samples (F); and the circos plot with all genomic alterations and recurrently 
altered cancer genes [42] (G).  
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Additional files 
Additional file 1 – Samples used for the comparison of exome-based methods 
This file contains Supplementary Table S1 with the description of the 28 samples 
used for method comparison. The file is provided in XLS format. 
 
Additional file 2 – Amplified, deleted, and CN-LOH genes in the 28 tumor 
exomes. 
This file contains Supplementary Table S2 and reports the copy number status of all 
targeted genes in each of the 28 tumor exomes, as detected by ASCAT in the SNP 
array and by the four exome-based methods. The file is provided in XLS format. 
 
Additional file 3 – Performance of the four exome-based methods in detecting 
variant genes 
This file contains Supplementary Table S3 and reports sensitivity, specificity, 
accuracy, and Jaccard index of all four methods in identifying variant genes in 28 
tumor exomes. The file is provided in XLS format. 
 
Additional file 4 – Performance of the four exome-based methods in detecting 
amplified and deleted genes 
This file contains Supplementary Figure S1 and reports sensitivity, specificity, 
accuracy, and Jaccard index of all four methods in detecting amplified and deleted 
genes in the 28 tumor exomes. The file is provided in PDF format. 
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Additional file 5 – Clonally amplified, deleted, and CN-LOH genes in the 28 
tumor exomes 
This file contains Supplementary Table S4 and reports only clonal events occurring in 
each of the 28 tumor exomes. The file is provided in XLS format. 
 
Additional file 6 – Performance of the four exome-based methods in detecting 
clonal events 
This file contains Supplementary Table S5 and reports sensitivity, specificity, 
accuracy, and Jaccard index of all four methods in identifying clonal modifications 
occurring in each of the 28 tumor exomes. The file is provided in XLS format. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1
Figure 2
Figure 3
Additional files provided with this submission:
Additional file 1: Sinha_AdditionalFile1.xlsx, 47K
http://genomebiology.com/imedia/6199596331420146/supp1.xlsx
Additional file 2: Sinha_AdditionalFile2.xlsx, 49K
http://genomebiology.com/imedia/1825669148142014/supp2.xlsx
Additional file 3: Sinha_AdditionalFile3.xlsx, 43K
http://genomebiology.com/imedia/1721990715142014/supp3.xlsx
Additional file 4: Sinha_AdditionalFile4.pdf, 676K
http://genomebiology.com/imedia/1455992140142014/supp4.pdf
Additional file 5: Sinha_AdditionalFile5.xlsx, 47K
http://genomebiology.com/imedia/1061629542142014/supp5.xlsx
Additional file 6: Sinha_AdditionalFile6.xlsx, 44K
http://genomebiology.com/imedia/4766091131420146/supp6.xlsx
